| Cyclin-dependent kinase 1 |
IC50 |
= |
450.0 |
nM |
Inhibitory concentration against Cyclin dependent kinase 1. |
CHEMBL1136199 |
| MCF7 |
IC50 |
= |
11100.0 |
nM |
Cytotoxic property against MCF-7 cell line was determined |
CHEMBL1136199 |
| K562 |
IC50 |
= |
40000.0 |
nM |
Cytotoxic property against K562 cell line was determined |
CHEMBL1136199 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
200.0 |
nM |
Inhibitory activity against purified cdc2 p34/Cyclin B obtained from M phase oocytes of the starfish Marthasterias glacialis. |
CHEMBL1130316 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
450.0 |
nM |
Inhibition of Cyclin-dependent kinase 1-cyclin B1 from starfish. |
CHEMBL1130775 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
450.0 |
nM |
Inhibition of Cyclin-dependent kinase 1 (CDK1) |
CHEMBL1133090 |
| Cyclin-dependent kinase 5 |
IC50 |
|
|
nM |
Inhibitory activity against Cyclin-dependent kinase 5; ND means Not determined |
CHEMBL1133090 |
| Cyclin-dependent kinase 4 |
IC50 |
= |
100000.0 |
nM |
Inhibition of Cyclin-dependent kinase 4 (CDK4/cyclin Dl) |
CHEMBL1133408 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
600.0 |
nM |
Inhibition of Cyclin-dependent kinase 2 (CDK2/cyclin A) |
CHEMBL1133408 |
| A549 |
IC50 |
|
|
ug.mL-1 |
Inhibition of A549 cancer cell proliferation (Not tested) |
CHEMBL1133408 |
| COLO1 |
IC50 |
|
|
ug.mL-1 |
Inhibition of Col1 cancer cell proliferation (Not tested) |
CHEMBL1133408 |
| HL-60 |
IC50 |
|
|
ug.mL-1 |
Inhibition of HL60 cancer cell proliferation (Not tested) |
CHEMBL1133408 |
| HepG2 |
IC50 |
|
|
ug.mL-1 |
Inhibition of HepG2 cancer cell proliferation (Not tested) |
CHEMBL1133408 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
700000.0 |
nM |
Binding affinity to cyclin-dependent kinase 1 (CDK1) |
CHEMBL1135432 |
| Cyclin-dependent kinase 1/cyclin B |
IC50 |
= |
650.0 |
nM |
Inhibition of Cyclin B-cyclin-dependent kinase 1 |
CHEMBL1135432 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
700.0 |
nM |
Inhibition of Cyclin A-cyclin-dependent kinase 2 |
CHEMBL1135432 |
| Cyclin-dependent kinase 2/cyclin E |
IC50 |
= |
700.0 |
nM |
Inhibition of Cyclin E-cyclin-dependent kinase 2 |
CHEMBL1135432 |
| Cyclin-dependent kinase 4/cyclin D1 |
IC50 |
> |
100000.0 |
nM |
Inhibition of Cyclin D1-cyclin-dependent kinase 4 |
CHEMBL1135432 |
| MAP kinase ERK1 |
IC50 |
= |
34000.0 |
nM |
Inhibition of Mitogen-activated protein kinase 3 (MAPK-ERK1) |
CHEMBL1135432 |
| MAP kinase ERK2 |
IC50 |
= |
14000.0 |
nM |
Inhibition of Mitogen-activated protein kinase 1 (MAPK-ERK2) |
CHEMBL1135432 |
| cAMP-dependent protein kinase (PKA) |
IC50 |
> |
1000000.0 |
nM |
Inhibition of cAMP-dependent protein kinase |
CHEMBL1135432 |
| Unchecked |
IC50 |
= |
1000000.0 |
nM |
Inhibition of cGMP-dependent protein kinase |
CHEMBL1135432 |
| Cyclin-dependent kinase 1/cyclin B |
IC50 |
= |
450.0 |
nM |
Inhibition of recombinant Cyclin-dependent kinase 1-cyclin B |
CHEMBL1134966 |
| MCF7 |
IC50 |
= |
11100.0 |
nM |
In vitro cytotoxic effect on MCF-7 cancer cell line |
CHEMBL1134966 |
| K562 |
IC50 |
= |
40000.0 |
nM |
In vitro cytotoxic effect on K562 cancer cell line |
CHEMBL1134966 |
| CCRF-CEM |
IC50 |
= |
18200.0 |
nM |
In vitro cytotoxic effect on CEM cancer cell line |
CHEMBL1134966 |
| HOS |
IC50 |
= |
32000.0 |
nM |
In vitro cytotoxic effect on HOS cancer cell line |
CHEMBL1134966 |
| G-361 |
IC50 |
= |
34000.0 |
nM |
In vitro cytotoxic effect on G361 cancer cell line |
CHEMBL1134966 |
| Cyclin-dependent kinase 1/cyclin B |
IC50 |
= |
450.0 |
nM |
Inhibition of cyclin-dependent kinase 1-cyclin B |
CHEMBL1148433 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
160.0 |
nM |
Inhibition of human Cyclin-dependent kinase 5-p35nck5a |
CHEMBL1148433 |
| cAMP-dependent protein kinase (PKA) |
IC50 |
> |
1000000.0 |
nM |
Inhibition of PKA (protein kinase A) |
CHEMBL1148433 |
| Unchecked |
IC50 |
> |
1000000.0 |
nM |
Inhibition of PKG (protein kinase G) |
CHEMBL1148433 |
| Glycogen synthase kinase-3 beta |
IC50 |
= |
130000.0 |
nM |
Inhibition of glycogen synthase kinase-3 beta |
CHEMBL1148433 |
| Casein kinase I |
IC50 |
= |
17000.0 |
nM |
Inhibition of Casein kinase I (CK1) |
CHEMBL1148433 |
| Cyclin-dependent kinase 1/cyclin B |
IC50 |
= |
650.0 |
nM |
In vitro inhibitory activity against Cyclin-dependent kinase 1-cyclin B complex from starfish oocytes |
CHEMBL1132992 |
| Cyclin-dependent kinase 1/cyclin B |
ID50 |
= |
0.65 |
uM |
Inhibition of Cyclin-dependent kinase 1-cyclin B |
CHEMBL1133166 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
800.0 |
nM |
Inhibition of Cyclin-dependent kinase 5-p35nck5a |
CHEMBL1135277 |
| Cyclin-dependent kinase 2/cyclin E |
IC50 |
= |
650.0 |
nM |
Inhibition of cyclic dependent kinase 2 (CDK2)/cyclin E |
CHEMBL1134344 |
| Protein kinase Pfmrk |
IC50 |
> |
1000000.0 |
nM |
Inhibitory activity against Plasmodium falciparum cyclin dependent protein kinase, Pfmrk |
CHEMBL1145071 |
| Plasmodium falciparum |
IC50 |
= |
28000.0 |
nM |
Inhibitory activity against Plasmodium falciparum W2 |
CHEMBL1145071 |
| Plasmodium falciparum |
IC50 |
= |
33000.0 |
nM |
Inhibitory activity against Plasmodium falciparum D6 |
CHEMBL1145071 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
200.0 |
nM |
Inhibition of cyclin-dependent kinase 5/p25; range 0.1-0.2 |
CHEMBL1145180 |
| CaM-kinase kinase alpha |
Kd |
|
|
|
Average Binding Constant for CAMKK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Cyclin-dependent kinase 5 |
Kd |
= |
2000.0 |
nM |
Average Binding Constant for CDK5; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase PCTAIRE-1 |
Kd |
= |
990.0 |
nM |
Average Binding Constant for PCTK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Cyclin-dependent kinase 2 |
Kd |
= |
2900.0 |
nM |
Average Binding Constant for CDK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| CaM-kinase kinase beta |
Kd |
|
|
|
Average Binding Constant for CAMKK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase PIM1 |
Kd |
|
|
|
Average Binding Constant for PIM1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase PIM2 |
Kd |
|
|
|
Average Binding Constant for PIM2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Dual specificity protein kinase CLK3 |
Kd |
|
|
|
Average Binding Constant for CLK3; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase GAK |
Kd |
|
|
|
Average Binding Constant for GAK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| CaM kinase II alpha |
Kd |
|
|
|
Average Binding Constant for CAMK2A; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Dual specificity protein kinase CLK2 |
Kd |
= |
470.0 |
nM |
Average Binding Constant for CLK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ribosomal protein S6 kinase alpha 2 |
Kd |
= |
3200.0 |
nM |
Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM |
CHEMBL1144455 |
| MAP kinase signal-integrating kinase 2 |
Kd |
|
|
|
Average Binding Constant for MKNK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ribosomal protein S6 kinase alpha 5 |
Kd |
|
|
|
Average Binding Constant for RPS6KA5 (Kin.Dom 1); NA=Not Active at 10 uM |
CHEMBL1144455 |
| Phosphorylase kinase gamma subunit 2 |
Kd |
|
|
|
Average Binding Constant for PHkg2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Dual specificty protein kinase CLK1 |
Kd |
= |
2100.0 |
nM |
Average Binding Constant for CLK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ephrin type-B receptor 1 |
Kd |
|
|
|
Average Binding Constant for EPHB1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| CaM kinase II beta |
Kd |
|
|
|
Average Binding Constant for CAMK2B; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase PLK4 |
Kd |
|
|
|
Average Binding Constant for STK18; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ephrin type-A receptor 5 |
Kd |
|
|
|
Average Binding Constant for EPHA5; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase 17B |
Kd |
|
|
|
Average Binding Constant for STK17B; NA=Not Active at 10 uM |
CHEMBL1144455 |
| AMP-activated protein kinase, alpha-1 subunit |
Kd |
|
|
|
Average Binding Constant for PRKAA1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Casein kinase I epsilon |
Kd |
= |
160.0 |
nM |
Average Binding Constant for CSNK1E; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Casein kinase I gamma 2 |
Kd |
= |
1400.0 |
nM |
Average Binding Constant for CSNK1G2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Dual specificity protein kinase TTK |
Kd |
= |
2100.0 |
nM |
Average Binding Constant for TTK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Casein kinase I gamma 1 |
Kd |
= |
3300.0 |
nM |
Average Binding Constant for CSNK1G1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Dual specificity protein kinase CLK4 |
Kd |
= |
4500.0 |
nM |
Average Binding Constant for CLK4; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Vascular endothelial growth factor receptor 3 |
Kd |
|
|
|
Average Binding Constant for FLT4; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase receptor FLT3 |
Kd |
|
|
|
Average Binding Constant for FLT3; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Platelet-derived growth factor receptor beta |
Kd |
|
|
|
Average Binding Constant for PDGFRB; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Vascular endothelial growth factor receptor 2 |
Kd |
|
|
|
Average Binding Constant for VEGFR2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase ABL |
Kd |
|
|
|
Average Binding Constant for ABL1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase 10 |
Kd |
|
|
|
Average Binding Constant for STK10; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase ABL |
Kd |
|
|
|
Average Binding Constant for ABL1(T315I); NA=Not Active at 10 uM |
CHEMBL1144455 |
| MAP kinase p38 beta |
Kd |
|
|
|
Average Binding Constant for p38-beta; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase ABL |
Kd |
|
|
|
Average Binding Constant for ABL1(M351T); NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ephrin type-A receptor 6 |
Kd |
|
|
|
Average Binding Constant for EPHA6; NA=Not Active at 10 uM |
CHEMBL1144455 |
| MAP kinase p38 alpha |
Kd |
|
|
|
Average Binding Constant for p38-alpha; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase FRK |
Kd |
|
|
|
Average Binding Constant for FRK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase ABL |
Kd |
|
|
|
Average Binding Constant for ABL1(Q252H); NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase ABL |
Kd |
|
|
|
Average Binding Constant for ABL1(Y253F); NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ephrin type-A receptor 7 |
Kd |
|
|
|
Average Binding Constant for EPHA7; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Stem cell growth factor receptor |
Kd |
|
|
|
Average Binding Constant for KIT; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ephrin type-A receptor 8 |
Kd |
|
|
|
Average Binding Constant for EPHA8; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase ABL |
Kd |
|
|
|
Average Binding Constant for ABL1(H396P); NA=Not Active at 10 uM |
CHEMBL1144455 |
| myosin light chain kinase 2 |
Kd |
|
|
|
Average Binding Constant for MYLK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase ABL2 |
Kd |
|
|
|
Average Binding Constant for ABL2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ephrin type-A receptor 4 |
Kd |
|
|
|
Average Binding Constant for EPHA4; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase 2 |
Kd |
|
|
|
Average Binding Constant for SLK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Mitogen-activated protein kinase kinase kinase kinase 5 |
Kd |
|
|
|
Average Binding Constant for MAP4K5; NA=Not Active at 10 uM |
CHEMBL1144455 |
| LIM domain kinase 1 |
Kd |
|
|
|
Average Binding Constant for LIMK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Fibroblast growth factor receptor 1 |
Kd |
|
|
|
Average Binding Constant for FGFR1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase RIPK2 |
Kd |
|
|
|
Average Binding Constant for RIPK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase TIE-2 |
Kd |
|
|
|
Average Binding Constant for TEK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Nerve growth factor receptor Trk-A |
Kd |
|
|
|
Average Binding Constant for NTRK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| c-Jun N-terminal kinase 2 |
Kd |
|
|
|
Average Binding Constant for JNK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ephrin type-B receptor 4 |
Kd |
|
|
|
Average Binding Constant for EPHB4; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase ABL |
Kd |
|
|
|
Average Binding Constant for ABL1(E255K); NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ephrin type-A receptor 2 |
Kd |
|
|
|
Average Binding Constant for EPHA2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase 36 |
Kd |
|
|
|
Average Binding Constant for STK36; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ephrin type-A receptor 3 |
Kd |
|
|
|
Average Binding Constant for EPHA3; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase LCK |
Kd |
|
|
|
Average Binding Constant for LCK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| MAP kinase p38 gamma |
Kd |
|
|
|
Average Binding Constant for p38-gamma; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase MST2 |
Kd |
|
|
|
Average Binding Constant for STK3_m; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase MST1 |
Kd |
|
|
|
Average Binding Constant for STK4; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Adaptor-associated kinase |
Kd |
|
|
|
Average Binding Constant for AAK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Death-associated protein kinase 3 |
Kd |
|
|
|
Average Binding Constant for DAPK3; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Ribosomal protein S6 kinase alpha 3 |
Kd |
|
|
|
Average Binding Constant for RPS6KA3 (Kin.Dom. 1); NA=Not Active at 10 uM |
CHEMBL1144455 |
| MAP/microtubule affinity-regulating kinase 2 |
Kd |
|
|
|
Average Binding Constant for MARK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| BMP-2-inducible protein kinase |
Kd |
|
|
|
Average Binding Constant for BIKE; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Death-associated protein kinase 2 |
Kd |
|
|
|
Average Binding Constant for DAPK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| CaM kinase I delta |
Kd |
|
|
|
Average Binding Constant for CAMK1D; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Phosphorylase kinase gamma subunit 1 |
Kd |
|
|
|
Average Binding Constant for PHkg1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase HCK |
Kd |
|
|
|
Average Binding Constant for HCK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase Aurora-C |
Kd |
|
|
|
Average Binding Constant for Aurora3; NA=Not Active at 10 uM |
CHEMBL1144455 |
| TRAF2- and NCK-interacting kinase |
Kd |
|
|
|
Average Binding Constant for TNIK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase JAK1 |
Kd |
|
|
|
Average Binding Constant for JAK1 (Kin.Dom. 1); NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase 17A |
Kd |
|
|
|
Average Binding Constant for STK17A; NA=Not Active at 10 uM |
CHEMBL1144455 |
| ULK3 kinase |
Kd |
|
|
|
Average Binding Constant for ULK3 m; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Insulin receptor |
Kd |
|
|
|
Average Binding Constant for INSR; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase YES |
Kd |
|
|
|
Average Binding Constant for YES; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase FGR |
Kd |
|
|
|
Average Binding Constant for FGR; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Fibroblast growth factor receptor 3 |
Kd |
|
|
|
Average Binding Constant for FGFR3; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase 16 |
Kd |
|
|
|
Average Binding Constant for STK16; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase NEK2 |
Kd |
|
|
|
Average Binding Constant for NEK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Fibroblast growth factor receptor 2 |
Kd |
|
|
|
Average Binding Constant for FGFR2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase Lyn |
Kd |
|
|
|
Average Binding Constant for LYN; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Focal adhesion kinase 1 |
Kd |
|
|
|
Average Binding Constant for PTK2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| CaM kinase II gamma |
Kd |
|
|
|
Average Binding Constant for CAMK2G; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase JAK2 |
Kd |
|
|
|
Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM |
CHEMBL1144455 |
| CaM kinase I gamma |
Kd |
|
|
|
Average Binding Constant for CAMK1G; NA=Not Active at 10 uM |
CHEMBL1144455 |
| CaM kinase II delta |
Kd |
|
|
|
Average Binding Constant for CAMK2D; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase FER |
Kd |
|
|
|
Average Binding Constant for FER; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase 38-like |
Kd |
|
|
|
Average Binding Constant for STK38L; NA=Not Active at 10 uM |
CHEMBL1144455 |
| CaM kinase I alpha |
Kd |
|
|
|
Average Binding Constant for CAMK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine kinase non-receptor protein 2 |
Kd |
|
|
|
Average Binding Constant for ACK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase SRC |
Kd |
|
|
|
Average Binding Constant for SRC; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Mitogen-activated protein kinase kinase kinase 4 |
Kd |
|
|
|
Average Binding Constant for MAP3K4; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase FYN |
Kd |
|
|
|
Average Binding Constant for FYN; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Protein kinase C alpha |
Kd |
|
|
|
Average Binding Constant for PRKACA; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase Aurora-A |
Kd |
|
|
|
Average Binding Constant for Aurora2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase BRK |
Kd |
|
|
|
Average Binding Constant for PTK6; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Epidermal growth factor receptor erbB1 |
Kd |
|
|
|
Average Binding Constant for EGFR; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Receptor protein-tyrosine kinase erbB-2 |
Kd |
|
|
|
Average Binding Constant for ERBB2; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine- and threonine-specific cdc2-inhibitory kinase |
Kd |
|
|
|
Average Binding Constant for PKMYT1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase SYK |
Kd |
|
|
|
Average Binding Constant for SYK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase BTK |
Kd |
|
|
|
Average Binding Constant for BTK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase PAK 1 |
Kd |
|
|
|
Average Binding Constant for PAK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase CSK |
Kd |
|
|
|
Average Binding Constant for CSK; NA=Not Active at 10 uM |
CHEMBL1144455 |
| c-Jun N-terminal kinase 3 |
Kd |
|
|
|
Average Binding Constant for JNK3; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase PAK 3 |
Kd |
|
|
|
Average Binding Constant for PAK3; NA=Not Active at 10 uM |
CHEMBL1144455 |
| c-Jun N-terminal kinase 1 |
Kd |
|
|
|
Average Binding Constant for JNK1; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Tyrosine-protein kinase BMX |
Kd |
|
|
|
Average Binding Constant for BMX; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase NEK9 |
Kd |
|
|
|
Average Binding Constant for NEK9; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Mitogen-activated protein kinase kinase kinase 5 |
Kd |
|
|
|
Average Binding Constant for MAP3K5; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase NEK6 |
Kd |
|
|
|
Average Binding Constant for NEK6; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase PAK6 |
Kd |
|
|
|
Average Binding Constant for PAK6; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase PAK7 |
Kd |
|
|
|
Average Binding Constant for PAK7/PAK5; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Serine/threonine-protein kinase PAK 4 |
Kd |
|
|
|
Average Binding Constant for PAK4; NA=Not Active at 10 uM |
CHEMBL1144455 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Inhibition |
= |
63.0 |
% |
Inhibition of mouse Dyrk1A autophosphorylation in HEk293 cells at 10 uM |
CHEMBL1138920 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
IC50 |
= |
5000.0 |
nM |
Inhibition of mouse Dyrk1A autophosphorylation in HEk293 cells |
CHEMBL1138920 |
| HT-29 |
Activity |
= |
48.0 |
% |
Cell cycle arrest in HT29 cells by accumulation at G0/G1 phase at 70 uM after 3 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
1.1 |
% |
Cell cycle arrest in HT29 cells by accumulation at S phase at 70 uM after 3 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
50.9 |
% |
Cell cycle arrest in HT29 cells by accumulation at G2/M phase at 70 uM after 3 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
44.0 |
% |
Cell cycle arrest in HT29 cells by accumulation at G0/G1 phase at 70 uM after 6 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
0.1 |
% |
Cell cycle arrest in HT29 cells by accumulation at S phase at 70 uM after 6 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
55.9 |
% |
Cell cycle arrest in HT29 cells by accumulation at G2/M phase at 70 uM after 6 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
64.5 |
% |
Cell cycle arrest in HT29 cells by accumulation at G0/G1 phase at 70 uM after 12 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
1.1 |
% |
Cell cycle arrest in HT29 cells by accumulation at S phase at 70 uM after 12 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
34.5 |
% |
Cell cycle arrest in HT29 cells by accumulation at G2/M phase at 70 uM after 12 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
|
|
|
Inhibition of GAPDH mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
3945095.0 |
|
Inhibition of GAPDH mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM after 3 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
3146605.0 |
|
Inhibition of GAPDH mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM after 6 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
3926015.0 |
|
Inhibition of GAPDH mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM after 12 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
|
|
|
Inhibition of CEA mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
30568.0 |
|
Inhibition of CEA mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM after 3 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
19150.0 |
|
Inhibition of CEA mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM after 6 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
24350.0 |
|
Inhibition of CEA mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM after 12 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
|
|
|
Inhibition of EpCAM mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
8258813.0 |
|
Inhibition of EpCAM mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM after 3 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
6151085.0 |
|
Inhibition of EpCAM mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM after 6 hrs |
CHEMBL1137343 |
| HT-29 |
Activity |
= |
6863365.0 |
|
Inhibition of EpCAM mRNA synthesis in HT29 cells measured as number of copies per 10^6 cells by RT PCR at 70 uM after 12 hrs |
CHEMBL1137343 |
| NON-PROTEIN TARGET |
IC50 |
= |
25000.0 |
nM |
Growth inhibition of human Granta519 cells after 72 hrs by TUNEL assay |
CHEMBL1145498 |
| NON-PROTEIN TARGET |
IC50 |
= |
50000.0 |
nM |
Growth inhibition of human NCEB1 cells after 72 hrs by TUNEL assay |
CHEMBL1145498 |
| ADMET |
IC50 |
= |
25000.0 |
nM |
Growth inhibition of human renal epithelial cells after 72 hrs by TUNEL assay |
CHEMBL1145498 |
| Unchecked |
IC50 |
= |
650.0 |
nM |
Inhibition of Cdk1/cyclin B |
CHEMBL1145498 |
| Unchecked |
IC50 |
= |
700.0 |
nM |
Inhibition Cdk2/cyclin A |
CHEMBL1145498 |
| Unchecked |
IC50 |
= |
700.0 |
nM |
Inhibition of Cdk2/ cyclin E |
CHEMBL1145498 |
| Unchecked |
IC50 |
= |
200.0 |
nM |
Inhibition of Cdk5/p35 |
CHEMBL1145498 |
| MAP kinase ERK1 |
IC50 |
= |
34000.0 |
nM |
Inhibition of ERK1 |
CHEMBL1145498 |
| MAP kinase ERK2 |
IC50 |
= |
14000.0 |
nM |
Inhibition of ERK2 |
CHEMBL1145498 |
| NON-PROTEIN TARGET |
IC50 |
= |
25000.0 |
nM |
Growth inhibition of human JeKo-1 MCL cells after 72 hrs by TUNEL assay |
CHEMBL1145498 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
200.0 |
nM |
Inhibition of Cdc2 |
CHEMBL1150819 |
| Unchecked |
IC50 |
= |
450.0 |
nM |
Inhibition of starfish oocyte CDK1/cyclin B |
CHEMBL1149828 |
| Unchecked |
IC50 |
= |
160.0 |
nM |
Inhibition of human recombinant CDK5/p25 |
CHEMBL1149828 |
| Glycogen synthase kinase-3 |
IC50 |
> |
100000.0 |
nM |
Inhibition of pig brain GSK3alpha/beta |
CHEMBL1149828 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
IC50 |
= |
18000.0 |
nM |
Inhibition of human recombinant DYRK1A |
CHEMBL1149828 |
| Unchecked |
IC50 |
= |
20000.0 |
nM |
Inhibition of pig brain CK1 |
CHEMBL1149828 |
| Unchecked |
IC50 |
= |
450.0 |
nM |
Inhibition of cyclin dependent kinase |
CHEMBL1149915 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
100.0 |
nM |
Binding affinity to CDK2 |
CHEMBL1156625 |
| Unchecked |
IC50 |
= |
350.0 |
nM |
Inhibition of starfish oocyte CDK1/cyclin B by scintillation method |
CHEMBL1139411 |
| Unchecked |
IC50 |
= |
200.0 |
nM |
Inhibition of human recombinant CDK5/p25 by scintillation method |
CHEMBL1139411 |
| Glycogen synthase kinase-3 |
IC50 |
> |
10000.0 |
nM |
Inhibition of pig brain GSK3alpha/beta |
CHEMBL1139411 |
| Unchecked |
IC50 |
= |
2300.0 |
nM |
Inhibition of pig brain CK1 |
CHEMBL1139411 |
| SH-SY5Y |
IC50 |
= |
17500.0 |
nM |
Antiproliferative activity against human SH-SY5Y cells assessed as survival after 48 hrs by MTS reduction assay |
CHEMBL1139411 |
| HEK293 |
IC50 |
= |
46700.0 |
nM |
Antiproliferative activity against HEK293 cells assessed as survival after 48 hrs by MTS reduction assay |
CHEMBL1139411 |
| Casein kinase I alpha |
Activity |
|
|
|
Inhibition of CK1 in mouse N2A cells assessed as inhibition of amyloid beta production by sandwich ELISA |
CHEMBL1139411 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
IC50 |
= |
5000.0 |
nM |
Inhibition of Dyrk1 autophosphorylation |
CHEMBL1153959 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Inhibition |
= |
63.0 |
% |
Inhibition of Dyrk1 at 10 uM |
CHEMBL1153959 |
| Unchecked |
IC50 |
= |
330.0 |
nM |
Inhibition of starfish oocytes CDK1/cyclin B |
CHEMBL1143353 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
220.0 |
nM |
Inhibition of human recombinant CDK2/cyclin A expressed in baculovirus-infected insect cells |
CHEMBL1143353 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
270.0 |
nM |
Inhibition of human recombinant CDK5/p25 expressed in Escherichia coli |
CHEMBL1143353 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
800.0 |
nM |
Inhibition of human recombinant CDK7/cyclin H expressed in baculovirus-infected insect cells |
CHEMBL1143353 |
| CDK9/cyclin T1 |
IC50 |
= |
230.0 |
nM |
Inhibition of human recombinant CDK9/cyclin T expressed in baculovirus-infected insect cells |
CHEMBL1143353 |
| SH-SY5Y |
IC50 |
= |
16100.0 |
nM |
Antiproliferative activity against human SH-SY5Y cells after 48 hrs by MTS reduction assay |
CHEMBL1143353 |
| HEK293 |
IC50 |
= |
48900.0 |
nM |
Antiproliferative activity against human HEK293 cells after 48 hrs by MTS reduction assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
Activity |
= |
73.0 |
% |
Antitumor activity against human A4573 cells xenografted athymic nude BALB/c mouse as inhibition of tumor growth at 50 mg/kg, ip daily for 5 days measured after 8 days |
CHEMBL1143353 |
| CCRF-CEM |
GI50 |
= |
100000.0 |
nM |
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CCRF-CEM |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| K562 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MOLT-4 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human RPMI8266 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SR |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A549 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-62 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-92 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H226 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H322M |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H460 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCC 2998 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-116 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-15 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HT-29 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SW-620 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-268 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-295 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-75 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| U-251 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| Malme-3M |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UACC-62 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| IGROV-1 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-3 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-5 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-OV-3 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| 786-0 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| ACHN |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CAKI-1 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| RXF 393 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| TK-10 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| PC-3 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| DU-145 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MCF7 |
TGI |
= |
100000.0 |
nM |
Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CCRF-CEM |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| K562 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MOLT-4 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human RPMI8266 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SR |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A549 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| EKVX |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-62 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-92 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H226 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H23 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H322M |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H460 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H522 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| COLO 205 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCC 2998 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-116 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-15 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HT-29 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| KM12 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SW-620 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-268 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-295 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-539 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-19 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SNB19 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-75 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| U-251 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| LOX IMVI |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| Malme-3M |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-2 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-5 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UACC-62 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| IGROV-1 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-3 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-4 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-5 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-OV-3 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| 786-0 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A498 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| ACHN |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CAKI-1 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| RXF 393 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| TK-10 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UO-31 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| PC-3 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| DU-145 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MCF7 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| T47D |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-468 |
LC50 |
= |
100000.0 |
nM |
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SW-620 |
GI50 |
= |
79432.82 |
nM |
Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| 786-0 |
GI50 |
= |
79432.82 |
nM |
Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-539 |
TGI |
= |
79432.82 |
nM |
Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A498 |
TGI |
= |
79432.82 |
nM |
Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| T47D |
TGI |
= |
79432.82 |
nM |
Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| M14 |
LC50 |
= |
79432.82 |
nM |
Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-231 |
LC50 |
= |
79432.82 |
nM |
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UO-31 |
GI50 |
= |
63095.73 |
nM |
Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H522 |
TGI |
= |
63095.73 |
nM |
Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| KM12 |
TGI |
= |
63095.73 |
nM |
Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-4 |
TGI |
= |
63095.73 |
nM |
Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UO-31 |
TGI |
= |
63095.73 |
nM |
Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| K562 |
GI50 |
= |
50118.72 |
nM |
Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-92 |
GI50 |
= |
50118.72 |
nM |
Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-75 |
GI50 |
= |
50118.72 |
nM |
Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| ACHN |
GI50 |
= |
50118.72 |
nM |
Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| EKVX |
TGI |
= |
50118.72 |
nM |
Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H23 |
TGI |
= |
50118.72 |
nM |
Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| LOX IMVI |
TGI |
= |
50118.72 |
nM |
Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| M14 |
TGI |
= |
50118.72 |
nM |
Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-5 |
GI50 |
= |
39810.72 |
nM |
Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| T47D |
GI50 |
= |
39810.72 |
nM |
Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-2 |
TGI |
= |
39810.72 |
nM |
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H322M |
GI50 |
= |
31622.78 |
nM |
Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCC 2998 |
GI50 |
= |
31622.78 |
nM |
Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-4 |
GI50 |
= |
31622.78 |
nM |
Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| COLO 205 |
TGI |
= |
31622.78 |
nM |
Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-19 |
TGI |
= |
31622.78 |
nM |
Antiproliferative activity against human SNB19 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-5 |
TGI |
= |
31622.78 |
nM |
Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MOLT-4 |
GI50 |
= |
25118.86 |
nM |
Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
GI50 |
= |
25118.86 |
nM |
Antiproliferative activity against human RPMI8266 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-62 |
GI50 |
= |
25118.86 |
nM |
Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H460 |
GI50 |
= |
25118.86 |
nM |
Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-295 |
GI50 |
= |
25118.86 |
nM |
Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| Malme-3M |
GI50 |
= |
25118.86 |
nM |
Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A498 |
GI50 |
= |
25118.86 |
nM |
Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MCF7 |
GI50 |
= |
25118.86 |
nM |
Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-468 |
GI50 |
= |
25118.86 |
nM |
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
GI50 |
= |
19952.62 |
nM |
Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| EKVX |
GI50 |
= |
19952.62 |
nM |
Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H226 |
GI50 |
= |
19952.62 |
nM |
Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-15 |
GI50 |
= |
19952.62 |
nM |
Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HT-29 |
GI50 |
= |
19952.62 |
nM |
Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-268 |
GI50 |
= |
19952.62 |
nM |
Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| LOX IMVI |
GI50 |
= |
19952.62 |
nM |
Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| DU-145 |
GI50 |
= |
19952.62 |
nM |
Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H522 |
GI50 |
= |
15848.93 |
nM |
Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-539 |
GI50 |
= |
15848.93 |
nM |
Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-2 |
GI50 |
= |
15848.93 |
nM |
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A549 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H23 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| COLO 205 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-19 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human SNB19 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| U-251 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| M14 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-3 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CAKI-1 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| PC-3 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-231 |
GI50 |
= |
12589.25 |
nM |
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-231 |
TGI |
= |
12589.25 |
nM |
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| RXF 393 |
GI50 |
= |
5000.0 |
nM |
Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-5 |
GI50 |
= |
10000.0 |
nM |
Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SR |
GI50 |
= |
5010.0 |
nM |
Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-116 |
GI50 |
= |
5010.0 |
nM |
Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| KM12 |
GI50 |
= |
5010.0 |
nM |
Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UACC-62 |
GI50 |
= |
7943.28 |
nM |
Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| IGROV-1 |
GI50 |
= |
6309.57 |
nM |
Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-OV-3 |
GI50 |
= |
6309.57 |
nM |
Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| RXF 393 |
GI50 |
= |
6309.57 |
nM |
Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SR |
GI50 |
= |
5011.87 |
nM |
Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-116 |
GI50 |
= |
5011.87 |
nM |
Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| KM12 |
GI50 |
= |
5011.87 |
nM |
Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| TK-10 |
GI50 |
= |
5011.87 |
nM |
Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| IGROV-1 |
GI50 |
= |
6300.0 |
nM |
Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CAKI-1 |
GI50 |
= |
6300.0 |
nM |
Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI/ADR-RES |
GI50 |
= |
6300.0 |
nM |
Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UACC-62 |
GI50 |
= |
7900.0 |
nM |
Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-5 |
GI50 |
= |
10000.0 |
nM |
Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A549 |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H23 |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| COLO 205 |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-75 |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| LOX IMVI |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-3 |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| ACHN |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UO-31 |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MCF7 |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-435 |
GI50 |
= |
12600.0 |
nM |
Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
TGI |
= |
12600.0 |
nM |
Antiproliferative activity against human Hs 578T cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
GI50 |
= |
12800.0 |
nM |
Antiproliferative activity against human Hs 578T cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H522 |
GI50 |
= |
15800.0 |
nM |
Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-539 |
GI50 |
= |
15800.0 |
nM |
Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-2 |
GI50 |
= |
15800.0 |
nM |
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| DU-145 |
GI50 |
= |
15800.0 |
nM |
Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| T47D |
GI50 |
= |
16800.0 |
nM |
Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
GI50 |
= |
19300.0 |
nM |
Antitumor activity against human A4573 cells xenografted athymic nude BALB/c mouse as inhibition of tumor growth at 50 mg/kg, ip daily for 5 days measured after 8 days |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
GI50 |
= |
19900.0 |
nM |
Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| EKVX |
GI50 |
= |
19900.0 |
nM |
Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H226 |
GI50 |
= |
19900.0 |
nM |
Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-15 |
GI50 |
= |
19900.0 |
nM |
Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HT-29 |
GI50 |
= |
19900.0 |
nM |
Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-268 |
GI50 |
= |
19900.0 |
nM |
Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| Malme-3M |
GI50 |
= |
19900.0 |
nM |
Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| PC-3 |
GI50 |
= |
19900.0 |
nM |
Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MOLT-4 |
GI50 |
= |
25100.0 |
nM |
Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
GI50 |
= |
25100.0 |
nM |
Antiproliferative activity against human RPMI8266 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-62 |
GI50 |
= |
25100.0 |
nM |
Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H460 |
GI50 |
= |
25100.0 |
nM |
Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-295 |
GI50 |
= |
25100.0 |
nM |
Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| M14 |
GI50 |
= |
25100.0 |
nM |
Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| 786-0 |
GI50 |
= |
25100.0 |
nM |
Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H322M |
GI50 |
= |
31600.0 |
nM |
Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCC 2998 |
GI50 |
= |
31600.0 |
nM |
Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-4 |
GI50 |
= |
31600.0 |
nM |
Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| COLO 205 |
TGI |
= |
31600.0 |
nM |
Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-75 |
TGI |
= |
31600.0 |
nM |
Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-5 |
TGI |
= |
31600.0 |
nM |
Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UACC-62 |
TGI |
= |
31600.0 |
nM |
Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-5 |
GI50 |
= |
39800.0 |
nM |
Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-231 |
GI50 |
= |
39800.0 |
nM |
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-2 |
TGI |
= |
39800.0 |
nM |
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| K562 |
GI50 |
= |
50100.0 |
nM |
Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-92 |
GI50 |
= |
50100.0 |
nM |
Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| U-251 |
GI50 |
= |
50100.0 |
nM |
Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A498 |
GI50 |
= |
50100.0 |
nM |
Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| EKVX |
TGI |
= |
50100.0 |
nM |
Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H23 |
TGI |
= |
50100.0 |
nM |
Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| Malme-3M |
TGI |
= |
50100.0 |
nM |
Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-435 |
TGI |
= |
50100.0 |
nM |
Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| TK-10 |
GI50 |
= |
63100.0 |
nM |
Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H522 |
TGI |
= |
63100.0 |
nM |
Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| KM12 |
TGI |
= |
63100.0 |
nM |
Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| PC-3 |
TGI |
= |
63100.0 |
nM |
Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI/ADR-RES |
TGI |
= |
63100.0 |
nM |
Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
TGI |
= |
78300.0 |
nM |
Antitumor activity against human A4573 cells xenografted athymic nude BALB/c mouse as inhibition of tumor growth at 50 mg/kg, ip daily for 5 days measured after 8 days |
CHEMBL1143353 |
| SW-620 |
GI50 |
= |
79400.0 |
nM |
Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-OV-3 |
GI50 |
= |
79400.0 |
nM |
Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-539 |
TGI |
= |
79400.0 |
nM |
Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| ACHN |
TGI |
= |
79400.0 |
nM |
Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| T47D |
TGI |
= |
79400.0 |
nM |
Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-5 |
LC50 |
= |
79400.0 |
nM |
Antiproliferative activity against human SK-MEL-5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
LC50 |
= |
79400.0 |
nM |
Antiproliferative activity against human Hs 578T cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
LC50 |
= |
99400.0 |
nM |
Antitumor activity against human A4573 cells xenografted athymic nude BALB/c mouse as inhibition of tumor growth at 50 mg/kg, ip daily for 5 days measured after 8 days |
CHEMBL1143353 |
| CCRF-CEM |
GI50 |
> |
100000.0 |
nM |
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CCRF-CEM |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| K562 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MOLT-4 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human RPMI8266 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SR |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A549 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-62 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-92 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H226 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H322M |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H460 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCC 2998 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-116 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-15 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HT-29 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SW-620 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-268 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-295 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| U-251 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| LOX IMVI |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| M14 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| IGROV-1 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-3 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-4 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-5 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-OV-3 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| 786-0 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A498 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CAKI-1 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| RXF 393 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| TK-10 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UO-31 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| DU-145 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MCF7 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-231 |
TGI |
> |
100000.0 |
nM |
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CCRF-CEM |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human CCRF-CEM cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human HL60(TB) cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| K562 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human K562 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MOLT-4 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human MOLT4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human RPMI8266 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SR |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human SR cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A549 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human A549 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| EKVX |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human EKVX cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-62 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human HOP62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HOP-92 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human HOP92 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H226 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human NCI-H226 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H23 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human NCI-H23 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H322M |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human NCI-H322M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H460 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human NCI-H460 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI-H522 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human NCI-H522 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| COLO 205 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human COLO205 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCC 2998 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human HCC2998 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-116 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human HCT116 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HCT-15 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human HCT15 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| HT-29 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human HT29 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| KM12 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human KM12 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SW-620 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human SW620 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-268 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human SF268 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-295 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human SF295 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SF-539 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human SF539 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-75 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human SNB75 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| U-251 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human U251 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| LOX IMVI |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human LOXIMVI cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| Malme-3M |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human MALME-3M cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| M14 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human M14 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-2 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UACC-62 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human UACC62 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| IGROV-1 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human IGROV1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-3 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-4 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human OVCAR4 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-5 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human OVCAR5 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-OV-3 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human SKOV3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| 786-0 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human 786-0 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| A498 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human A498 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| ACHN |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human ACHN cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| CAKI-1 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human Caki1 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| RXF 393 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human RFX393 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| TK-10 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human TK10 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UO-31 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human UO31 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| PC-3 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human PC3 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| DU-145 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human DU145 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MCF7 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human MCF7 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NCI/ADR-RES |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human NCI/ADR-RES cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-231 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-435 |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human MDA-MB-435 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| T47D |
LC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human T47D cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-28 |
GI50 |
|
|
|
Antiproliferative activity against human SK-MEL-28 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UACC-257 |
GI50 |
|
|
|
Antiproliferative activity against human UACC257 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-8 |
GI50 |
|
|
|
Antiproliferative activity against human OVCAR8 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SN12C |
GI50 |
|
|
|
Antiproliferative activity against human SN12C cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| BT-549 |
GI50 |
|
|
|
Antiproliferative activity against human BT549 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-468 |
GI50 |
|
|
|
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-19 |
TGI |
|
|
|
Antiproliferative activity against human SNB19 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-28 |
TGI |
|
|
|
Antiproliferative activity against human SK-MEL-28 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UACC-257 |
TGI |
|
|
|
Antiproliferative activity against human UACC257 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-8 |
TGI |
|
|
|
Antiproliferative activity against human OVCAR8 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SN12C |
TGI |
|
|
|
Antiproliferative activity against human SN12C cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| BT-549 |
TGI |
|
|
|
Antiproliferative activity against human BT549 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-468 |
TGI |
|
|
|
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-19 |
LC50 |
|
|
|
Antiproliferative activity against human SNB19 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SK-MEL-28 |
LC50 |
|
|
|
Antiproliferative activity against human SK-MEL-28 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| UACC-257 |
LC50 |
|
|
|
Antiproliferative activity against human UACC257 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| OVCAR-8 |
LC50 |
|
|
|
Antiproliferative activity against human OVCAR8 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SN12C |
LC50 |
|
|
|
Antiproliferative activity against human SN12C cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| BT-549 |
LC50 |
|
|
|
Antiproliferative activity against human BT549 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| MDA-MB-468 |
LC50 |
|
|
|
Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| SNB-19 |
GI50 |
|
|
|
Antiproliferative activity against human SNB19 cells after 72 hrs by ViaLight assay |
CHEMBL1143353 |
| NON-PROTEIN TARGET |
Activity |
= |
73.0 |
% |
Antitumor activity against human A4573 cells xenografted athymic nude BALB/c mouse as inhibition of tumor growth at 50 mg/kg, ip daily for 5 days measured after 8 days |
CHEMBL1143353 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
450.0 |
nM |
Inhibition of CDK1/cyclinB |
CHEMBL1140958 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
160.0 |
nM |
Inhibition of CDK5/p25 |
CHEMBL1140958 |
| Glycogen synthase kinase-3 |
IC50 |
= |
130000.0 |
nM |
Inhibition of GSK3alpha/beta |
CHEMBL1140958 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
370.0 |
nM |
Inhibition of CDK2/Cyclin A by radiometric assay |
CHEMBL1156543 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
700.0 |
nM |
Inhibition of CDK2/Cyclin A |
CHEMBL1154450 |
| Tyrosine-protein kinase receptor FLT3 |
Kd |
> |
10000.0 |
nM |
Binding constant for FLT3(ITD) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase receptor FLT3 |
Kd |
> |
10000.0 |
nM |
Binding constant for FLT3(N841I) kinase domain |
CHEMBL1150977 |
| Vascular endothelial growth factor receptor 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for FLT4 kinase domain |
CHEMBL1150977 |
| MAP kinase p38 gamma |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length p38-gamma |
CHEMBL1150977 |
| Serine/threonine-protein kinase PAK 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PAK3 |
CHEMBL1150977 |
| Serine/threonine-protein kinase PCTAIRE-2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PCTK2 |
CHEMBL1150977 |
| Serine/threonine-protein kinase PCTAIRE-3 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PCTK3 |
CHEMBL1150977 |
| 3-phosphoinositide dependent protein kinase-1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PDPK1 |
CHEMBL1150977 |
| Serine/threonine-protein kinase PFTAIRE-1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PFTK1 |
CHEMBL1150977 |
| Phosphorylase kinase gamma subunit 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PHKG1 |
CHEMBL1150977 |
| Phosphatidylinositol-4-phosphate 5-kinase type-1 alpha |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PIP5K1A |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 6 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA6(Kin.Dom.1 - C-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 6 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA6(Kin.Dom.2 - N-terminal) kinase domain |
CHEMBL1150977 |
| Myosin light chain kinase family member 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for SgK085 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase receptor TYRO3 |
Kd |
> |
10000.0 |
nM |
Binding constant for TYRO3 kinase domain |
CHEMBL1150977 |
| Vascular endothelial growth factor receptor 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for VEGFR2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase WEE1 |
Kd |
> |
10000.0 |
nM |
Binding constant for WEE1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase 32C |
Kd |
> |
10000.0 |
nM |
Binding constant for YANK3 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase YES |
Kd |
> |
10000.0 |
nM |
Binding constant for YES kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase 25 |
Kd |
> |
10000.0 |
nM |
Binding constant for YSK1 kinase domain |
CHEMBL1150977 |
| Mixed lineage kinase 7 |
Kd |
> |
10000.0 |
nM |
Binding constant for ZAK kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ZAP-70 |
Kd |
> |
10000.0 |
nM |
Binding constant for ZAP70 kinase domain |
CHEMBL1150977 |
| Rho-associated protein kinase 2 |
Activity |
= |
90.0 |
% |
Percentage ROCK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Ribosomal protein S6 kinase alpha 1 |
Activity |
= |
97.0 |
% |
Percentage RSK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase p38 beta |
Activity |
= |
94.0 |
% |
Percentage p38beta MAPK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase p38 delta |
Activity |
= |
92.0 |
% |
Percentage p38delta MAPK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase p38 gamma |
Activity |
= |
99.0 |
% |
Percentage p38-gamma MAPK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PAK 4 |
Activity |
= |
90.0 |
% |
Percentage PAK4 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Phosphatidylinositol-5-phosphate 4-kinase type-2 beta |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PIP5K2B |
CHEMBL1150977 |
| cAMP-dependent protein kinase beta-1 catalytic subunit |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PKAC-beta |
CHEMBL1150977 |
| Serine/threonine-protein kinase PRKX |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PRKX |
CHEMBL1150977 |
| Protein tyrosine kinase 2 beta |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length PTK2B |
CHEMBL1150977 |
| Dual specificty protein kinase CLK1 |
Kd |
= |
1200.0 |
nM |
Binding constant for full-length CLK1 |
CHEMBL1150977 |
| Dual specificity protein kinase CLK3 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length CLK3 |
CHEMBL1150977 |
| Tyrosine-protein kinase CSK |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length CSK |
CHEMBL1150977 |
| Casein kinase I isoform alpha-like |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length CSNK1A1L |
CHEMBL1150977 |
| Casein kinase I delta |
Kd |
= |
260.0 |
nM |
Binding constant for full-length CSNK1D |
CHEMBL1150977 |
| Casein kinase I epsilon |
Kd |
= |
320.0 |
nM |
Binding constant for full-length CSNK1E |
CHEMBL1150977 |
| Casein kinase I gamma 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length CSNK1G2 |
CHEMBL1150977 |
| Cyclin-dependent kinase 2 |
Selectivity |
= |
0.0313 |
|
Selectivity for CDK2 as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0 |
CHEMBL1150977 |
| Tyrosine-protein kinase receptor Tie-1 |
Kd |
> |
10000.0 |
nM |
Binding constant for TIE1 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase TIE-2 |
Kd |
> |
10000.0 |
nM |
Binding constant for TIE2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase tousled-like 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for TLK1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase tousled-like 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for TLK2 kinase domain |
CHEMBL1150977 |
| TRAF2- and NCK-interacting kinase |
Kd |
> |
10000.0 |
nM |
Binding constant for TNIK kinase domain |
CHEMBL1150977 |
| Tyrosine kinase non-receptor protein 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for TNK2 kinase domain |
CHEMBL1150977 |
| Nerve growth factor receptor Trk-A |
Kd |
> |
10000.0 |
nM |
Binding constant for TRKA kinase domain |
CHEMBL1150977 |
| Neurotrophic tyrosine kinase receptor type 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for TRKB kinase domain |
CHEMBL1150977 |
| NT-3 growth factor receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for TRKC kinase domain |
CHEMBL1150977 |
| Dual specificity protein kinase TTK |
Kd |
= |
1600.0 |
nM |
Binding constant for TTK kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PAK7 |
Activity |
= |
74.0 |
% |
Percentage PAK5 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PAK6 |
Activity |
= |
80.0 |
% |
Percentage PAK6 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| 3-phosphoinositide dependent protein kinase-1 |
Activity |
= |
80.0 |
% |
Percentage PDK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Unchecked |
Activity |
= |
93.0 |
% |
Percentage PHK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PIM1 |
Activity |
= |
83.0 |
% |
Percentage PIM1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Casein kinase I isoform gamma-3 |
Kd |
= |
2900.0 |
nM |
Binding constant for full-length CSNK1G3 |
CHEMBL1150977 |
| Casein kinase II alpha |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length CSNK2A1 |
CHEMBL1150977 |
| Casein kinase II alpha (prime) |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length CSNK2A2 |
CHEMBL1150977 |
| Death-associated protein kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length DAPK2 |
CHEMBL1150977 |
| Death-associated protein kinase 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length DLK |
CHEMBL1150977 |
| Serine/threonine-protein kinase 17B |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length DRAK2 |
CHEMBL1150977 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1B |
Kd |
= |
1100.0 |
nM |
Binding constant for full-length DYRK1B |
CHEMBL1150977 |
| MAP kinase ERK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length ERK1 |
CHEMBL1150977 |
| MAP kinase ERK2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length ERK2 |
CHEMBL1150977 |
| Glycogen synthase kinase-3 alpha |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length GSK3A |
CHEMBL1150977 |
| Glycogen synthase kinase-3 beta |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length GSK3B |
CHEMBL1150977 |
| Inhibitor of nuclear factor kappa B kinase epsilon subunit |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length IKK-epsilon |
CHEMBL1150977 |
| Tyrosine-protein kinase TXK |
Kd |
> |
10000.0 |
nM |
Binding constant for TXK kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase TYK2 |
Kd |
> |
10000.0 |
nM |
Binding constant for TYK2(Kin.Dom.2/JH1 - catalytic) kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PIM2 |
Activity |
= |
106.0 |
% |
Percentage PIM2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PIM3 |
Activity |
= |
83.0 |
% |
Percentage PIM3 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| cAMP-dependent protein kinase alpha-catalytic subunit |
Activity |
= |
73.0 |
% |
Percentage PKA activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase AKT |
Activity |
= |
100.0 |
% |
Percentage PKBalpha activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase AKT2 |
Activity |
= |
83.0 |
% |
Percentage PKBbeta activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| c-Jun N-terminal kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length JNK1 |
CHEMBL1150977 |
| c-Jun N-terminal kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length JNK2 |
CHEMBL1150977 |
| LIM domain kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length LIMK1 |
CHEMBL1150977 |
| LIM domain kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length LIMK2 |
CHEMBL1150977 |
| Serine/threonine-protein kinase 11 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length LKB1 |
CHEMBL1150977 |
| Serine/threonine-protein kinase c-TAK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length MARK3 |
CHEMBL1150977 |
| Dual specificity mitogen-activated protein kinase kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length MEK1 |
CHEMBL1150977 |
| Dual specificity mitogen-activated protein kinase kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length MEK2 |
CHEMBL1150977 |
| Dual specificity mitogen-activated protein kinase kinase 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length MEK3 |
CHEMBL1150977 |
| Maternal embryonic leucine zipper kinase |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length MELK |
CHEMBL1150977 |
| MAP kinase-interacting serine/threonine-protein kinase MNK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length MKNK1 |
CHEMBL1150977 |
| Protein kinase C alpha |
Activity |
= |
89.0 |
% |
Percentage PKCalpha activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Protein kinase C zeta |
Activity |
= |
82.0 |
% |
Percentage PKCzeta activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Protein kinase C mu |
Activity |
= |
90.0 |
% |
Percentage PKD1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase SRPK1 |
Activity |
= |
84.0 |
% |
Percentage SRPK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Adaptor-associated kinase |
Kd |
> |
10000.0 |
nM |
Binding constant for AAK1 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ABL |
Kd |
> |
10000.0 |
nM |
Binding constant for ABL1 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ABL |
Kd |
> |
10000.0 |
nM |
Binding constant for ABL1(E255K) kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase MST1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length MST1 |
CHEMBL1150977 |
| Serine/threonine-protein kinase MST4 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length MST4 |
CHEMBL1150977 |
| Serine/threonine-protein kinase NEK7 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length NEK7 |
CHEMBL1150977 |
| Serine/threonine protein kinase NLK |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length NLK |
CHEMBL1150977 |
| MAP kinase p38 alpha |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length p38-alpha |
CHEMBL1150977 |
| MAP kinase p38 beta |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length p38-beta |
CHEMBL1150977 |
| Eukaryotic translation initiation factor 2-alpha kinase 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase HCK |
Kd |
> |
10000.0 |
nM |
Binding constant for HCK kinase domain |
CHEMBL1150977 |
| Insulin-like growth factor I receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for IGF1R kinase domain |
CHEMBL1150977 |
| Insulin receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for INSR kinase domain |
CHEMBL1150977 |
| Insulin receptor-related protein |
Kd |
> |
10000.0 |
nM |
Binding constant for INSRR kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ABL |
Kd |
> |
10000.0 |
nM |
Binding constant for ABL1(H396P) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ABL |
Kd |
> |
10000.0 |
nM |
Binding constant for ABL1(M351T) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ABL |
Kd |
> |
10000.0 |
nM |
Binding constant for ABL1(Q252H) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ABL |
Kd |
> |
10000.0 |
nM |
Binding constant for ABL1(T315I) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ABL |
Kd |
> |
10000.0 |
nM |
Binding constant for ABL1(Y253F) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ABL2 |
Kd |
> |
10000.0 |
nM |
Binding constant for ABL2 kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 3 |
Activity |
= |
71.0 |
% |
Percentage RSK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Ribosomal protein S6 kinase 1 |
Activity |
= |
90.0 |
% |
Percentage S6K1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Interleukin-1 receptor-associated kinase 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for IRAK3 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase ITK/TSK |
Kd |
> |
10000.0 |
nM |
Binding constant for ITK kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase JAK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for JAK1(Kin.Dom.1/JH2 - pseudokinase) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase JAK2 |
Kd |
> |
10000.0 |
nM |
Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase JAK3 |
Kd |
> |
10000.0 |
nM |
Binding constant for JAK3(Kin.Dom.2/JH1 - catalytic) kinase domain |
CHEMBL1150977 |
| c-Jun N-terminal kinase 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for JNK3 kinase domain |
CHEMBL1150977 |
| Stem cell growth factor receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for KIT kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase RIO1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length RIOK1 |
CHEMBL1150977 |
| Serine/threonine-protein kinase RIO3 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length RIOK3 |
CHEMBL1150977 |
| Serine/threonine-protein kinase SIK2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length SNF1LK2 |
CHEMBL1150977 |
| Serine/threonine-protein kinase SRPK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length SRPK1 |
CHEMBL1150977 |
| Serine/threonine-protein kinase Sgk1 |
Activity |
= |
75.0 |
% |
Percentage SGK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Myosin light chain kinase, smooth muscle |
Activity |
= |
84.0 |
% |
Percentage SmMLCK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Tyrosine-protein kinase SRC |
Activity |
= |
89.0 |
% |
Percentage Src activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Activin receptor type-1 |
Kd |
> |
10000.0 |
nM |
Binding constant for ACVR1 kinase domain |
CHEMBL1150977 |
| Activin receptor type-1B |
Kd |
> |
10000.0 |
nM |
Binding constant for ACVR1B kinase domain |
CHEMBL1150977 |
| Activin receptor type-2A |
Kd |
> |
10000.0 |
nM |
Binding constant for ACVR2A kinase domain |
CHEMBL1150977 |
| Activin receptor type-2B |
Kd |
> |
10000.0 |
nM |
Binding constant for ACVR2B kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase SRPK2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length SRPK2 |
CHEMBL1150977 |
| Serine/threonine-protein kinase 33 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length STK33 |
CHEMBL1150977 |
| Non-receptor tyrosine-protein kinase TNK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length TNK1 |
CHEMBL1150977 |
| Serine/threonine-protein kinase TNNI3K |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length TNNI3K |
CHEMBL1150977 |
| Testis-specific serine/threonine-protein kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length TSSK1 |
CHEMBL1150977 |
| Serine/threonine-protein kinase 32B |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length YANK2 |
CHEMBL1150977 |
| Tyrosine-protein kinase FYN |
Kd |
> |
10000.0 |
nM |
Binding constant for FYN kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase GAK |
Kd |
> |
10000.0 |
nM |
Binding constant for GAK kinase domain |
CHEMBL1150977 |
| Stem cell growth factor receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for KIT(D816V) kinase domain |
CHEMBL1150977 |
| Stem cell growth factor receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for KIT(V559D,T670I) kinase domain |
CHEMBL1150977 |
| Stem cell growth factor receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for KIT(V559D,V654A) kinase domain |
CHEMBL1150977 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
140.0 |
nM |
Inhibition of CDK2-cyclinA in the presence of 20uM ATP |
CHEMBL1150976 |
| Serine/threonine-protein kinase PAK 4 |
IC50 |
= |
6900.0 |
nM |
Inhibition of PAK4 in the presence of 5uM ATP |
CHEMBL1150976 |
| ALK tyrosine kinase receptor |
Kd |
= |
2300.0 |
nM |
Binding constant for ALK kinase domain |
CHEMBL1150977 |
| AMP-activated protein kinase, alpha-1 subunit |
Kd |
> |
10000.0 |
nM |
Binding constant for AMPK-alpha1 kinase domain |
CHEMBL1150977 |
| AMP-activated protein kinase, alpha-2 subunit |
Kd |
> |
10000.0 |
nM |
Binding constant for AMPK-alpha2 kinase domain |
CHEMBL1150977 |
| Epithelial discoidin domain-containing receptor 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for DDR1 kinase domain |
CHEMBL1150977 |
| Discoidin domain-containing receptor 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for DDR2 kinase domain |
CHEMBL1150977 |
| Myotonin-protein kinase |
Kd |
> |
10000.0 |
nM |
Binding constant for DMPK kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase receptor R3 |
Kd |
> |
10000.0 |
nM |
Binding constant for ACVRL1 kinase domain |
CHEMBL1150977 |
| Chaperone activity of bc1 complex-like, mitochondrial |
Kd |
> |
10000.0 |
nM |
Binding constant for ADCK3 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase AKT |
Kd |
> |
10000.0 |
nM |
Binding constant for AKT1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase AKT2 |
Kd |
> |
10000.0 |
nM |
Binding constant for AKT2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase AKT3 |
Kd |
> |
10000.0 |
nM |
Binding constant for AKT3 kinase domain |
CHEMBL1150977 |
| Stem cell growth factor receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for KIT(V559D) kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase LATS1 |
Kd |
> |
10000.0 |
nM |
Binding constant for LATS1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase LATS2 |
Kd |
> |
10000.0 |
nM |
Binding constant for LATS2 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase LCK |
Kd |
> |
10000.0 |
nM |
Binding constant for LCK kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase 10 |
Kd |
> |
10000.0 |
nM |
Binding constant for LOK kinase domain |
CHEMBL1150977 |
| Leukocyte tyrosine kinase receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for LTK kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase Lyn |
Kd |
> |
10000.0 |
nM |
Binding constant for LYN kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase kinase kinase 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for MAP3K4 kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase kinase kinase 5 |
Kd |
> |
10000.0 |
nM |
Binding constant for MAP3K5 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PAK6 |
Kd |
> |
10000.0 |
nM |
Binding constant for PAK6 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PAK7 |
Kd |
> |
10000.0 |
nM |
Binding constant for PAK7/PAK5 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PCTAIRE-1 |
Kd |
> |
10000.0 |
nM |
Binding constant for PCTK1 kinase domain |
CHEMBL1150977 |
| Unchecked |
Activity |
= |
91.0 |
% |
Percentage AMPK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Aurora-B |
Activity |
= |
94.0 |
% |
Percentage Aurora B activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Aurora-C |
Activity |
= |
96.0 |
% |
Percentage Aurora C activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| BR serine/threonine-protein kinase 2 |
Activity |
= |
79.0 |
% |
Percentage BRSK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| CaM kinase I alpha |
Activity |
= |
104.0 |
% |
Percentage CaMK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase MRCK gamma |
Kd |
> |
10000.0 |
nM |
Binding constant for DMPK2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase 17A |
Kd |
> |
10000.0 |
nM |
Binding constant for DRAK1 kinase domain |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR kinase domain |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR(E746-A750del) kinase domain |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR(G719C) kinase domain |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR(G719S) kinase domain |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR(L747-E749del, A750P) kinase domain |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR(L747-S752del, P753S) kinase domain |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR(L747-T751del,Sins) kinase domain |
CHEMBL1150977 |
| Ankyrin repeat and protein kinase domain-containing protein 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for ANKK1 kinase domain |
CHEMBL1150977 |
| NUAK family SNF1-like kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for ARK5 kinase domain |
CHEMBL1150977 |
| Platelet-derived growth factor receptor alpha |
Kd |
> |
10000.0 |
nM |
Binding constant for PDGFRA kinase domain |
CHEMBL1150977 |
| Platelet-derived growth factor receptor beta |
Kd |
> |
10000.0 |
nM |
Binding constant for PDGFRB kinase domain |
CHEMBL1150977 |
| Phosphorylase kinase gamma subunit 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for PHKG2 kinase domain |
CHEMBL1150977 |
| PI3-kinase p110-alpha subunit |
Kd |
> |
10000.0 |
nM |
Binding constant for PIK3CA kinase domain |
CHEMBL1150977 |
| PI3-kinase p110-alpha subunit |
Kd |
> |
10000.0 |
nM |
Binding constant for PIK3CA(E545K) kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PIM1 |
Kd |
> |
10000.0 |
nM |
Binding constant for PIM1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PIM2 |
Kd |
> |
10000.0 |
nM |
Binding constant for PIM2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PIM3 |
Kd |
> |
10000.0 |
nM |
Binding constant for PIM3 kinase domain |
CHEMBL1150977 |
| cAMP-dependent protein kinase alpha-catalytic subunit |
Kd |
> |
10000.0 |
nM |
Binding constant for PKAC-alpha kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase kinase kinase kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for MAP4K1 kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase kinase kinase kinase 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for MAP4K3 kinase domain |
CHEMBL1150977 |
| CaM-kinase kinase alpha |
Activity |
= |
73.0 |
% |
Percentage CaMKKalpha activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| CaM-kinase kinase beta |
Activity |
= |
71.0 |
% |
Percentage CaMKKbeta activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Cyclin-dependent kinase 2/cyclin A |
Activity |
= |
4.0 |
% |
Percentage CDK2-cyclinA activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Chk1 |
Activity |
= |
87.0 |
% |
Percentage CHK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Chk2 |
Activity |
= |
93.0 |
% |
Percentage CHK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Aurora-A |
Kd |
> |
10000.0 |
nM |
Binding constant for AURKA kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase Aurora-B |
Kd |
> |
10000.0 |
nM |
Binding constant for AURKB kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase receptor UFO |
Kd |
> |
10000.0 |
nM |
Binding constant for AXL kinase domain |
CHEMBL1150977 |
| BMP-2-inducible protein kinase |
Kd |
> |
10000.0 |
nM |
Binding constant for BIKE kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase BLK |
Kd |
> |
10000.0 |
nM |
Binding constant for BLK kinase domain |
CHEMBL1150977 |
| Bone morphogenetic protein receptor type-1A |
Kd |
> |
10000.0 |
nM |
Binding constant for BMPR1A kinase domain |
CHEMBL1150977 |
| Bone morphogenetic protein receptor type-2 |
Kd |
> |
10000.0 |
nM |
Binding constant for BMPR2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase B-raf |
Kd |
> |
10000.0 |
nM |
Binding constant for BRAF kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase B-raf |
Kd |
> |
10000.0 |
nM |
Binding constant for BRAF(V600E) kinase domain |
CHEMBL1150977 |
| BR serine/threonine-protein kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for BRSK1 kinase domain |
CHEMBL1150977 |
| CaM kinase I delta |
Kd |
> |
10000.0 |
nM |
Binding constant for CAMK1D kinase domain |
CHEMBL1150977 |
| CaM kinase I gamma |
Kd |
> |
10000.0 |
nM |
Binding constant for CAMK1G kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase kinase kinase kinase 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for MAP4K4 kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase kinase kinase kinase 5 |
Kd |
> |
10000.0 |
nM |
Binding constant for MAP4K5 kinase domain |
CHEMBL1150977 |
| MAP kinase-activated protein kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for MAPKAPK2 kinase domain |
CHEMBL1150977 |
| MAP kinase-activated protein kinase 5 |
Kd |
> |
10000.0 |
nM |
Binding constant for MAPKAPK5 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase MARK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for MARK1 kinase domain |
CHEMBL1150977 |
| MAP/microtubule affinity-regulating kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for MARK2 kinase domain |
CHEMBL1150977 |
| MAP/microtubule affinity-regulating kinase 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for MARK4 kinase domain |
CHEMBL1150977 |
| Dual specificity mitogen-activated protein kinase kinase 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for MEK4 kinase domain |
CHEMBL1150977 |
| Dual specificity mitogen-activated protein kinase kinase 6 |
Kd |
> |
10000.0 |
nM |
Binding constant for MEK6 kinase domain |
CHEMBL1150977 |
| Proto-oncogene tyrosine-protein kinase MER |
Kd |
> |
10000.0 |
nM |
Binding constant for MERTK kinase domain |
CHEMBL1150977 |
| Hepatocyte growth factor receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for MET kinase domain |
CHEMBL1150977 |
| Casein kinase I delta |
Activity |
= |
76.0 |
% |
Percentage CK1delta activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Casein kinase II |
Activity |
= |
92.0 |
% |
Percentage CK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Tyrosine-protein kinase CSK |
Activity |
= |
88.0 |
% |
Percentage CSK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Activity |
= |
87.0 |
% |
Percentage DYRK1A activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 2 |
Activity |
= |
90.0 |
% |
Percentage DYRK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| CaM kinase II alpha |
Kd |
> |
10000.0 |
nM |
Binding constant for CAMK2A kinase domain |
CHEMBL1150977 |
| CaM kinase II beta |
Kd |
> |
10000.0 |
nM |
Binding constant for CAMK2B kinase domain |
CHEMBL1150977 |
| CaM kinase II delta |
Kd |
> |
10000.0 |
nM |
Binding constant for CAMK2D kinase domain |
CHEMBL1150977 |
| CaM kinase II gamma |
Kd |
> |
10000.0 |
nM |
Binding constant for CAMK2G kinase domain |
CHEMBL1150977 |
| CaM kinase IV |
Kd |
> |
10000.0 |
nM |
Binding constant for CAMK4 kinase domain |
CHEMBL1150977 |
| CaM-kinase kinase alpha |
Kd |
> |
10000.0 |
nM |
Binding constant for CAMKK1 kinase domain |
CHEMBL1150977 |
| CaM-kinase kinase beta |
Kd |
> |
10000.0 |
nM |
Binding constant for CAMKK2 kinase domain |
CHEMBL1150977 |
| PITSLRE serine/threonine-protein kinase CDC2L1 |
Kd |
> |
10000.0 |
nM |
Binding constant for CDC2L1 kinase domain |
CHEMBL1150977 |
| PITSLRE serine/threonine-protein kinase CDC2L2 |
Kd |
> |
10000.0 |
nM |
Binding constant for CDC2L2 kinase domain |
CHEMBL1150977 |
| Cell division cycle 2-like protein kinase 6 |
Kd |
> |
10000.0 |
nM |
Binding constant for CDK11 kinase domain |
CHEMBL1150977 |
| Cell division protein kinase 8 |
Kd |
> |
10000.0 |
nM |
Binding constant for CDK8 kinase domain |
CHEMBL1150977 |
| MAP kinase signal-integrating kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for MKNK2 kinase domain |
CHEMBL1150977 |
| Myosin light chain kinase, smooth muscle |
Kd |
> |
10000.0 |
nM |
Binding constant for MLCK kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase kinase kinase 9 |
Kd |
> |
10000.0 |
nM |
Binding constant for MLK1 kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase kinase kinase 10 |
Kd |
> |
10000.0 |
nM |
Binding constant for MLK2 kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase kinase kinase 11 |
Kd |
> |
10000.0 |
nM |
Binding constant for MLK3 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase MRCK-A |
Kd |
> |
10000.0 |
nM |
Binding constant for MRCKA kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase MRCK beta |
Kd |
> |
10000.0 |
nM |
Binding constant for MRCKB kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase MST2 |
Kd |
> |
10000.0 |
nM |
Binding constant for MST2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase 24 |
Kd |
> |
10000.0 |
nM |
Binding constant for MST3 kinase domain |
CHEMBL1150977 |
| Muscle, skeletal receptor tyrosine protein kinase |
Kd |
> |
10000.0 |
nM |
Binding constant for MUSK kinase domain |
CHEMBL1150977 |
| Myosin light chain kinase, smooth muscle |
Kd |
> |
10000.0 |
nM |
Binding constant for MYLK kinase domain |
CHEMBL1150977 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 3 |
Activity |
= |
97.0 |
% |
Percentage DYRK3 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase EEF2K |
Activity |
= |
85.0 |
% |
Percentage EF2K activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase ERK1 |
Activity |
= |
82.0 |
% |
Percentage ERK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase ERK2 |
Activity |
= |
83.0 |
% |
Percentage ERK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Mitogen-activated protein kinase 15 |
Activity |
= |
40.0 |
% |
Percentage ERK8 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase Chk1 |
Kd |
> |
10000.0 |
nM |
Binding constant for CHEK1 kinase domain |
CHEMBL1150977 |
| Citron Rho-interacting kinase |
Kd |
> |
10000.0 |
nM |
Binding constant for CIT kinase domain |
CHEMBL1150977 |
| Dual specificity protein kinase CLK2 |
Kd |
= |
700.0 |
nM |
Binding constant for CLK2 kinase domain |
CHEMBL1150977 |
| Dual specificity protein kinase CLK4 |
Kd |
> |
10000.0 |
nM |
Binding constant for CLK4 kinase domain |
CHEMBL1150977 |
| Macrophage colony stimulating factor receptor |
Kd |
> |
10000.0 |
nM |
Binding constant for CSF1R kinase domain |
CHEMBL1150977 |
| Casein kinase I gamma 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for CSNK1G1 kinase domain |
CHEMBL1150977 |
| Death-associated protein kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for DAPK1 kinase domain |
CHEMBL1150977 |
| Death-associated protein kinase 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for DAPK3 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase DCLK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for DCAMKL1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase DCLK2 |
Kd |
> |
10000.0 |
nM |
Binding constant for DCAMKL2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase DCLK3 |
Kd |
> |
10000.0 |
nM |
Binding constant for DCAMKL3 kinase domain |
CHEMBL1150977 |
| myosin light chain kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for MYLK2 kinase domain |
CHEMBL1150977 |
| Myosin IIIA |
Kd |
> |
10000.0 |
nM |
Binding constant for MYO3A kinase domain |
CHEMBL1150977 |
| Myosin-IIIB |
Kd |
> |
10000.0 |
nM |
Binding constant for MYO3B kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase 38-like |
Kd |
> |
10000.0 |
nM |
Binding constant for NDR2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase Nek1 |
Kd |
> |
10000.0 |
nM |
Binding constant for NEK1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase NEK2 |
Kd |
> |
10000.0 |
nM |
Binding constant for NEK2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase Nek5 |
Kd |
> |
10000.0 |
nM |
Binding constant for NEK5 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase NEK6 |
Kd |
> |
10000.0 |
nM |
Binding constant for NEK6 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase NEK9 |
Kd |
> |
10000.0 |
nM |
Binding constant for NEK9 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PAK 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for PAK1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PAK 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for PAK2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PAK 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for PAK4 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase MST2 |
Activity |
= |
95.0 |
% |
Percentage MST2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase NEK2 |
Activity |
= |
85.0 |
% |
Percentage NEK2a activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase NEK6 |
Activity |
= |
92.0 |
% |
Percentage NEK6 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase NEK7 |
Activity |
= |
87.0 |
% |
Percentage NEK7 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase p38 alpha |
Activity |
= |
96.0 |
% |
Percentage p38alpha MAPK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Tyrosine-protein kinase FRK |
Kd |
> |
10000.0 |
nM |
Binding constant for FRK kinase domain |
CHEMBL1150977 |
| Uncharacterized aarF domain-containing protein kinase 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length ADCK4 |
CHEMBL1150977 |
| Serine/threonine-protein kinase Aurora-C |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length AURKC |
CHEMBL1150977 |
| Tyrosine-protein kinase BMX |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length BMX |
CHEMBL1150977 |
| BR serine/threonine-protein kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length BRSK2 |
CHEMBL1150977 |
| Tyrosine-protein kinase BTK |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length BTK |
CHEMBL1150977 |
| CaM kinase I alpha |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length CAMK1 |
CHEMBL1150977 |
| Cyclin-dependent kinase 2 |
Kd |
= |
3400.0 |
nM |
Binding constant for full-length CDK2 |
CHEMBL1150977 |
| Cyclin-dependent kinase 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length CDK3 |
CHEMBL1150977 |
| Cyclin-dependent kinase 5 |
Kd |
= |
1900.0 |
nM |
Binding constant for full-length CDK5 |
CHEMBL1150977 |
| Cyclin-dependent kinase 7 |
Kd |
= |
1800.0 |
nM |
Binding constant for full-length CDK7 |
CHEMBL1150977 |
| Serine/threonine-protein kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for SLK kinase domain |
CHEMBL1150977 |
| NUAK family SNF1-like kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for SNARK kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase SIK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for SNF1LK kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase SRC |
Kd |
> |
10000.0 |
nM |
Binding constant for SRC kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase Srms |
Kd |
> |
10000.0 |
nM |
Binding constant for SRMS kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase 16 |
Kd |
> |
10000.0 |
nM |
Binding constant for STK16 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase 36 |
Kd |
> |
10000.0 |
nM |
Binding constant for STK36 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase SYK |
Kd |
> |
10000.0 |
nM |
Binding constant for SYK kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase TEC |
Kd |
> |
10000.0 |
nM |
Binding constant for TEC kinase domain |
CHEMBL1150977 |
| Dual specificity testis-specific protein kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for TESK1 kinase domain |
CHEMBL1150977 |
| TGF-beta receptor type I |
Kd |
> |
10000.0 |
nM |
Binding constant for TGFBR1 kinase domain |
CHEMBL1150977 |
| Glycogen synthase kinase-3 beta |
Activity |
= |
76.0 |
% |
Percentage GSK3-beta activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Homeodomain-interacting protein kinase 2 |
Activity |
= |
84.0 |
% |
Percentage HIPK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Homeodomain-interacting protein kinase 3 |
Activity |
= |
90.0 |
% |
Percentage HIPK3 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Inhibitor of nuclear factor kappa B kinase beta subunit |
Activity |
= |
80.0 |
% |
Percentage IKK-beta activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| c-Jun N-terminal kinase 1 |
Activity |
= |
89.0 |
% |
Percentage JNK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Cyclin-dependent kinase 9 |
Kd |
> |
10000.0 |
nM |
Binding constant for full-length CDK9 |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR(L858R) kinase domain |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR(L861Q) kinase domain |
CHEMBL1150977 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EGFR(S752-I759del) kinase domain |
CHEMBL1150977 |
| Ephrin type-A receptor 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHA1 kinase domain |
CHEMBL1150977 |
| Ephrin type-A receptor 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHA2 kinase domain |
CHEMBL1150977 |
| Ephrin type-A receptor 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHA3 kinase domain |
CHEMBL1150977 |
| Ephrin type-A receptor 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHA4 kinase domain |
CHEMBL1150977 |
| Ephrin type-A receptor 5 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHA5 kinase domain |
CHEMBL1150977 |
| Ephrin type-A receptor 6 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHA6 kinase domain |
CHEMBL1150977 |
| Ephrin type-A receptor 7 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHA7 kinase domain |
CHEMBL1150977 |
| Ephrin type-A receptor 8 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHA8 kinase domain |
CHEMBL1150977 |
| TGF-beta receptor type II |
Kd |
> |
10000.0 |
nM |
Binding constant for TGFBR2 kinase domain |
CHEMBL1150977 |
| Tyrosine- and threonine-specific cdc2-inhibitory kinase |
Kd |
> |
10000.0 |
nM |
Binding constant for PKMYT1 kinase domain |
CHEMBL1150977 |
| Protein kinase N1 |
Kd |
> |
10000.0 |
nM |
Binding constant for PKN1 kinase domain |
CHEMBL1150977 |
| Protein kinase N2 |
Kd |
> |
10000.0 |
nM |
Binding constant for PKN2 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PLK1 |
Kd |
> |
10000.0 |
nM |
Binding constant for PLK1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PLK3 |
Kd |
> |
10000.0 |
nM |
Binding constant for PLK3 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase PLK4 |
Kd |
> |
10000.0 |
nM |
Binding constant for PLK4 kinase domain |
CHEMBL1150977 |
| Protein kinase C delta |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKCD kinase domain |
CHEMBL1150977 |
| Protein kinase C epsilon |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKCE kinase domain |
CHEMBL1150977 |
| Protein kinase C eta |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKCH kinase domain |
CHEMBL1150977 |
| Protein kinase C theta |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKCQ kinase domain |
CHEMBL1150977 |
| c-Jun N-terminal kinase 2 |
Activity |
= |
88.0 |
% |
Percentage JNK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| c-Jun N-terminal kinase 3 |
Activity |
= |
87.0 |
% |
Percentage JNK3 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Tyrosine-protein kinase LCK |
Activity |
= |
76.0 |
% |
Percentage Lck activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase-activated protein kinase 2 |
Activity |
= |
97.0 |
% |
Percentage MAPKAPK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase-activated protein kinase 3 |
Activity |
= |
86.0 |
% |
Percentage MAPKAPK3 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Ephrin type-B receptor 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHB1 kinase domain |
CHEMBL1150977 |
| Ephrin type-B receptor 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHB2 kinase domain |
CHEMBL1150977 |
| Ephrin type-B receptor 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHB3 kinase domain |
CHEMBL1150977 |
| Ephrin type-B receptor 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for EPHB4 kinase domain |
CHEMBL1150977 |
| Receptor protein-tyrosine kinase erbB-2 |
Kd |
> |
10000.0 |
nM |
Binding constant for ERBB2 kinase domain |
CHEMBL1150977 |
| Tubulin alpha-1 chain |
Kd |
> |
10000.0 |
nM |
Binding constant for ERBB4 kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase 6 |
Kd |
> |
10000.0 |
nM |
Binding constant for ERK3 kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for ERK4 kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase 7 |
Kd |
> |
10000.0 |
nM |
Binding constant for ERK5 kinase domain |
CHEMBL1150977 |
| Mitogen-activated protein kinase 15 |
Kd |
> |
10000.0 |
nM |
Binding constant for ERK8 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase FER |
Kd |
> |
10000.0 |
nM |
Binding constant for FER kinase domain |
CHEMBL1150977 |
| Protein kinase C mu |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKD1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase D2 |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKD2 kinase domain |
CHEMBL1150977 |
| Protein kinase C nu |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKD3 kinase domain |
CHEMBL1150977 |
| cGMP-dependent protein kinase 1 beta |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKG1 kinase domain |
CHEMBL1150977 |
| cGMP-dependent protein kinase 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKG2 kinase domain |
CHEMBL1150977 |
| Interferon-induced, double-stranded RNA-activated protein kinase |
Kd |
> |
10000.0 |
nM |
Binding constant for PRKR kinase domain |
CHEMBL1150977 |
| Focal adhesion kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for PTK2 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase BRK |
Kd |
> |
10000.0 |
nM |
Binding constant for PTK6 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase RAF |
Kd |
> |
10000.0 |
nM |
Binding constant for RAF1 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase receptor RET |
Kd |
> |
10000.0 |
nM |
Binding constant for RET kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase receptor RET |
Kd |
> |
10000.0 |
nM |
Binding constant for RET(M918T) kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase c-TAK1 |
Activity |
= |
87.0 |
% |
Percentage MARK3 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Maternal embryonic leucine zipper kinase |
Activity |
= |
88.0 |
% |
Percentage MELK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Dual specificity mitogen-activated protein kinase kinase 1 |
Activity |
= |
81.0 |
% |
Percentage MKK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase-interacting serine/threonine-protein kinase MNK1 |
Activity |
= |
90.0 |
% |
Percentage MNK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase signal-integrating kinase 2 |
Activity |
= |
97.0 |
% |
Percentage MNK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Tyrosine-protein kinase FES |
Kd |
> |
10000.0 |
nM |
Binding constant for FES kinase domain |
CHEMBL1150977 |
| Fibroblast growth factor receptor 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for FGFR1 kinase domain |
CHEMBL1150977 |
| Fibroblast growth factor receptor 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for FGFR2 kinase domain |
CHEMBL1150977 |
| Fibroblast growth factor receptor 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for FGFR3 kinase domain |
CHEMBL1150977 |
| Fibroblast growth factor receptor 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for FGFR3(G697C) kinase domain |
CHEMBL1150977 |
| Fibroblast growth factor receptor 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for FGFR4 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase FGR |
Kd |
> |
10000.0 |
nM |
Binding constant for FGR kinase domain |
CHEMBL1150977 |
| Vascular endothelial growth factor receptor 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for FLT1 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase receptor FLT3 |
Kd |
> |
10000.0 |
nM |
Binding constant for FLT3 kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase receptor FLT3 |
Kd |
> |
10000.0 |
nM |
Binding constant for FLT3(D835H) kinase domain |
CHEMBL1150977 |
| Tyrosine-protein kinase receptor FLT3 |
Kd |
> |
10000.0 |
nM |
Binding constant for FLT3(D835Y) kinase domain |
CHEMBL1150977 |
| Receptor-interacting serine/threonine-protein kinase 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for RIPK1 kinase domain |
CHEMBL1150977 |
| Serine/threonine-protein kinase RIPK2 |
Kd |
> |
10000.0 |
nM |
Binding constant for RIPK2 kinase domain |
CHEMBL1150977 |
| Proto-oncogene tyrosine-protein kinase ROS |
Kd |
> |
10000.0 |
nM |
Binding constant for ROS1 kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA1(Kin.Dom.1 - N-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 1 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA1(Kin.Dom.2 - C-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 2 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 3 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA3(Kin.Dom.1 - N-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA4(Kin.Dom.1 - C-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 4 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA4(Kin.Dom.2 - N-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 5 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA5(Kin.Dom.1 - C-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 5 |
Kd |
> |
10000.0 |
nM |
Binding constant for RPS6KA5(Kin.Dom.2 - N-terminal) kinase domain |
CHEMBL1150977 |
| Ribosomal protein S6 kinase alpha 5 |
Activity |
= |
78.0 |
% |
Percentage MSK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Serine/threonine-protein kinase PLK1 |
Activity |
= |
91.0 |
% |
Percentage PLK1 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| MAP kinase-activated protein kinase 5 |
Activity |
= |
83.0 |
% |
Percentage PRAK activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Protein kinase N2 |
Activity |
= |
89.0 |
% |
Percentage PRK2 activity remaining in the presence of 1uM inhibitor |
CHEMBL1150976 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
4600.0 |
nM |
Inhibition of recombinant CDK2/cyclin A |
CHEMBL1154643 |
| Cyclin-dependent kinase 2/cyclin E |
IC50 |
= |
520.0 |
nM |
Inhibition of recombinant CDK2/cyclin E |
CHEMBL1154643 |
| NON-PROTEIN TARGET |
GI50 |
= |
20000.0 |
nM |
Antiproliferative activity against human HeLaS3 cells by sulforhodamine B assay |
CHEMBL1154643 |
| Cyclin-dependent kinase 2/cyclin E |
IC50 |
= |
520.0 |
nM |
Inhibition of Cdk2/cyclinE |
CHEMBL1154657 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
4600.0 |
nM |
Inhibition of recombinant Cdk2/cyclinA |
CHEMBL1154657 |
| NON-PROTEIN TARGET |
GI50 |
= |
20000.0 |
nM |
Growth inhibition of human HeLaS3 cells |
CHEMBL1154657 |
| Huh-7 |
IC50 |
= |
5000.0 |
nM |
Antiproliferative activity against human HuH7 cells after 72 hrs by imaging analysis |
CHEMBL1152528 |
| HCT-116 |
IC50 |
= |
5000.0 |
nM |
Antiproliferative activity against human HCT116 cells after 72 hrs by imaging analysis |
CHEMBL1152528 |
| Caco-2 |
IC50 |
= |
6000.0 |
nM |
Antiproliferative activity against human Caco-2 cells after 72 hrs by imaging analysis |
CHEMBL1152528 |
| NON-PROTEIN TARGET |
IC50 |
= |
6000.0 |
nM |
Antiproliferative activity against human NCI/ADR cells after 72 hrs by imaging analysis |
CHEMBL1152528 |
| PC-3 |
IC50 |
= |
8000.0 |
nM |
Antiproliferative activity against human PC3 cells after 72 hrs by imaging analysis |
CHEMBL1152528 |
| ADMET |
IC50 |
> |
25000.0 |
nM |
Antiproliferative activity against human fibroblast after 72 hrs by imaging analysis |
CHEMBL1152528 |
| A549 |
IC50 |
= |
14700.0 |
nM |
Antiproliferative activity against human A549 cells after 3 days by SRB assay |
CHEMBL1157914 |
| HT-1080 |
IC50 |
= |
16800.0 |
nM |
Antiproliferative activity against human HT1080 cells after 3 days by SRB assay |
CHEMBL1157914 |
| NON-PROTEIN TARGET |
IC50 |
= |
17800.0 |
nM |
Antiproliferative activity against human HT116 cells after 3 days by SRB assay |
CHEMBL1157914 |
| K562 |
IC50 |
> |
20000.0 |
nM |
Antiproliferative activity against human K562 cells after 3 days by SRB assay |
CHEMBL1157914 |
| SNU-638 |
IC50 |
= |
9770.0 |
nM |
Antiproliferative activity against human SNU638 cells after 3 days by SRB assay |
CHEMBL1157914 |
| KB |
IC50 |
= |
30100.0 |
nM |
Antiproliferative activity against human KB cells after 3 days by SRB assay |
CHEMBL1157914 |
| MCF7 |
IC50 |
= |
14700.0 |
nM |
Antiproliferative activity against human MCF7 cells after 3 days by SRB assay |
CHEMBL1157914 |
| Plasmodium falciparum |
IC50 |
= |
28000.0 |
nM |
Antimicrobial activity against Plasmodium falciparum |
CHEMBL1212812 |
| PC-3 |
FC |
= |
0.797 |
|
Antiproliferative activity against human PC3 cells at 5 uM after 120 hrs by MTT assay relative to DMSO |
CHEMBL1221184 |
| Cyclin-dependent kinase 5 |
IC50 |
= |
160.0 |
nM |
Inhibition of CDK5 |
CHEMBL1240533 |
| Cyclin-dependent kinase 4 |
IC50 |
> |
100000.0 |
nM |
Inhibition of CDK4 |
CHEMBL1240533 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
700.0 |
nM |
Inhibition of CDK2 |
CHEMBL1240533 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
450.0 |
nM |
Inhibition of CDK1 |
CHEMBL1240533 |
| Cyclin-dependent kinase 2/cyclin E |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2/cyclin E |
CHEMBL1240297 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
360.0 |
nM |
Inhibition of CDK7/cyclin H |
CHEMBL1240297 |
| Unchecked |
IC50 |
= |
810.0 |
nM |
Inhibition of CDK9/cyclin T |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells at 30 uM after 3 hrs using TUNEL staining by flow cytometry |
CHEMBL1240297 |
| LP-1 |
Activity |
|
|
|
Induction of apoptosis in human LP-1 cells at 30 uM after 3 hrs using TUNEL staining by flow cytometry |
CHEMBL1240297 |
| RPMI-8226 |
Activity |
|
|
|
Induction of apoptosis in human RPM18226 cells at 30 uM after 3 hrs using TUNEL staining by flow cytometry |
CHEMBL1240297 |
| NCI-H929 |
Activity |
>= |
60.0 |
% |
Induction of apoptosis in human NCI-H929 cells at 30 uM after 24 hrs using TUNEL staining by flow cytometry |
CHEMBL1240297 |
| LP-1 |
Activity |
>= |
60.0 |
% |
Induction of apoptosis in human LP-1 cells at 30 uM after 24 hrs using TUNEL staining by flow cytometry |
CHEMBL1240297 |
| RPMI-8226 |
Activity |
>= |
60.0 |
% |
Induction of apoptosis in human RPM18226 cells at 30 uM after 24 hrs using TUNEL staining by flow cytometry |
CHEMBL1240297 |
| NON-PROTEIN TARGET |
IC50 |
= |
8840.0 |
nM |
Cytotoxicity against human NCI-H929 cells after 72 hrs by alamar blue assay |
CHEMBL1240297 |
| LP-1 |
IC50 |
= |
12680.0 |
nM |
Cytotoxicity against human LP-1 cells after 72 hrs by alamar blue assay |
CHEMBL1240297 |
| U-266 |
IC50 |
= |
17930.0 |
nM |
Cytotoxicity against human U266 cells after 72 hrs by alamar blue assay |
CHEMBL1240297 |
| OPM-2 |
IC50 |
= |
18460.0 |
nM |
Cytotoxicity against human OPM2 cells after 72 hrs by alamar blue assay |
CHEMBL1240297 |
| NON-PROTEIN TARGET |
IC50 |
= |
19500.0 |
nM |
Cytotoxicity against human RPM18226 cells after 72 hrs by alamar blue assay |
CHEMBL1240297 |
| NON-PROTEIN TARGET |
Activity |
= |
50.0 |
% |
Cytotoxicity against human NCI-H929 cells assessed as reduction of cell viability at 20 to 30 uM treated for 8 hrs followed by washout measured after total 72 hrs growth period alamar blue assay relative to control |
CHEMBL1240297 |
| LP-1 |
Activity |
= |
50.0 |
% |
Cytotoxicity against human LP-1 cells assessed as reduction of cell viability at 20 to 30 uM treated for 8 hrs followed by washout measured after total 72 hrs growth period alamar blue assay relative to control |
CHEMBL1240297 |
| NON-PROTEIN TARGET |
Activity |
= |
50.0 |
% |
Cytotoxicity against human RPM18226 cells assessed as reduction of cell viability at 20 to 30 uM treated for 8 hrs followed by washout measured after total 72 hrs growth period alamar blue assay relative to control |
CHEMBL1240297 |
| NON-PROTEIN TARGET |
Activity |
|
|
|
Cytotoxicity against human NCI-H929 cells assessed as reduction of cell viability at 20 to 30 uM treated for 16 hrs followed by washout measured after total 72 hrs growth period alamar blue assay relative to control |
CHEMBL1240297 |
| LP-1 |
Activity |
|
|
|
Cytotoxicity against human LP-1 cells assessed as reduction of cell viability at 20 to 30 uM treated for 24 hrs followed by washout measured after total 72 hrs growth period alamar blue assay relative to control |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as reduction of RNA polymerase 2 phosphoserine 2 level at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as reduction of RNA polymerase 2 phosphoserine 5 level at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as reduction of total RNA polymerase 2 level at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as fast migrating hypophosphorylated RNA polymerase 2A form at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as fast slow migrating hyperphosphorylated RNA polymerase 2O form at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as dephosphorylation of pRb at S249/T252 at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as effect on total pRb level at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as reduction of Mcl-1 protein level at 30 uM after 3 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as changes in XIAP protein level at 30 uM after 3 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as changes in survivin protein level at 30 uM after 3 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as changes in Bcl-2 protein level at 30 uM after 3 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as increase in level of cleaved PARP at 30 uM after 5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as reduction of Hdm2 level at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
Activity |
|
|
|
Induction of apoptosis in human NCI-H929 cells assessed as increase of p53 accumulation at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| LP-1 |
Activity |
|
|
|
Induction of apoptosis in human LP-1 cells assessed as reduction of RNA polymerase 2 phosphoserine 2 level at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| RPMI-8226 |
Activity |
|
|
|
Induction of apoptosis in human RPM18226 cells assessed as reduction of RNA polymerase 2 phosphoserine 2 level at 30 uM after 1.5 hrs by immunoblotting |
CHEMBL1240297 |
| LP-1 |
Activity |
|
|
|
Induction of apoptosis in human LP-1 cells assessed as reduction of Mcl-1 protein level at 30 uM after 3 hrs by immunoblotting |
CHEMBL1240297 |
| RPMI-8226 |
Activity |
|
|
|
Induction of apoptosis in human RPM18226 cells assessed as reduction of Mcl-1 protein level at 30 uM after 3 hrs by immunoblotting |
CHEMBL1240297 |
| LP-1 |
Activity |
|
|
|
Induction of apoptosis in human LP-1 cells assessed as increase in level of cleaved PARP at 30 uM after 3 to 5 hrs by immunoblotting |
CHEMBL1240297 |
| RPMI-8226 |
Activity |
|
|
|
Induction of apoptosis in human RPM18226 cells assessed as increase in level of cleaved PARP at 30 uM after 3 to 5 hrs by immunoblotting |
CHEMBL1240297 |
| NCI-H929 |
FC |
= |
2.0 |
|
Reduction of Mcl-1 mRNA level in human NCI-H929 cells at 30 uM after up to 8 hrs by RT-PCR analysis relative to control |
CHEMBL1240297 |
| LP-1 |
FC |
= |
2.0 |
|
Reduction of Mcl-1 mRNA level in human LP-1 cells at 30 uM after up to 8 hrs by RT-PCR analysis relative to control |
CHEMBL1240297 |
| Plasmodium falciparum |
IC50 |
= |
3981.07 |
nM |
Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay |
CHEMBL1255382 |
| Plasmodium falciparum |
IC50 |
= |
6309.57 |
nM |
Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay |
CHEMBL1255382 |
| Plasmodium falciparum |
IC50 |
= |
10000.0 |
nM |
Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay |
CHEMBL1255382 |
| Plasmodium falciparum |
IC50 |
= |
6309.57 |
nM |
Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay |
CHEMBL1255382 |
| Plasmodium falciparum |
IC50 |
= |
6309.57 |
nM |
Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay |
CHEMBL1255382 |
| Plasmodium falciparum |
IC50 |
= |
3981.07 |
nM |
Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay |
CHEMBL1255382 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay |
CHEMBL1255231 |
| NON-PROTEIN TARGET |
Potency |
= |
3981.1 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2. (Class of assay: confirmatory) [Related PubChem assays: 1876 (Assay for Plasmodium falciparum line 7D3), 1815 (Assay for Plasmodium falciparum line 7G8), 1877 (Assay for Plasmodium falciparum line D10), 1816 (Assay for Plasmodium falciparum line GB4), 1828 (Summary assay)] |
CHEMBL1201862 |
| Prelamin-A/C |
Potency |
= |
22387.2 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Thyroid hormone receptor beta-1 |
Potency |
= |
50118.7 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
3162.3 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7. (Class of assay: confirmatory) [Related PubChem assays: 1815 (Assay for Plasmodium falciparum line 7G8), 1816 (Assay for Plasmodium falciparum line GB4), 1828 (Summary assay)] |
CHEMBL1201862 |
| Survival motor neuron protein |
Potency |
= |
17782.8 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Survival motor neuron protein |
Potency |
= |
8912.5 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Survival motor neuron protein |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
5623.4 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2. (Class of assay: confirmatory) [Related PubChem assays: 1815 (Assay for Plasmodium falciparum line 7G8), 1877 (Assay for Plasmodium falciparum line D10), 1816 (Assay for Plasmodium falciparum line GB4), 1876 (Assay for Plasmodium falciparum line 7D3), 1828 (Summary assay)] |
CHEMBL1201862 |
| Thyroid hormone receptor beta-1 |
Potency |
= |
50118.7 |
nM |
PUBCHEM_BIOASSAY: Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Aldehyde dehydrogenase 1A1 |
Potency |
= |
199.5 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
6309.6 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Peripheral myelin protein 22 |
Potency |
= |
37933.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Prelamin-A/C |
Potency |
= |
17782.8 |
nM |
PUBCHEM_BIOASSAY: Validation of Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Inositol monophosphatase 1 |
Potency |
= |
2818.4 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium. (Class of assay: confirmatory) [Related pubchem assays: 901 ] |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
5011.9 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
10000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10. (Class of assay: confirmatory) [Related PubChem assays: 1815 (Assay for Plasmodium falciparum line 7G8), 1816 (Assay for Plasmodium falciparum line GB4), 1828 (Summary assay)] |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
5623.4 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3. (Class of assay: confirmatory) [Related PubChem assays: 1815 (Assay for Plasmodium falciparum line 7G8), 1877 (Assay for Plasmodium falciparum line D10), 1816 (Assay for Plasmodium falciparum line GB4), 1876 (Assay for Plasmodium falciparum line 3D7), 1828 (Summary assay)] |
CHEMBL1201862 |
| Geminin |
Potency |
= |
15848.9 |
nM |
PUBCHEM_BIOASSAY: Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
160.0 |
nM |
Inhibition of CDK5/P25 GST-fusion protein assessed as substrate histone H1 phosphorylation by scintillation counting |
CHEMBL1641601 |
| Cyclin-dependent kinase 5 |
IC50 |
= |
160.0 |
nM |
Inhibition of CDK5 |
CHEMBL1641601 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
700.0 |
nM |
Inhibition of CDK2/Cyclin A |
CHEMBL1641601 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans |
CHEMBL1697731 |
| Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 |
Potency |
|
10000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] |
CHEMBL1201862 |
| Plasmodium falciparum |
Potency |
|
1041.8 |
nM |
PUBCHEM_BIOASSAY: Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774] |
CHEMBL1201862 |
| Plasmodium falciparum |
Potency |
|
4653.5 |
nM |
PUBCHEM_BIOASSAY: Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488774] |
CHEMBL1201862 |
| Geminin |
Potency |
|
20596.2 |
nM |
PUBCHEM_BIOASSAY: Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463097, AID463113, AID493165, AID493166, AID504806, AID504809] |
CHEMBL1201862 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
270.0 |
nM |
Inhibition of CDK5/p25 assessed as [33P]gamma-ATP incorporation into peptide PKTPKKAKKL substrate after 45 mins by scintillation counter |
CHEMBL1759882 |
| CDK9/cyclin T1 |
Inhibition |
= |
19.0 |
% |
Inhibition of at human CDK9/cyclin T1 at 0.1 uM after 40 mins relative to control |
CHEMBL1765024 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
Inhibition |
= |
40.0 |
% |
Inhibition of human CDK5/p25 at 0.1 uM after 40 mins relative to control |
CHEMBL1765024 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
Inhibition |
= |
41.0 |
% |
Inhibition of human CDK5/p35 at 0.1 uM after 40 mins relative to control |
CHEMBL1765024 |
| Cyclin-dependent kinase 2/cyclin A |
Inhibition |
= |
41.0 |
% |
Inhibition of human CDK2/cyclin A at 0.1 uM after 40 mins relative to control |
CHEMBL1765024 |
| Cyclin-dependent kinase 2/cyclin E1 |
Inhibition |
= |
57.0 |
% |
Inhibition of human CDK2/cyclin E at 0.1 uM after 40 mins relative to control |
CHEMBL1765024 |
| Cyclin-dependent kinase 1/cyclin B1 |
Inhibition |
= |
10.0 |
% |
Inhibition of human CDK1/cyclin B at 0.1 uM after 40 mins relative to control |
CHEMBL1765024 |
| Cyclin-dependent kinase 7/ cyclin H |
Inhibition |
= |
26.0 |
% |
Inhibition of human CDK7/cyclinH/MAT1 at 0.1 uM after 40 mins relative to control |
CHEMBL1765024 |
| CDK3/cyclin E |
Inhibition |
= |
20.0 |
% |
Inhibition of human CDK3/cyclin E at 0.1 uM after 40 mins relative to control |
CHEMBL1765024 |
| MCF7 |
IC50 |
= |
55010.0 |
nM |
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by WST-1 assay |
CHEMBL1765024 |
| MDA-MB-231 |
IC50 |
= |
54640.0 |
nM |
Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells after 48 hrs by WST-1 assay |
CHEMBL1765024 |
| MCF7 |
Activity |
= |
6.56 |
% |
Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 10 uM after 24 hrs using annexinV-propidium iodide staining by flow cytometry (Rvb = 12.09%) |
CHEMBL1765024 |
| MCF7 |
Activity |
= |
7.13 |
% |
Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 10 uM after 24 hrs using annexinV-propidium iodide staining by flow cytometry (Rvb = 4.24%) |
CHEMBL1765024 |
| MCF7 |
Activity |
= |
13.2 |
% |
Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 10 uM after 24 hrs using annexinV-propidium iodide staining by flow cytometry (Rvb = 13.35%) |
CHEMBL1765024 |
| MCF7 |
Activity |
= |
73.12 |
% |
Induction of apoptosis in human MCF7 cells assessed as viable cells at 10 uM after 24 hrs using annexinV-propidium iodide staining by flow cytometry (Rvb = 70.32%) |
CHEMBL1765024 |
| MDA-MB-231 |
Activity |
|
|
|
Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2/M phase treated at 5 uM for 24 hrs measured after drug washout following 48 hrs growth recovery using propidium iodide staining by flow cytometry |
CHEMBL1765024 |
| MDA-MB-231 |
Activity |
|
|
|
Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2/M phase treated at 10 uM for 24 hrs measured after drug washout following 48 hrs growth recovery using propidium iodide staining by flow cytometry |
CHEMBL1765024 |
| MDA-MB-231 |
Activity |
|
|
|
Induction of apoptosis in human MDA-MB-231 cells assessed as decrease in Bcl2 protein level at 40 uM after 48 hrs by Western blotting |
CHEMBL1765024 |
| MDA-MB-231 |
Activity |
|
|
|
Induction of apoptosis in human MDA-MB-231 cells assessed as increase in Bax protein level at 40 uM after 48 hrs by Western blotting |
CHEMBL1765024 |
| MDA-MB-231 |
Activity |
|
|
|
Induction of apoptosis in human MDA-MB-231 cells assessed as decrease in caspase 3 protein level at 40 uM after 48 hrs by Western blotting |
CHEMBL1765024 |
| MDA-MB-231 |
Activity |
|
|
|
Induction of apoptosis in human MDA-MB-231 cells assessed as decrease in caspase 7 protein level at 40 uM after 48 hrs by Western blotting |
CHEMBL1765024 |
| MDA-MB-231 |
Activity |
|
|
|
Induction of apoptosis in human MDA-MB-231 cells assessed as induction of PARP cleavage at 40 uM after 48 hrs by Western blotting |
CHEMBL1765024 |
| Cyclin-dependent kinase 1/cyclin B1 |
Inhibition |
= |
70.0 |
% |
Inhibition of human recombinant CDK1/cyclin B at 10 uM |
CHEMBL1765057 |
| Cyclin-dependent kinase 2/cyclin A |
Inhibition |
= |
94.0 |
% |
Inhibition of human recombinant CDK2/cyclin A at 10 uM |
CHEMBL1765057 |
| Cyclin-dependent kinase 2/cyclin E1 |
Inhibition |
= |
95.0 |
% |
Inhibition of human recombinant CDK2/cyclin E at 10 uM |
CHEMBL1765057 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
Inhibition |
= |
85.0 |
% |
Inhibition of human recombinant CDK5/p35 at 10 uM |
CHEMBL1765057 |
| Cyclin-dependent kinase 7/ cyclin H |
Inhibition |
= |
87.0 |
% |
Inhibition of human recombinant CDK7/cyclin H/MAT1 at 10 uM |
CHEMBL1765057 |
| CDK9/cyclin T1 |
Inhibition |
= |
87.0 |
% |
Inhibition of human recombinant CDK9/cyclin T1 at 10 uM |
CHEMBL1765057 |
| Casein kinase I alpha |
Inhibition |
= |
1.0 |
% |
Inhibition of human recombinant CK1 at 10 uM |
CHEMBL1765057 |
| Casein kinase II |
Inhibition |
= |
10.0 |
% |
Inhibition of human recombinant CK2 at 10 uM |
CHEMBL1765057 |
| Glycogen synthase kinase-3 alpha |
Inhibition |
= |
13.0 |
% |
Inhibition of human recombinant GSK3A at 10 uM |
CHEMBL1765057 |
| Glycogen synthase kinase-3 beta |
Inhibition |
= |
25.0 |
% |
Inhibition of human recombinant GSK3B at 10 uM |
CHEMBL1765057 |
| Dual specificity mitogen-activated protein kinase kinase 1 |
Inhibition |
= |
38.0 |
% |
Inhibition of human recombinant MEK1 at 10 uM |
CHEMBL1765057 |
| MAP kinase-activated protein kinase 5 |
Inhibition |
= |
28.0 |
% |
Inhibition of human recombinant PRAK at 10 uM |
CHEMBL1765057 |
| Ribosomal protein S6 kinase alpha 5 |
Inhibition |
= |
29.0 |
% |
Inhibition of human recombinant MSK1 at 10 uM |
CHEMBL1765057 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
220.0 |
nM |
Inhibition of human recombinant CDK2/cyclin E |
CHEMBL1765057 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
940.0 |
nM |
Inhibition of human recombinant CDK5/p35 |
CHEMBL1765057 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
480.0 |
nM |
Inhibition of human recombinant CDK7/cyclin H/MAT1 |
CHEMBL1765057 |
| CDK9/cyclin T1 |
IC50 |
= |
1770.0 |
nM |
Inhibition of human recombinant CDK9/cyclin T1 |
CHEMBL1765057 |
| Retinoblastoma-associated protein |
Inhibition |
|
|
% |
Inhibition of retinoblastoma protein in human HT-29 cells assessed as reduction of cyclin A level at 2.5 to 40 uM after 24 hrs by immunoblotting |
CHEMBL1765057 |
| Retinoblastoma-associated protein |
Inhibition |
|
|
% |
Inhibition of retinoblastoma protein in human HT-29 cells assessed as reduction of CDK4 level at 2.5 to 40 uM after 24 hrs by immunoblotting |
CHEMBL1765057 |
| MCF7 |
Activity |
|
|
|
Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide and BrdU staining by flow cytometry |
CHEMBL1765057 |
| RPMI-8226 |
Activity |
|
|
|
Cell cycle arrest in human RPMI8226 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide and BrdU staining by flow cytometry |
CHEMBL1765057 |
| MCF7 |
Activity |
|
|
|
Cell cycle arrest in human MCF7 cells assessed as decrease in S phase cell population after 24 hrs using propidium iodide and BrdU staining by flow cytometry |
CHEMBL1765057 |
| RPMI-8226 |
Activity |
|
|
|
Cell cycle arrest in human RPMI8226 cells assessed as decrease in S phase cell population after 24 hrs using propidium iodide and BrdU staining by flow cytometry |
CHEMBL1765057 |
| MCF7 |
Activity |
|
|
|
Cell cycle arrest in human MCF7 cells assessed as reduction of actively replicating DNA level at 80 uM after 24 hrs using propidium iodide and BrdU staining by flow cytometry |
CHEMBL1765057 |
| RPMI-8226 |
Activity |
|
|
|
Cell cycle arrest in human RPMI8226 cells assessed as reduction of actively replicating DNA level at 80 uM after 24 hrs using propidium iodide and BrdU staining by flow cytometry |
CHEMBL1765057 |
| MCF7 |
Activity |
|
|
|
Cell cycle arrest in human MCF7 cells assessed as accumulation at sub-G1 phase after 24 hrs using propidium iodide and BrdU staining by flow cytometry |
CHEMBL1765057 |
| RPMI-8226 |
Activity |
|
|
|
Cell cycle arrest in human RPMI8226 cells assessed as accumulation at sub-G1 phase after 24 hrs using propidium iodide and BrdU staining by flow cytometry |
CHEMBL1765057 |
| Cellular tumor antigen p53 |
Activity |
|
|
|
Induction of p53-dependent transcriptional activity in human MCF7 cells assessed as increase of p21 WAF1 level at 20 uM after 24 hrs by immunofluorescence assay |
CHEMBL1765057 |
| U2OS |
Inhibition |
|
|
% |
Reduction of homologous recombination in human DR-U2OS-GFP cells expressing I-SceI nuclease at 10 uM after 56 hrs by immunoblotting |
CHEMBL1765057 |
| Stem cell growth factor receptor |
Kd |
> |
10000.0 |
nM |
Binding affinity to human KIT incubated for 1 hr by kinase binding assay |
CHEMBL1782045 |
| Stem cell growth factor receptor |
Kd |
> |
10000.0 |
nM |
Binding affinity to human KIT D816V mutant incubated for 1 hr by kinase binding assay |
CHEMBL1782045 |
| NON-PROTEIN TARGET |
Activity |
|
|
|
Neuroprotective activity against Amyloid beta-induced mouse hippocampal neuronal death at 1 uM pretreated for 1 hr before Amyloid beta treatment measured after 48 hrs using propidium iodide staining by fluorescence electron microscopy |
CHEMBL1795339 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
280.0 |
nM |
Inhibition of CDK5/p25 assessed as [33P]gamma-ATP incorporation into biotinylated PKTPKKAKKL substrate after 60 mins by scintillation counting |
CHEMBL1795325 |
| Dual specificty protein kinase CLK1 |
Inhibition |
|
|
% |
Inhibition of CLK1 transfected in human HeLa cells assessed as increase in exon inclusion ratio after 24 hrs by RT-PCR analysis |
CHEMBL1800025 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2/cyclinE assessed as amount of ATP released by luciferase activity based PKLight assay |
CHEMBL1800061 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
540.0 |
nM |
Inhibition of CDK7/cyclinH/MAT1 assessed as amount of ATP released by luciferase activity based PKLight assay |
CHEMBL1800061 |
| HUVEC |
GI50 |
= |
3700.0 |
nM |
Antiproliferative activity against human HUVEC cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| SAOS-2 |
GI50 |
= |
13900.0 |
nM |
Antiproliferative activity against human Saos2 cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| HCT-116 |
GI50 |
= |
15500.0 |
nM |
Antiproliferative activity against human HCT116 cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| MCF-10A |
GI50 |
= |
16300.0 |
nM |
Antiproliferative activity against human MCF10A cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| MDA-MB-231 |
GI50 |
= |
22600.0 |
nM |
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| PC-3 |
GI50 |
= |
25200.0 |
nM |
Antiproliferative activity against human PC3 cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| CDK9/cyclin T1 |
IC50 |
= |
950.0 |
nM |
Inhibition of CDK9/cyclinT assessed as amount of ATP released by luciferase activity based PKLight assay |
CHEMBL1800061 |
| Cyclin-T1/Cyclin-dependent-like kinase 5 |
IC50 |
= |
160.0 |
nM |
Inhibition of CDK5/cyclinT assessed as amount of ATP released by luciferase activity based PKLight assay |
CHEMBL1800061 |
| MCF7 |
GI50 |
= |
7800.0 |
nM |
Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| Cyclin-dependent kinase 4/cyclin D1 |
IC50 |
= |
13500.0 |
nM |
Inhibition of CDK4/cyclinD1 assessed as amount of ATP released by luciferase activity based PKLight assay |
CHEMBL1800061 |
| A549 |
GI50 |
= |
15000.0 |
nM |
Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| COLO 205 |
GI50 |
= |
24900.0 |
nM |
Antiproliferative activity against human COLO205 cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| HepG2 |
GI50 |
= |
25900.0 |
nM |
Antiproliferative activity against human HepG2 cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| SK-OV-3 |
GI50 |
= |
35700.0 |
nM |
Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay |
CHEMBL1800061 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
2100.0 |
nM |
Inhibition of CDK1/cyclinB1 assessed as amount of ATP released by luciferase activity based PKLight assay |
CHEMBL1800061 |
| CDK6/cyclin D1 |
IC50 |
= |
23500.0 |
nM |
Inhibition of CDK6/cyclinD1 assessed as amount of ATP released by luciferase activity based PKLight assay |
CHEMBL1800061 |
| Cyclin A2 |
Inhibition |
|
|
% |
Inhibition of cyclin A in human HCT116 cells assessed as decrease in protein level at 30 to 40 umol/L after 24 hrs by immunoblotting analysis |
CHEMBL1800061 |
| G2/mitotic-specific cyclin B1 |
Inhibition |
|
|
% |
Inhibition of cyclin B in human HCT116 cells assessed as decrease in protein level at 30 to 40 umol/L after 24 hrs by immunoblotting analysis |
CHEMBL1800061 |
| G1/S-specific cyclin D1 |
Inhibition |
|
|
% |
Inhibition of cyclin D1 in human HCT116 cells assessed as decrease in protein level at 30 to 40 umol/L after 24 hrs by immunoblotting analysis |
CHEMBL1800061 |
| Cyclin-dependent kinase 2 |
Inhibition |
|
|
% |
Inhibition of CDK2 in human HCT116 cells assessed as decrease in protein level at 30 to 40 umol/L after 24 hrs by immunoblotting analysis |
CHEMBL1800061 |
| Thioredoxin reductase 1, cytoplasmic |
Potency |
|
37.7 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] |
CHEMBL1201862 |
| HERG |
Potency |
|
35481.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
35481.3 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
35481.3 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
35481.3 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Huh-7 |
IC50 |
= |
10000.0 |
nM |
Cytotoxicity against human HuH7 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis |
CHEMBL1909497 |
| Caco-2 |
IC50 |
= |
10000.0 |
nM |
Cytotoxicity against human Caco2 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis |
CHEMBL1909497 |
| MDA-MB-231 |
IC50 |
= |
15000.0 |
nM |
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis |
CHEMBL1909497 |
| HCT-116 |
IC50 |
= |
8000.0 |
nM |
Cytotoxicity against human HCT116 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis |
CHEMBL1909497 |
| PC-3 |
IC50 |
= |
8000.0 |
nM |
Cytotoxicity against human PC3 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis |
CHEMBL1909497 |
| NON-PROTEIN TARGET |
IC50 |
= |
20000.0 |
nM |
Cytotoxicity against human NCI60 cells after 48 hrs by Hoechst-33342 staining-based imaging analysis |
CHEMBL1909497 |
| ADMET |
IC50 |
> |
25000.0 |
nM |
Cytotoxicity against human fibroblast cells after 48 hrs by Hoechst-33342 staining-based imaging analysis |
CHEMBL1909497 |
| Unchecked |
IC50 |
= |
15000.0 |
nM |
Inhibition of CDK4/cyclin D expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay |
CHEMBL1909587 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
500.0 |
nM |
Inhibition of CDK2/cyclin A expressed in baculovirus infected insect Sf21 cells using [gamma-P32]ATP and histone H1 as substrate after 10 mins by radiometric assay |
CHEMBL1909587 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
220.0 |
nM |
Inhibition of CDK2/cyclin E |
CHEMBL1921760 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
17000.0 |
nM |
Inhibition of CDK1/cyclin B |
CHEMBL1921760 |
| Cyclin-dependent kinase 4/cyclin D1 |
IC50 |
= |
27000.0 |
nM |
Inhibition of CDK4/cyclin D1 |
CHEMBL1921760 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
520.0 |
nM |
Inhibition of CDK7/cyclin H |
CHEMBL1921760 |
| Unchecked |
IC50 |
> |
50000.0 |
nM |
Inhibition of PKA |
CHEMBL1921760 |
| MAP kinase ERK2 |
IC50 |
> |
25000.0 |
nM |
Inhibition of ERK2 |
CHEMBL1921760 |
| A2780 |
GI50 |
= |
4450.0 |
nM |
Growth inhibition of cisplatin-susceptible human A2780 cells after 96 hrs by sulforhodamine B assay |
CHEMBL1921760 |
| A2780 |
GI50 |
= |
12500.0 |
nM |
Growth inhibition of cisplatin-resistant human A2780 cells after 96 hrs by sulforhodamine B assay |
CHEMBL1921760 |
| CH1 |
GI50 |
= |
3250.0 |
nM |
Growth inhibition of doxorubicin-susceptible human CH1 cells after 96 hrs by sulforhodamine B assay |
CHEMBL1921760 |
| CH1 |
GI50 |
= |
5400.0 |
nM |
Growth inhibition of doxorubicin-resistant human CH1 cells after 96 hrs by sulforhodamine B assay |
CHEMBL1921760 |
| HCT-116 |
GI50 |
= |
5050.0 |
nM |
Growth inhibition of human HCT116 cells after 96 hrs by sulforhodamine B assay |
CHEMBL1921760 |
| HT-29 |
GI50 |
= |
6400.0 |
nM |
Growth inhibition of human HT-29 cells after 96 hrs by sulforhodamine B assay |
CHEMBL1921760 |
| KM12 |
GI50 |
= |
15000.0 |
nM |
Growth inhibition of human KM12 cells after 96 hrs by sulforhodamine B assay |
CHEMBL1921760 |
| Unchecked |
Ratio IC50 |
= |
80.0 |
|
Ratio of IC50 for CDK4/cyclin D1 to IC50 for CDK2/cyclin E |
CHEMBL1921760 |
| Unchecked |
Ratio IC50 |
= |
60.0 |
|
Ratio of IC50 for CDK1/cyclin B to IC50 for CDK2/cyclin E |
CHEMBL1921760 |
| Liver |
Activity |
= |
67.0 |
% |
Metabolic stability in mouse liver microsomes assessed as compound metabolized at 10 uM after 30 mins by LC-MS analysis |
CHEMBL1921760 |
| Mus musculus |
Cmax |
= |
93700.0 |
nM |
Cmax in BALB/c mouse plasma at 50 mg/kg, iv after 24 hrs by LC-MS analysis |
CHEMBL1921760 |
| Mus musculus |
AUC |
= |
18928.16 |
ng.hr.mL-1 |
AUC in BALB/c mouse plasma at 50 mg/kg, iv after 24 hrs by LC-MS analysis |
CHEMBL1921760 |
| Mus musculus |
T1/2 |
= |
1.4 |
hr |
Half life in BALB/c mouse plasma at 50 mg/kg, iv by LC-MS analysis |
CHEMBL1921760 |
| Mus musculus |
Vd |
= |
0.073 |
l |
Volume of distribution in BALB/c mouse plasma at 50 mg/kg, iv after 24 hrs by LC-MS analysis |
CHEMBL1921760 |
| Mus musculus |
CL |
= |
0.051 |
L/hr |
Clearance in BALB/c mouse plasma at 50 mg/kg, iv after 24 hrs by LC-MS analysis |
CHEMBL1921760 |
| NCI-H23 |
GI50 |
|
13152.25 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| UO-31 |
GI50 |
|
13645.83 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| ACHN |
GI50 |
|
12823.31 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| HL-60 |
GI50 |
|
21677.04 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| HOP-92 |
GI50 |
|
50933.09 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| DU-145 |
GI50 |
|
16865.53 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| SF-539 |
GI50 |
|
15776.11 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| SK-MEL-5 |
GI50 |
|
10715.19 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Malme-3M |
GI50 |
|
19319.68 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| A498 |
GI50 |
|
48083.93 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| K562 |
GI50 |
|
52966.34 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| OVCAR-3 |
GI50 |
|
11455.13 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| MOLT-4 |
GI50 |
|
25118.86 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| HOP-62 |
GI50 |
|
24603.68 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| U-251 |
GI50 |
|
53826.98 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NCI/ADR-RES |
GI50 |
|
6966.27 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| OVCAR-5 |
GI50 |
|
42756.29 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| SR |
GI50 |
|
5395.11 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| MDA-MB-231 |
GI50 |
|
39719.15 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| SW-620 |
GI50 |
|
82413.81 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| TK-10 |
GI50 |
|
64120.96 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NCI-H522 |
GI50 |
|
16368.17 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| KM12 |
GI50 |
|
5260.17 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| M14 |
GI50 |
|
27925.44 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| RPMI-8226 |
GI50 |
|
24154.61 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NCI-H322M |
GI50 |
|
29376.5 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| OVCAR-4 |
GI50 |
|
35156.04 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| LOX IMVI |
GI50 |
|
13995.87 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| SK-MEL-2 |
GI50 |
|
17498.47 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| A549 |
GI50 |
|
13645.83 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| HCC 2998 |
GI50 |
|
32210.69 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| SNB-75 |
GI50 |
|
11324.0 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| HCT-15 |
GI50 |
|
19319.68 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| SF-268 |
GI50 |
|
19815.27 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| HCT-116 |
GI50 |
|
5093.31 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| EKVX |
GI50 |
|
19098.53 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| MCF7 |
GI50 |
|
13489.63 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| PC-3 |
GI50 |
|
19906.73 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| SK-OV-3 |
GI50 |
|
86297.85 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| T47D |
GI50 |
|
16330.52 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NCI-H460 |
GI50 |
|
27861.21 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| UACC-62 |
GI50 |
|
8072.35 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| MDA-MB-435 |
GI50 |
|
13273.94 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| CAKI-1 |
GI50 |
|
6165.95 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| IGROV-1 |
GI50 |
|
5780.96 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| SF-295 |
GI50 |
|
25527.01 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| 786-0 |
GI50 |
|
23280.91 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| CCRF-CEM |
GI50 |
|
100000.0 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NCI-H226 |
GI50 |
|
19186.69 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| HT-29 |
GI50 |
|
19998.62 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| COLO 205 |
GI50 |
|
11641.26 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| RXF 393 |
GI50 |
|
4897.79 |
nM |
PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
IC50 |
= |
330.0 |
nM |
Inhibition of starfish oocyte CDK1/cyclin B |
CHEMBL2086256 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
210.0 |
nM |
Inhibition of human recombinant CDK2/cyclin A expressed in baculovirus-infected insect cells |
CHEMBL2086256 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
280.0 |
nM |
Inhibition of human recombinant CDK5/p25 expressed in Escherichia coli |
CHEMBL2086256 |
| CDK9/cyclin T1 |
IC50 |
= |
230.0 |
nM |
Inhibition of human recombinant CDK9/cyclin T expressed in baculovirus-infected insect cells |
CHEMBL2086256 |
| Glycogen synthase kinase-3 |
IC50 |
= |
60000.0 |
nM |
Inhibition of GSK3 alpha/beta |
CHEMBL2086256 |
| Casein kinase I alpha |
IC50 |
= |
4000.0 |
nM |
Inhibition of CK1 after 30 mins by liquid scintillation counter |
CHEMBL2086256 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
IC50 |
= |
3000.0 |
nM |
Inhibition of human recombinant DYRK1A expressed in Escherichia coli after 30 mins by liquid scintillation counter |
CHEMBL2086256 |
| Dual specificity protein kinase CLK1 |
IC50 |
= |
4300.0 |
nM |
Inhibition of mouse recombinant CLK1 expressed in Escherichia coli after 30 mins by liquid scintillation counter |
CHEMBL2086256 |
| SH-SY5Y |
IC50 |
= |
17000.0 |
nM |
Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTS reduction assay |
CHEMBL2086256 |
| NCI-H727 |
IC50 |
= |
20000.0 |
nM |
Antiproliferative activity against human NCI-H727 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay |
CHEMBL2086312 |
| ADMET |
IC50 |
> |
25000.0 |
nM |
Antiproliferative activity against human Skin fibroblasts incubated for 48 hrs by Hoechst 3342 dye staining based assay |
CHEMBL2086312 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A |
IC50 |
= |
11000.0 |
nM |
Inhibition of rat recombinant GST-tagged DYRK1A expressed in Escherichia coli using myelin basic protein substrate |
CHEMBL2086312 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
200.0 |
nM |
Inhibition of human recombinant CDK5/P25 using myelin basic protein substrate |
CHEMBL2086312 |
| PI3-kinase p110-alpha/p85-alpha |
IC50 |
|
|
|
Inhibition of PI3K p110alpha/p85alpha by fluorescence based immunoassay |
CHEMBL2086312 |
| PI3-kinase p110-alpha subunit |
IC50 |
|
|
|
Inhibition of PI3K p110gamma by fluorescence based immunoassay |
CHEMBL2086312 |
| Huh-7 |
IC50 |
= |
12000.0 |
nM |
Antiproliferative activity against human HuH7 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay |
CHEMBL2086312 |
| Caco-2 |
IC50 |
= |
5000.0 |
nM |
Antiproliferative activity against human Caco2 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay |
CHEMBL2086312 |
| MDA-MB-231 |
IC50 |
= |
12000.0 |
nM |
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay |
CHEMBL2086312 |
| HCT-116 |
IC50 |
= |
7000.0 |
nM |
Antiproliferative activity against human HCT116 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay |
CHEMBL2086312 |
| PC-3 |
IC50 |
= |
10000.0 |
nM |
Antiproliferative activity against human PC3 cells incubated for 48 hrs by Hoechst 3342 dye staining based assay |
CHEMBL2086312 |
| ADMET |
IC50 |
= |
20480.0 |
nM |
Cytotoxicity against human L02 cells after 48 hrs by SRB assay |
CHEMBL2157955 |
| HT-1080 |
IC50 |
= |
9620.0 |
nM |
Cytotoxicity against human HT1080 cells after 48 hrs by SRB assay |
CHEMBL2157955 |
| A549 |
IC50 |
= |
14140.0 |
nM |
Cytotoxicity against human A549 cells after 48 hrs by SRB assay |
CHEMBL2157955 |
| HepG2 |
IC50 |
= |
15470.0 |
nM |
Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay |
CHEMBL2157955 |
| MCF7 |
IC50 |
= |
12220.0 |
nM |
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay |
CHEMBL2157955 |
| HT-29 |
IC50 |
= |
11630.0 |
nM |
Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay |
CHEMBL2157955 |
| HCT-116 |
IC50 |
= |
16380.0 |
nM |
Cytotoxicity against human HCT116 cells after 48 hrs by SRB assay |
CHEMBL2157955 |
| Voltage-gated N-type calcium channel alpha-1B subunit |
EC50 |
= |
27580.0 |
nM |
Agonist activity at N-type Cav2.2 channel expressed in tsA201 cell assessed as calcium current by whole-cell patch clamp method |
CHEMBL2203054 |
| Cyclin-dependent kinase 2/cyclin A |
EC50 |
= |
151.0 |
nM |
Inhibition of human Cdk2/cyclin A activity |
CHEMBL2203054 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
700.0 |
nM |
Inhibition of GST-fused CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP |
CHEMBL3046684 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
700.0 |
nM |
Inhibition of GST-fused CDK2/cyclin A (unknown origin) expressed in baculovirus infected Sf9 cells after 10 min in presence of [gamma-32PP]ATP |
CHEMBL3046684 |
| CDK9/cyclin T1 |
Ki |
= |
790.0 |
nM |
Inhibition of CDK9/Cyclin T (1 to 330 amino acid residues) (unknown origin) by differential scanning fluorimetry assay |
CHEMBL2311463 |
| Cyclin-dependent kinase 2/cyclin A |
Ki |
= |
250.0 |
nM |
Inhibition of CDK2/Cyclin A (174 to 432 amino acid residues) (unknown origin) by differential scanning fluorimetry assay |
CHEMBL2311463 |
| Cyclin-dependent kinase 2/cyclin A |
Delta Tm |
= |
2.56 |
degrees C |
Stabilization of CDK2/Cyclin A (174 to 432 amino acid residues) (unknown origin) assessed as change in melting temperature at 20 uM by differential scanning fluorimetry assay |
CHEMBL2311463 |
| CDK9/cyclin T1 |
Delta Tm |
= |
1.57 |
degrees C |
Stabilization of CDK9/Cyclin T (1 to 330 amino acid residues) (unknown origin) assessed as change in melting temperature at 20 uM by differential scanning fluorimetry assay |
CHEMBL2311463 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
350.0 |
nM |
Inhibition of CDK2/cyclin B (unknown origin) after 30 mins by scintillation counting |
CHEMBL2311464 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Activity |
= |
88.0 |
% |
Inhibition of recombinant GST-fused human DYRK1A expressed in Escherichia coli using KKISGRLSPIMTEQ as substrate assessed as remaining activity at 0.1 uM |
CHEMBL2311464 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Activity |
= |
87.0 |
% |
Inhibition of recombinant GST-fused human DYRK1A expressed in Escherichia coli using KKISGRLSPIMTEQ as substrate assessed as remaining activity at 1 uM |
CHEMBL2311464 |
| NON-PROTEIN TARGET |
IC50 |
= |
17400.0 |
nM |
Cytotoxicity against human SH-SY5Y cells after 48 hrs by MTS assay |
CHEMBL2311464 |
| Unchecked |
IC50 |
= |
2300.0 |
nM |
Inhibition of porcine brain CK1 delta/epsilon using RRKHAAIGpSAYSITA as substrate measured after 30 mins by scintillation counting |
CHEMBL2311464 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
200.0 |
nM |
Inhibition of recombinant human CDK5/p25 after 30 mins by scintillation counting |
CHEMBL2311464 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
700.0 |
nM |
Inhibition of recombinant human CDK2/cyclin A after 30 mins by scintillation counting |
CHEMBL2311464 |
| MCF7 |
IC50 |
= |
11000.0 |
nM |
Antiproliferative activity against human MCF7 cells |
CHEMBL2321815 |
| K562 |
IC50 |
= |
42000.0 |
nM |
Antiproliferative activity against human K562 cells |
CHEMBL2321815 |
| Aurora kinase A/B |
Ratio |
= |
0.11 |
|
Activity at Aurora kinase A/B in human MCF7 cells assessed as histone H3 phosphorylation at Ser10 at 100 uM after 24 hrs by flow cytometry relative to untreated control |
CHEMBL2331324 |
| MCF7 |
Ratio |
= |
1.5 |
|
Cell cycle arrest in human MCF7 cells assessed as accumulation of cells in G2+M phase at 100 uM after 24 hrs by propidium iodide staining based flow cytometry relative to untreated control |
CHEMBL2331324 |
| MCF7 |
IC50 |
= |
20200.0 |
nM |
Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by calcien AM dye based fluorescence analysis |
CHEMBL2331324 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
170.0 |
nM |
Inhibition of recombinant CDK2/cyclin E (unknown origin) using histone H1 as substrate in presence of [gamma-33P]ATP |
CHEMBL2331324 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
2400.0 |
nM |
Inhibition of recombinant CDK1/cyclin B (unknown origin) using histone H1 as substrate in presence of [gamma-33P]ATP |
CHEMBL2331324 |
| CDK9/cyclin T1 |
IC50 |
= |
800.0 |
nM |
Inhibition of CDK9/CyclinT1 (unknown origin) |
CHEMBL2346630 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
500.0 |
nM |
Inhibition of CDK7/cyclin H (unknown origin) |
CHEMBL2346630 |
| Cyclin-dependent kinase 2/cyclin A |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2/Cyclin A (unknown origin) |
CHEMBL2346630 |
| Unchecked |
Activity |
|
|
|
Induction of apoptosis in human neutrophils assessed as primary necrosis at 10 uM after 8 hrs by annexin V/propidium iodide staining based flow cytometric analysis |
CHEMBL2346509 |
| Unchecked |
Activity |
|
|
|
Induction of apoptosis in human neutrophils at 10 uM by annexin V/propidium iodide staining based flow cytometric analysis |
CHEMBL2346509 |
| Unchecked |
Activity |
|
|
|
Induction of apoptosis in human neutrophils assessed as pre-necrotic cells at 3 uM after 6 hrs by annexin V/propidium iodide staining based flow cytometric analysis in presence of PTIO |
CHEMBL2346509 |
| Unchecked |
Activity |
|
|
|
Induction of apoptosis in human neutrophils assessed as pre-necrotic cells at 3 to 10 uM after 6 hrs by annexin V/propidium iodide staining based flow cytometric analysis in presence of ODQ |
CHEMBL2346509 |
| Unchecked |
Activity |
|
|
|
Induction of apoptosis in human neutrophils assessed as pre-necrotic cells at 3 to 10 uM after 6 hrs by annexin V/propidium iodide staining based flow cytometric analysis in presence of L-NAME |
CHEMBL2346509 |
| Unchecked |
Activity |
|
|
|
Induction of apoptosis in human neutrophils assessed as cellular shrinkage and nuclear pyknosis at 3 uM after 6 hrs by light microscopy analysis |
CHEMBL2346509 |
| Unchecked |
Activity |
= |
6.98 |
% |
Induction of apoptosis in human neutrophils assessed as apoptotic cells at 3 uM after 6 hrs by annexin V/propidium iodide staining based flow cytometric analysis |
CHEMBL2346509 |
| Unchecked |
Activity |
= |
0.386 |
% |
Induction of apoptosis in human neutrophils assessed as necrotic cells at 3 uM after 6 hrs by annexin V/propidium iodide staining based flow cytometric analysis |
CHEMBL2346509 |
| Unchecked |
Activity |
= |
92.6 |
% |
Induction of apoptosis in human neutrophils assessed as viable cells at 3 uM after 6 hrs by annexin V/propidium iodide staining based flow cytometric analysis |
CHEMBL2346509 |
| Unchecked |
Activity |
= |
0.033 |
% |
Induction of apoptosis in human neutrophils assessed as pre-necrotic cells at 3 uM after 6 hrs by annexin V/propidium iodide staining based flow cytometric analysis |
CHEMBL2346509 |
| Cyclin-dependent kinase |
INH |
= |
24.5 |
uM |
Inhibition of CDK (unknown origin) expressed in human ARN8 cells assessed as increase in p53-dependent transcriptional activity after 24 hrs by beta-galactosidase reporter gene assay |
CHEMBL2346655 |
| CDK9/cyclin T1 |
IC50 |
= |
2694.0 |
nM |
Inhibition of CDK9/CyclinT1 (unknown origin) using (YSPTSPS)2KK as substrate |
CHEMBL2346655 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
793.0 |
nM |
Inhibition of CDK7/CyclinH/MAT1 (unknown origin) using (YSPTSPS)2KK as substrate |
CHEMBL2346655 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
1080.0 |
nM |
Inhibition of CDK5/P35 (unknown origin) using histone H1 as substrate |
CHEMBL2346655 |
| HOS |
IC50 |
= |
24300.0 |
nM |
Cytotoxicity against human HOS cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay |
CHEMBL2346655 |
| G-361 |
IC50 |
= |
22400.0 |
nM |
Cytotoxicity against human G361 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay |
CHEMBL2346655 |
| CCRF-CEM |
IC50 |
= |
16300.0 |
nM |
Cytotoxicity against human CEM cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay |
CHEMBL2346655 |
| HCT-116 |
IC50 |
= |
14400.0 |
nM |
Cytotoxicity against human HCT116 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay |
CHEMBL2346655 |
| MCF7 |
IC50 |
= |
12300.0 |
nM |
Cytotoxicity against human MCF7 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay |
CHEMBL2346655 |
| K562 |
IC50 |
= |
45500.0 |
nM |
Cytotoxicity against human K562 cells assessed as reduction in number of viable cells after 72 hrs by fluorescence assay |
CHEMBL2346655 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
180.0 |
nM |
Inhibition of CDK2/Cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate |
CHEMBL2346655 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
22024.8 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
24712.2 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| DSH1 |
IC50 |
= |
253600.45 |
nM |
SANGER: Inhibition of human DSH1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| Daudi |
IC50 |
= |
3151547.87 |
nM |
SANGER: Inhibition of human Daudi cell growth in a cell viability assay. |
CHEMBL1201861 |
| DU-4475 |
IC50 |
= |
48493.71 |
nM |
SANGER: Inhibition of human DU-4475 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EHEB |
IC50 |
= |
79182.87 |
nM |
SANGER: Inhibition of human EHEB cell growth in a cell viability assay. |
CHEMBL1201861 |
| EKVX |
IC50 |
= |
529923.15 |
nM |
SANGER: Inhibition of human EKVX cell growth in a cell viability assay. |
CHEMBL1201861 |
| EM-2 |
IC50 |
= |
923655.35 |
nM |
SANGER: Inhibition of human EM-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ES1 |
IC50 |
= |
271582.51 |
nM |
SANGER: Inhibition of human ES1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ES4 |
IC50 |
= |
293211.15 |
nM |
SANGER: Inhibition of human ES4 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ES5 |
IC50 |
= |
4414875.88 |
nM |
SANGER: Inhibition of human ES5 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ES3 |
IC50 |
= |
29958.23 |
nM |
SANGER: Inhibition of human ES3 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EB-3 |
IC50 |
= |
23183.11 |
nM |
SANGER: Inhibition of human EB-3 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EB2 |
IC50 |
= |
1284013.5 |
nM |
SANGER: Inhibition of human EB2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EC-GI-10 |
IC50 |
= |
3488600.74 |
nM |
SANGER: Inhibition of human EC-GI-10 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ECC12 |
IC50 |
= |
288995.18 |
nM |
SANGER: Inhibition of human ECC12 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ECC4 |
IC50 |
= |
381103.5 |
nM |
SANGER: Inhibition of human ECC4 cell growth in a cell viability assay. |
CHEMBL1201861 |
| COLO-800 |
IC50 |
= |
3345314.54 |
nM |
SANGER: Inhibition of human COLO-800 cell growth in a cell viability assay. |
CHEMBL1201861 |
| DG-75 |
IC50 |
= |
42654.59 |
nM |
SANGER: Inhibition of human DG-75 cell growth in a cell viability assay. |
CHEMBL1201861 |
| DJM-1 |
IC50 |
= |
268865.97 |
nM |
SANGER: Inhibition of human DJM-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| C2BBe1 |
IC50 |
= |
70477.75 |
nM |
SANGER: Inhibition of human C2BBe1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| COLO-824 |
IC50 |
= |
719245.68 |
nM |
SANGER: Inhibition of human COLO-824 cell growth in a cell viability assay. |
CHEMBL1201861 |
| DMS-114 |
IC50 |
= |
167435.8 |
nM |
SANGER: Inhibition of human DMS-114 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ACN |
IC50 |
= |
21338.95 |
nM |
SANGER: Inhibition of human ACN cell growth in a cell viability assay. |
CHEMBL1201861 |
| C8166 |
IC50 |
= |
1143513.71 |
nM |
SANGER: Inhibition of human C8166 cell growth in a cell viability assay. |
CHEMBL1201861 |
| CA46 |
IC50 |
= |
92430.78 |
nM |
SANGER: Inhibition of human CA46 cell growth in a cell viability assay. |
CHEMBL1201861 |
| COLO-829 |
IC50 |
= |
742149.72 |
nM |
SANGER: Inhibition of human COLO-829 cell growth in a cell viability assay. |
CHEMBL1201861 |
| DMS-79 |
IC50 |
= |
89108.79 |
nM |
SANGER: Inhibition of human DMS-79 cell growth in a cell viability assay. |
CHEMBL1201861 |
| DOHH-2 |
IC50 |
= |
174048.85 |
nM |
SANGER: Inhibition of human DOHH-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ALL-PO |
IC50 |
= |
143212.28 |
nM |
SANGER: Inhibition of human ALL-PO cell growth in a cell viability assay. |
CHEMBL1201861 |
| COR-L279 |
IC50 |
= |
12290.71 |
nM |
SANGER: Inhibition of human COR-L279 cell growth in a cell viability assay. |
CHEMBL1201861 |
| COR-L88 |
IC50 |
= |
2516947.16 |
nM |
SANGER: Inhibition of human COR-L88 cell growth in a cell viability assay. |
CHEMBL1201861 |
| DMS-153 |
IC50 |
= |
65496.58 |
nM |
SANGER: Inhibition of human DMS-153 cell growth in a cell viability assay. |
CHEMBL1201861 |
| AM-38 |
IC50 |
= |
486181.98 |
nM |
SANGER: Inhibition of human AM-38 cell growth in a cell viability assay. |
CHEMBL1201861 |
| CAL-148 |
IC50 |
= |
181377.41 |
nM |
SANGER: Inhibition of human CAL-148 cell growth in a cell viability assay. |
CHEMBL1201861 |
| CP66-MEL |
IC50 |
= |
652087.01 |
nM |
SANGER: Inhibition of human CP66-MEL cell growth in a cell viability assay. |
CHEMBL1201861 |
| ARH-77 |
IC50 |
= |
96021.87 |
nM |
SANGER: Inhibition of human ARH-77 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ATN-1 |
IC50 |
= |
81680.39 |
nM |
SANGER: Inhibition of human ATN-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| CPC-N |
IC50 |
= |
307404.66 |
nM |
SANGER: Inhibition of human CPC-N cell growth in a cell viability assay. |
CHEMBL1201861 |
| CTB-1 |
IC50 |
= |
263426.13 |
nM |
SANGER: Inhibition of human CTB-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| CTV-1 |
IC50 |
= |
237377.57 |
nM |
SANGER: Inhibition of human CTV-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| CW-2 |
IC50 |
= |
99493.17 |
nM |
SANGER: Inhibition of human CW-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| 697 |
IC50 |
= |
12600.71 |
nM |
SANGER: Inhibition of human 697 cell growth in a cell viability assay. |
CHEMBL1201861 |
| BB30-HNC |
IC50 |
= |
29948.34 |
nM |
SANGER: Inhibition of human BB30-HNC cell growth in a cell viability assay. |
CHEMBL1201861 |
| BB49-HNC |
IC50 |
= |
85068.26 |
nM |
SANGER: Inhibition of human BB49-HNC cell growth in a cell viability assay. |
CHEMBL1201861 |
| BB65-RCC |
IC50 |
= |
9974.95 |
nM |
SANGER: Inhibition of human BB65-RCC cell growth in a cell viability assay. |
CHEMBL1201861 |
| BC1 cell line |
IC50 |
= |
19119.83 |
nM |
SANGER: Inhibition of human BC-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| CAS-1 |
IC50 |
= |
994666.0 |
nM |
SANGER: Inhibition of human CAS-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| 8-MG-BA |
IC50 |
= |
167901.08 |
nM |
SANGER: Inhibition of human 8-MG-BA cell growth in a cell viability assay. |
CHEMBL1201861 |
| BC-3 |
IC50 |
= |
18030.54 |
nM |
SANGER: Inhibition of human BC-3 cell growth in a cell viability assay. |
CHEMBL1201861 |
| BE-13 |
IC50 |
= |
259090.91 |
nM |
SANGER: Inhibition of human BE-13 cell growth in a cell viability assay. |
CHEMBL1201861 |
| CCRF-CEM |
IC50 |
= |
106625.21 |
nM |
SANGER: Inhibition of human CCRF-CEM cell growth in a cell viability assay. |
CHEMBL1201861 |
| Calu-6 |
IC50 |
= |
32474.53 |
nM |
SANGER: Inhibition of human Calu-6 cell growth in a cell viability assay. |
CHEMBL1201861 |
| A101D |
IC50 |
= |
18320.78 |
nM |
SANGER: Inhibition of human A101D cell growth in a cell viability assay. |
CHEMBL1201861 |
| CESS |
IC50 |
= |
20854.94 |
nM |
SANGER: Inhibition of human CESS cell growth in a cell viability assay. |
CHEMBL1201861 |
| CGTH-W-1 |
IC50 |
= |
44969.75 |
nM |
SANGER: Inhibition of human CGTH-W-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| D-247MG |
IC50 |
= |
12351.58 |
nM |
SANGER: Inhibition of human D-247MG cell growth in a cell viability assay. |
CHEMBL1201861 |
| CHP-126 |
IC50 |
= |
1177183.5 |
nM |
SANGER: Inhibition of human CHP-126 cell growth in a cell viability assay. |
CHEMBL1201861 |
| D-263MG |
IC50 |
= |
68047.3 |
nM |
SANGER: Inhibition of human D-263MG cell growth in a cell viability assay. |
CHEMBL1201861 |
| D283 Med |
IC50 |
= |
772001.89 |
nM |
SANGER: Inhibition of human D-283MED cell growth in a cell viability assay. |
CHEMBL1201861 |
| A253 cell line |
IC50 |
= |
271299.4 |
nM |
SANGER: Inhibition of human A253 cell growth in a cell viability assay. |
CHEMBL1201861 |
| BL-41 |
IC50 |
= |
25959.74 |
nM |
SANGER: Inhibition of human BL-41 cell growth in a cell viability assay. |
CHEMBL1201861 |
| BL-70 |
IC50 |
= |
20327.36 |
nM |
SANGER: Inhibition of human BL-70 cell growth in a cell viability assay. |
CHEMBL1201861 |
| CMK |
IC50 |
= |
207544.75 |
nM |
SANGER: Inhibition of human CMK cell growth in a cell viability assay. |
CHEMBL1201861 |
| D-336MG |
IC50 |
= |
543555.6 |
nM |
SANGER: Inhibition of human D-336MG cell growth in a cell viability assay. |
CHEMBL1201861 |
| D-392MG |
IC50 |
= |
292958.51 |
nM |
SANGER: Inhibition of human D-392MG cell growth in a cell viability assay. |
CHEMBL1201861 |
| A3-KAW |
IC50 |
= |
5761.16 |
nM |
SANGER: Inhibition of human A3-KAW cell growth in a cell viability assay. |
CHEMBL1201861 |
| COLO-320-HSR |
IC50 |
= |
18768.84 |
nM |
SANGER: Inhibition of human COLO-320-HSR cell growth in a cell viability assay. |
CHEMBL1201861 |
| COLO-668 |
IC50 |
= |
81901.8 |
nM |
SANGER: Inhibition of human COLO-668 cell growth in a cell viability assay. |
CHEMBL1201861 |
| D-502MG |
IC50 |
= |
247038.2 |
nM |
SANGER: Inhibition of human D-502MG cell growth in a cell viability assay. |
CHEMBL1201861 |
| A388 |
IC50 |
= |
466316.23 |
nM |
SANGER: Inhibition of human A388 cell growth in a cell viability assay. |
CHEMBL1201861 |
| A4-Fuk |
IC50 |
= |
258377.84 |
nM |
SANGER: Inhibition of human A4-Fuk cell growth in a cell viability assay. |
CHEMBL1201861 |
| BT-474 |
IC50 |
= |
569912.59 |
nM |
SANGER: Inhibition of human BT-474 cell growth in a cell viability assay. |
CHEMBL1201861 |
| BV-173 |
IC50 |
= |
2125913.77 |
nM |
SANGER: Inhibition of human BV-173 cell growth in a cell viability assay. |
CHEMBL1201861 |
| D-542MG |
IC50 |
= |
67095.43 |
nM |
SANGER: Inhibition of human D-542MG cell growth in a cell viability assay. |
CHEMBL1201861 |
| DB |
IC50 |
= |
69546.74 |
nM |
SANGER: Inhibition of human DB cell growth in a cell viability assay. |
CHEMBL1201861 |
| Becker |
IC50 |
= |
9460.82 |
nM |
SANGER: Inhibition of human Becker cell growth in a cell viability assay. |
CHEMBL1201861 |
| COLO-684 |
IC50 |
= |
37011.99 |
nM |
SANGER: Inhibition of human COLO-684 cell growth in a cell viability assay. |
CHEMBL1201861 |
| DEL |
IC50 |
= |
91329.79 |
nM |
SANGER: Inhibition of human DEL cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1838 |
IC50 |
= |
657700.07 |
nM |
SANGER: Inhibition of human NCI-H1838 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H526 |
IC50 |
= |
33493.62 |
nM |
SANGER: Inhibition of human NCI-H526 cell growth in a cell viability assay. |
CHEMBL1201861 |
| OMC-1 |
IC50 |
= |
1803656.01 |
nM |
SANGER: Inhibition of human OMC-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| RPMI-6666 |
IC50 |
= |
13912.09 |
nM |
SANGER: Inhibition of human RPMI-6666 cell growth in a cell viability assay. |
CHEMBL1201861 |
| RPMI-8226 |
IC50 |
= |
111476.52 |
nM |
SANGER: Inhibition of human RPMI-8226 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SK-MEL-1 |
IC50 |
= |
1799649.14 |
nM |
SANGER: Inhibition of human SK-MEL-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TGW |
IC50 |
= |
17812.38 |
nM |
SANGER: Inhibition of human TGW cell growth in a cell viability assay. |
CHEMBL1201861 |
| THP-1 |
IC50 |
= |
3237831.19 |
nM |
SANGER: Inhibition of human THP-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| GI-1 |
IC50 |
= |
29011.29 |
nM |
SANGER: Inhibition of human GI-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| GI-ME-N |
IC50 |
= |
42667.14 |
nM |
SANGER: Inhibition of human GI-ME-N cell growth in a cell viability assay. |
CHEMBL1201861 |
| HH |
IC50 |
= |
24381.87 |
nM |
SANGER: Inhibition of human HH cell growth in a cell viability assay. |
CHEMBL1201861 |
| HL-60 |
IC50 |
= |
27986.86 |
nM |
SANGER: Inhibition of human HL-60 cell growth in a cell viability assay. |
CHEMBL1201861 |
| IST-SL1 |
IC50 |
= |
67643.75 |
nM |
SANGER: Inhibition of human IST-SL1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| IST-SL2 |
IC50 |
= |
24534.35 |
nM |
SANGER: Inhibition of human IST-SL2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KS-1 |
IC50 |
= |
9457.85 |
nM |
SANGER: Inhibition of human KS-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LNCaP-Clone-FGC |
IC50 |
= |
1380352.25 |
nM |
SANGER: Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay. |
CHEMBL1201861 |
| LOUCY |
IC50 |
= |
32125.3 |
nM |
SANGER: Inhibition of human LOUCY cell growth in a cell viability assay. |
CHEMBL1201861 |
| MFH-ino |
IC50 |
= |
164277.16 |
nM |
SANGER: Inhibition of human MFH-ino cell growth in a cell viability assay. |
CHEMBL1201861 |
| MFM-223 |
IC50 |
= |
1846263.23 |
nM |
SANGER: Inhibition of human MFM-223 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB13 |
IC50 |
= |
1151643.12 |
nM |
SANGER: Inhibition of human NB13 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB14 |
IC50 |
= |
2022490.6 |
nM |
SANGER: Inhibition of human NB14 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H187 |
IC50 |
= |
361473.6 |
nM |
SANGER: Inhibition of human NCI-H187 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1882 |
IC50 |
= |
40599.79 |
nM |
SANGER: Inhibition of human NCI-H1882 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1963 |
IC50 |
= |
56454.89 |
nM |
SANGER: Inhibition of human NCI-H1963 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H64 |
IC50 |
= |
33859.72 |
nM |
SANGER: Inhibition of human NCI-H64 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ONS-76 |
IC50 |
= |
262492.63 |
nM |
SANGER: Inhibition of human ONS-76 cell growth in a cell viability assay. |
CHEMBL1201861 |
| RPMI 8402 |
IC50 |
= |
13626.18 |
nM |
SANGER: Inhibition of human RPMI-8402 cell growth in a cell viability assay. |
CHEMBL1201861 |
| RPMI-8866 |
IC50 |
= |
1325586.13 |
nM |
SANGER: Inhibition of human RPMI-8866 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SK-MEL-2 |
IC50 |
= |
3199666.93 |
nM |
SANGER: Inhibition of human SK-MEL-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SW684 |
IC50 |
= |
125195.19 |
nM |
SANGER: Inhibition of human SW684 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TK-10 |
IC50 |
= |
126376.05 |
nM |
SANGER: Inhibition of human TK10 cell growth in a cell viability assay. |
CHEMBL1201861 |
| GOTO |
IC50 |
= |
32912.91 |
nM |
SANGER: Inhibition of human GOTO cell growth in a cell viability assay. |
CHEMBL1201861 |
| J-RT3-T3-5 |
IC50 |
= |
64020.73 |
nM |
SANGER: Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KU812 cell line |
IC50 |
= |
69210.81 |
nM |
SANGER: Inhibition of human KU812 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KURAMOCHI |
IC50 |
= |
26808.23 |
nM |
SANGER: Inhibition of human KURAMOCHI cell growth in a cell viability assay. |
CHEMBL1201861 |
| LOX IMVI |
IC50 |
= |
57569.45 |
nM |
SANGER: Inhibition of human LOXIMVI cell growth in a cell viability assay. |
CHEMBL1201861 |
| LP-1 |
IC50 |
= |
33890.81 |
nM |
SANGER: Inhibition of human LP-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MHH-CALL-2 |
IC50 |
= |
322126.72 |
nM |
SANGER: Inhibition of human MHH-CALL-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB17 |
IC50 |
= |
163480.55 |
nM |
SANGER: Inhibition of human NB17 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB5 |
IC50 |
= |
256416.74 |
nM |
SANGER: Inhibition of human NB5 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H69 |
IC50 |
= |
907720.04 |
nM |
SANGER: Inhibition of human NCI-H69 cell growth in a cell viability assay. |
CHEMBL1201861 |
| OPM-2 |
IC50 |
= |
37294.95 |
nM |
SANGER: Inhibition of human OPM-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| OS-RC-2 |
IC50 |
= |
15838.22 |
nM |
SANGER: Inhibition of human OS-RC-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| RS4-11 |
IC50 |
= |
37706.93 |
nM |
SANGER: Inhibition of human RS4-11 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TUR |
IC50 |
= |
2055521.78 |
nM |
SANGER: Inhibition of human TUR cell growth in a cell viability assay. |
CHEMBL1201861 |
| GR-ST |
IC50 |
= |
557476.86 |
nM |
SANGER: Inhibition of human GR-ST cell growth in a cell viability assay. |
CHEMBL1201861 |
| HOP-62 |
IC50 |
= |
25442.53 |
nM |
SANGER: Inhibition of human HOP-62 cell growth in a cell viability assay. |
CHEMBL1201861 |
| JAR |
IC50 |
= |
17015.23 |
nM |
SANGER: Inhibition of human JAR cell growth in a cell viability assay. |
CHEMBL1201861 |
| KY821 |
IC50 |
= |
231382.23 |
nM |
SANGER: Inhibition of human KY821 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LS-1034 |
IC50 |
= |
123979.1 |
nM |
SANGER: Inhibition of human LS-1034 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LS-123 |
IC50 |
= |
197264.41 |
nM |
SANGER: Inhibition of human LS-123 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MHH-NB-11 |
IC50 |
= |
73389.58 |
nM |
SANGER: Inhibition of human MHH-NB-11 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MHH-PREB-1 |
IC50 |
= |
20035.63 |
nM |
SANGER: Inhibition of human MHH-PREB-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB6 |
IC50 |
= |
977399.04 |
nM |
SANGER: Inhibition of human NB6 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB69 |
IC50 |
= |
3271124.21 |
nM |
SANGER: Inhibition of human NB69 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H2081 |
IC50 |
= |
291494.17 |
nM |
SANGER: Inhibition of human NCI-H2081 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H716 |
IC50 |
= |
4070874.01 |
nM |
SANGER: Inhibition of human NCI-H716 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H719 |
IC50 |
= |
576484.82 |
nM |
SANGER: Inhibition of human NCI-H719 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H720 |
IC50 |
= |
335973.74 |
nM |
SANGER: Inhibition of human NCI-H720 cell growth in a cell viability assay. |
CHEMBL1201861 |
| OVCAR-4 |
IC50 |
= |
460315.44 |
nM |
SANGER: Inhibition of human OVCAR-4 cell growth in a cell viability assay. |
CHEMBL1201861 |
| RXF 393 |
IC50 |
= |
288118.25 |
nM |
SANGER: Inhibition of human RXF393 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SK-MM-2 |
IC50 |
= |
817603.91 |
nM |
SANGER: Inhibition of human SK-MM-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SW872 |
IC50 |
= |
470292.57 |
nM |
SANGER: Inhibition of human SW872 cell growth in a cell viability assay. |
CHEMBL1201861 |
| U-266 |
IC50 |
= |
1993318.27 |
nM |
SANGER: Inhibition of human U-266 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ES6 |
IC50 |
= |
86404.61 |
nM |
SANGER: Inhibition of human ES6 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ES7 |
IC50 |
= |
535327.66 |
nM |
SANGER: Inhibition of human ES7 cell growth in a cell viability assay. |
CHEMBL1201861 |
| GT3TKB |
IC50 |
= |
115394.77 |
nM |
SANGER: Inhibition of human GT3TKB cell growth in a cell viability assay. |
CHEMBL1201861 |
| JVM-2 |
IC50 |
= |
93717.13 |
nM |
SANGER: Inhibition of human JVM-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| JVM-3 |
IC50 |
= |
3699829.44 |
nM |
SANGER: Inhibition of human JVM-3 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LS-411N |
IC50 |
= |
228842.04 |
nM |
SANGER: Inhibition of human LS-411N cell growth in a cell viability assay. |
CHEMBL1201861 |
| LS-513 |
IC50 |
= |
23517.86 |
nM |
SANGER: Inhibition of human LS-513 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB7 |
IC50 |
= |
489817.07 |
nM |
SANGER: Inhibition of human NB7 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H209 |
IC50 |
= |
46011.53 |
nM |
SANGER: Inhibition of human NCI-H209 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H747 |
IC50 |
= |
245147.48 |
nM |
SANGER: Inhibition of human NCI-H747 cell growth in a cell viability assay. |
CHEMBL1201861 |
| Raji |
IC50 |
= |
13789.44 |
nM |
SANGER: Inhibition of human Raji cell growth in a cell viability assay. |
CHEMBL1201861 |
| Ramos-2G6-4C10 |
IC50 |
= |
97742.94 |
nM |
SANGER: Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SK-N-DZ |
IC50 |
= |
102847.78 |
nM |
SANGER: Inhibition of human SK-N-DZ cell growth in a cell viability assay. |
CHEMBL1201861 |
| SW 954 |
IC50 |
= |
290923.4 |
nM |
SANGER: Inhibition of human SW954 cell growth in a cell viability assay. |
CHEMBL1201861 |
| U-698-M |
IC50 |
= |
1257210.93 |
nM |
SANGER: Inhibition of human U-698-M cell growth in a cell viability assay. |
CHEMBL1201861 |
| U-87 MG |
IC50 |
= |
187904.9 |
nM |
SANGER: Inhibition of human U-87-MG cell growth in a cell viability assay. |
CHEMBL1201861 |
| ES8 |
IC50 |
= |
21060.03 |
nM |
SANGER: Inhibition of human ES8 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HAL-01 |
IC50 |
= |
79665.77 |
nM |
SANGER: Inhibition of human HAL-01 cell growth in a cell viability assay. |
CHEMBL1201861 |
| JIYOYE |
IC50 |
= |
8502.64 |
nM |
SANGER: Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay. |
CHEMBL1201861 |
| K562 |
IC50 |
= |
130531.16 |
nM |
SANGER: Inhibition of human K-562 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LU-134-A |
IC50 |
= |
272690.38 |
nM |
SANGER: Inhibition of human LU-134-A cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCCIT |
IC50 |
= |
7554.82 |
nM |
SANGER: Inhibition of human NCCIT cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1092 |
IC50 |
= |
69677.19 |
nM |
SANGER: Inhibition of human NCI-H1092 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H2107 |
IC50 |
= |
109311.87 |
nM |
SANGER: Inhibition of human NCI-H2107 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H2126 |
IC50 |
= |
25652.88 |
nM |
SANGER: Inhibition of human NCI-H2126 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H748 |
IC50 |
= |
263974.37 |
nM |
SANGER: Inhibition of human NCI-H748 cell growth in a cell viability assay. |
CHEMBL1201861 |
| P30-OHK |
IC50 |
= |
2492757.98 |
nM |
SANGER: Inhibition of human P30-OHK cell growth in a cell viability assay. |
CHEMBL1201861 |
| P31-FUJ |
IC50 |
= |
3063548.0 |
nM |
SANGER: Inhibition of human P31-FUJ cell growth in a cell viability assay. |
CHEMBL1201861 |
| SK-N-FI |
IC50 |
= |
31753.5 |
nM |
SANGER: Inhibition of human SK-N-FI cell growth in a cell viability assay. |
CHEMBL1201861 |
| SK-NEP-1 |
IC50 |
= |
283583.33 |
nM |
SANGER: Inhibition of human SK-NEP-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SW 962 |
IC50 |
= |
140782.48 |
nM |
SANGER: Inhibition of human SW962 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ETK-1 |
IC50 |
= |
185096.81 |
nM |
SANGER: Inhibition of human ETK-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EVSA-T |
IC50 |
= |
152104.99 |
nM |
SANGER: Inhibition of human EVSA-T cell growth in a cell viability assay. |
CHEMBL1201861 |
| HC-1 |
IC50 |
= |
64145.7 |
nM |
SANGER: Inhibition of human HC-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HCC1187 |
IC50 |
= |
312627.38 |
nM |
SANGER: Inhibition of human HCC1187 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HT |
IC50 |
= |
42002.75 |
nM |
SANGER: Inhibition of human HT cell growth in a cell viability assay. |
CHEMBL1201861 |
| K5 |
IC50 |
= |
35086.06 |
nM |
SANGER: Inhibition of human K5 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LU-139 |
IC50 |
= |
37185.65 |
nM |
SANGER: Inhibition of human LU-139 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LU-165 |
IC50 |
= |
514066.17 |
nM |
SANGER: Inhibition of human LU-165 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ML-2 |
IC50 |
= |
37671.17 |
nM |
SANGER: Inhibition of human ML-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MLMA |
IC50 |
= |
42278.68 |
nM |
SANGER: Inhibition of human MLMA cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1155 |
IC50 |
= |
54319.87 |
nM |
SANGER: Inhibition of human NCI-H1155 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H128 |
IC50 |
= |
3515053.41 |
nM |
SANGER: Inhibition of human NCI-H128 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H2141 |
IC50 |
= |
34653.34 |
nM |
SANGER: Inhibition of human NCI-H2141 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H82 |
IC50 |
= |
31013.48 |
nM |
SANGER: Inhibition of human NCI-H82 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H889 |
IC50 |
= |
885930.05 |
nM |
SANGER: Inhibition of human NCI-H889 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SBC-1 |
IC50 |
= |
489497.82 |
nM |
SANGER: Inhibition of human SBC-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SCC-15 |
IC50 |
= |
351370.07 |
nM |
SANGER: Inhibition of human SCC-15 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SK-PN-DW |
IC50 |
= |
86238.96 |
nM |
SANGER: Inhibition of human SK-PN-DW cell growth in a cell viability assay. |
CHEMBL1201861 |
| UACC-257 |
IC50 |
= |
66314.86 |
nM |
SANGER: Inhibition of human UACC-257 cell growth in a cell viability assay. |
CHEMBL1201861 |
| UACC-812 |
IC50 |
= |
711871.91 |
nM |
SANGER: Inhibition of human UACC-812 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EW-1 |
IC50 |
= |
65621.74 |
nM |
SANGER: Inhibition of human EW-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EW-11 |
IC50 |
= |
1512148.85 |
nM |
SANGER: Inhibition of human EW-11 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KALS-1 |
IC50 |
= |
71418.0 |
nM |
SANGER: Inhibition of human KALS-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KARPAS-299 |
IC50 |
= |
26864.62 |
nM |
SANGER: Inhibition of human KARPAS-299 cell growth in a cell viability assay. |
CHEMBL1201861 |
| L-363 |
IC50 |
= |
914521.52 |
nM |
SANGER: Inhibition of human L-363 cell growth in a cell viability assay. |
CHEMBL1201861 |
| Lu-65 |
IC50 |
= |
238629.47 |
nM |
SANGER: Inhibition of human LU-65 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MMAC-SF |
IC50 |
= |
422989.77 |
nM |
SANGER: Inhibition of human MMAC-SF cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1304 |
IC50 |
= |
16360.13 |
nM |
SANGER: Inhibition of human NCI-H1304 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H2171 |
IC50 |
= |
159236.9 |
nM |
SANGER: Inhibition of human NCI-H2171 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H2196 |
IC50 |
= |
155583.88 |
nM |
SANGER: Inhibition of human NCI-H2196 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H2227 |
IC50 |
= |
2388232.9 |
nM |
SANGER: Inhibition of human NCI-H2227 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SNU1 |
IC50 |
= |
31105.92 |
nM |
SANGER: Inhibition of human NCI-SNU-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SCC-3 |
IC50 |
= |
14295.59 |
nM |
SANGER: Inhibition of human SCC-3 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SK-UT-1 |
IC50 |
= |
10349.96 |
nM |
SANGER: Inhibition of human SK-UT-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EW-12 |
IC50 |
= |
3183581.18 |
nM |
SANGER: Inhibition of human EW-12 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EW-13 |
IC50 |
= |
541947.97 |
nM |
SANGER: Inhibition of human EW-13 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HCC1599 |
IC50 |
= |
14597.5 |
nM |
SANGER: Inhibition of human HCC1599 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HT-144 |
IC50 |
= |
63409.27 |
nM |
SANGER: Inhibition of human HT-144 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KARPAS-422 |
IC50 |
= |
9963.36 |
nM |
SANGER: Inhibition of human KARPAS-422 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KARPAS-45 |
IC50 |
= |
574588.42 |
nM |
SANGER: Inhibition of human KARPAS-45 cell growth in a cell viability assay. |
CHEMBL1201861 |
| Kasumi 1 |
IC50 |
= |
3862743.65 |
nM |
SANGER: Inhibition of human KASUMI-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| L-428 |
IC50 |
= |
704500.47 |
nM |
SANGER: Inhibition of human L-428 cell growth in a cell viability assay. |
CHEMBL1201861 |
| L-540 |
IC50 |
= |
155761.97 |
nM |
SANGER: Inhibition of human L-540 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LXF-289 cell line |
IC50 |
= |
113370.14 |
nM |
SANGER: Inhibition of human LXF-289 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MN-60 |
IC50 |
= |
487530.57 |
nM |
SANGER: Inhibition of human MN-60 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MOLT-16 |
IC50 |
= |
163948.44 |
nM |
SANGER: Inhibition of human MOLT-16 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1355 |
IC50 |
= |
72450.97 |
nM |
SANGER: Inhibition of human NCI-H1355 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1395 |
IC50 |
= |
630305.11 |
nM |
SANGER: Inhibition of human NCI-H1395 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H226 |
IC50 |
= |
705405.63 |
nM |
SANGER: Inhibition of human NCI-H226 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SNU-16 |
IC50 |
= |
117136.98 |
nM |
SANGER: Inhibition of human NCI-SNU-16 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SNU-5 |
IC50 |
= |
182814.32 |
nM |
SANGER: Inhibition of human NCI-SNU-5 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NEC8 |
IC50 |
= |
111724.94 |
nM |
SANGER: Inhibition of human NEC8 cell growth in a cell viability assay. |
CHEMBL1201861 |
| PF-382 |
IC50 |
= |
50966.93 |
nM |
SANGER: Inhibition of human PF-382 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SKM-1 |
IC50 |
= |
917722.45 |
nM |
SANGER: Inhibition of human SKM-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SNB-75 |
IC50 |
= |
207660.6 |
nM |
SANGER: Inhibition of human SNB75 cell growth in a cell viability assay. |
CHEMBL1201861 |
| VA-ES-BJ |
IC50 |
= |
187061.23 |
nM |
SANGER: Inhibition of human VA-ES-BJ cell growth in a cell viability assay. |
CHEMBL1201861 |
| EW-16 |
IC50 |
= |
74334.93 |
nM |
SANGER: Inhibition of human EW-16 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EW-18 |
IC50 |
= |
3731800.11 |
nM |
SANGER: Inhibition of human EW-18 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KE-37 |
IC50 |
= |
93498.84 |
nM |
SANGER: Inhibition of human KE-37 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KG-1 |
IC50 |
= |
795144.61 |
nM |
SANGER: Inhibition of human KG-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LAMA-84 |
IC50 |
= |
2640897.23 |
nM |
SANGER: Inhibition of human LAMA-84 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LAN-6 |
IC50 |
= |
158401.98 |
nM |
SANGER: Inhibition of human LAN-6 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MC-CAR |
IC50 |
= |
489089.26 |
nM |
SANGER: Inhibition of human MC-CAR cell growth in a cell viability assay. |
CHEMBL1201861 |
| MOLT-4 |
IC50 |
= |
36327.57 |
nM |
SANGER: Inhibition of human MOLT-4 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1417 |
IC50 |
= |
831094.08 |
nM |
SANGER: Inhibition of human NCI-H1417 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1436 |
IC50 |
= |
534165.12 |
nM |
SANGER: Inhibition of human NCI-H1436 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H23 |
IC50 |
= |
2970349.79 |
nM |
SANGER: Inhibition of human NCI-H23 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NH-12 |
IC50 |
= |
1424380.13 |
nM |
SANGER: Inhibition of human NH-12 cell growth in a cell viability assay. |
CHEMBL1201861 |
| PSN1 |
IC50 |
= |
427385.75 |
nM |
SANGER: Inhibition of human PSN1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SCH |
IC50 |
= |
134636.02 |
nM |
SANGER: Inhibition of human SCH cell growth in a cell viability assay. |
CHEMBL1201861 |
| SCLC-21H |
IC50 |
= |
325330.31 |
nM |
SANGER: Inhibition of human SCLC-21H cell growth in a cell viability assay. |
CHEMBL1201861 |
| TALL-1 |
IC50 |
= |
69736.44 |
nM |
SANGER: Inhibition of human TALL-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TE-1 |
IC50 |
= |
74627.49 |
nM |
SANGER: Inhibition of human TE-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EW-24 |
IC50 |
= |
1192057.4 |
nM |
SANGER: Inhibition of human EW-24 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HCC2157 |
IC50 |
= |
194528.37 |
nM |
SANGER: Inhibition of human HCC2157 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HCC2218 |
IC50 |
= |
1780897.98 |
nM |
SANGER: Inhibition of human HCC2218 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HuTu80 |
IC50 |
= |
310350.41 |
nM |
SANGER: Inhibition of human HUTU-80 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KGN |
IC50 |
= |
34252.45 |
nM |
SANGER: Inhibition of human KGN cell growth in a cell viability assay. |
CHEMBL1201861 |
| KINGS-1 |
IC50 |
= |
787988.9 |
nM |
SANGER: Inhibition of human KINGS-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LB1047-RCC |
IC50 |
= |
158950.05 |
nM |
SANGER: Inhibition of human LB1047-RCC cell growth in a cell viability assay. |
CHEMBL1201861 |
| LB2241-RCC |
IC50 |
= |
48620.15 |
nM |
SANGER: Inhibition of human LB2241-RCC cell growth in a cell viability assay. |
CHEMBL1201861 |
| MC116 |
IC50 |
= |
85282.14 |
nM |
SANGER: Inhibition of human MC116 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MONO-MAC-6 |
IC50 |
= |
38247.72 |
nM |
SANGER: Inhibition of human MONO-MAC-6 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MPP-89 |
IC50 |
= |
255825.87 |
nM |
SANGER: Inhibition of human MPP-89 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MRK-nu-1 |
IC50 |
= |
7129.69 |
nM |
SANGER: Inhibition of human MRK-nu-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1522 |
IC50 |
= |
124614.88 |
nM |
SANGER: Inhibition of human NCI-H1522 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NKM-1 |
IC50 |
= |
31139.75 |
nM |
SANGER: Inhibition of human NKM-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NMC-G1 |
IC50 |
= |
50928.62 |
nM |
SANGER: Inhibition of human NMC-G1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| QIMR-WIL |
IC50 |
= |
27914.44 |
nM |
SANGER: Inhibition of human QIMR-WIL cell growth in a cell viability assay. |
CHEMBL1201861 |
| RCC10RGB |
IC50 |
= |
392068.67 |
nM |
SANGER: Inhibition of human RCC10RGB cell growth in a cell viability assay. |
CHEMBL1201861 |
| SF-126 |
IC50 |
= |
98232.98 |
nM |
SANGER: Inhibition of human SF126 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SF-268 |
IC50 |
= |
131690.04 |
nM |
SANGER: Inhibition of human SF268 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SNU-C1 |
IC50 |
= |
521320.49 |
nM |
SANGER: Inhibition of human SNU-C1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TE-10 |
IC50 |
= |
34942.19 |
nM |
SANGER: Inhibition of human TE-10 cell growth in a cell viability assay. |
CHEMBL1201861 |
| WSU-NHL |
IC50 |
= |
2563674.86 |
nM |
SANGER: Inhibition of human WSU-NHL cell growth in a cell viability assay. |
CHEMBL1201861 |
| EW-3 |
IC50 |
= |
999510.84 |
nM |
SANGER: Inhibition of human EW-3 cell growth in a cell viability assay. |
CHEMBL1201861 |
| EOL1 |
IC50 |
= |
3603147.33 |
nM |
SANGER: Inhibition of human EoL-1-cell cell growth in a cell viability assay. |
CHEMBL1201861 |
| HCC 2998 |
IC50 |
= |
165626.13 |
nM |
SANGER: Inhibition of human HCC2998 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LB2518-MEL |
IC50 |
= |
47044.83 |
nM |
SANGER: Inhibition of human LB2518-MEL cell growth in a cell viability assay. |
CHEMBL1201861 |
| LB373-MEL-D |
IC50 |
= |
560842.99 |
nM |
SANGER: Inhibition of human LB373-MEL-D cell growth in a cell viability assay. |
CHEMBL1201861 |
| MDA-MB-134-VI |
IC50 |
= |
220192.9 |
nM |
SANGER: Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay. |
CHEMBL1201861 |
| MS-1 |
IC50 |
= |
42892.97 |
nM |
SANGER: Inhibition of human MS-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MSTO-211H |
IC50 |
= |
1903177.24 |
nM |
SANGER: Inhibition of human MSTO-211H cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1581 |
IC50 |
= |
101747.68 |
nM |
SANGER: Inhibition of human NCI-H1581 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NOMO-1 |
IC50 |
= |
21200.8 |
nM |
SANGER: Inhibition of human NOMO-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NOS-1 |
IC50 |
= |
28973.31 |
nM |
SANGER: Inhibition of human NOS-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SF-539 |
IC50 |
= |
823093.66 |
nM |
SANGER: Inhibition of human SF539 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SR |
IC50 |
= |
118844.75 |
nM |
SANGER: Inhibition of human SR cell growth in a cell viability assay. |
CHEMBL1201861 |
| TE-12 |
IC50 |
= |
124527.68 |
nM |
SANGER: Inhibition of human TE-12 cell growth in a cell viability assay. |
CHEMBL1201861 |
| YT |
IC50 |
= |
536409.57 |
nM |
SANGER: Inhibition of human YT cell growth in a cell viability assay. |
CHEMBL1201861 |
| KM-H2 |
IC50 |
= |
1831458.64 |
nM |
SANGER: Inhibition of human KM-H2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KM12 |
IC50 |
= |
29623.86 |
nM |
SANGER: Inhibition of human KM12 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LB647-SCLC |
IC50 |
= |
66308.76 |
nM |
SANGER: Inhibition of human LB647-SCLC cell growth in a cell viability assay. |
CHEMBL1201861 |
| LB771-HNC |
IC50 |
= |
48921.16 |
nM |
SANGER: Inhibition of human LB771-HNC cell growth in a cell viability assay. |
CHEMBL1201861 |
| MV4-11 |
IC50 |
= |
105590.46 |
nM |
SANGER: Inhibition of human MV-4-11 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MZ1-PC |
IC50 |
= |
1116559.1 |
nM |
SANGER: Inhibition of human MZ1-PC cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1648 |
IC50 |
= |
157184.3 |
nM |
SANGER: Inhibition of human NCI-H1648 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H322M |
IC50 |
= |
229043.51 |
nM |
SANGER: Inhibition of human NCI-H322M cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H345 |
IC50 |
= |
38910.65 |
nM |
SANGER: Inhibition of human NCI-H345 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NTERA-2-cl-D1 |
IC50 |
= |
39584.24 |
nM |
SANGER: Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| REH |
IC50 |
= |
1288588.87 |
nM |
SANGER: Inhibition of human REH cell growth in a cell viability assay. |
CHEMBL1201861 |
| RH-1 |
IC50 |
= |
592673.7 |
nM |
SANGER: Inhibition of human RH-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SH-4 |
IC50 |
= |
128960.48 |
nM |
SANGER: Inhibition of human SH-4 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SHP77 |
IC50 |
= |
124538.39 |
nM |
SANGER: Inhibition of human SHP-77 cell growth in a cell viability assay. |
CHEMBL1201861 |
| ST486 |
IC50 |
= |
10350.98 |
nM |
SANGER: Inhibition of human ST486 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SU-DHL-1 |
IC50 |
= |
162830.54 |
nM |
SANGER: Inhibition of human SU-DHL-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SUP-T1 |
IC50 |
= |
4498219.81 |
nM |
SANGER: Inhibition of human SUP-T1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TE-15 |
IC50 |
= |
878570.36 |
nM |
SANGER: Inhibition of human TE-15 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TE-441-T |
IC50 |
= |
36114.81 |
nM |
SANGER: Inhibition of human TE-441-T cell growth in a cell viability assay. |
CHEMBL1201861 |
| TE-5 |
IC50 |
= |
94354.13 |
nM |
SANGER: Inhibition of human TE-5 cell growth in a cell viability assay. |
CHEMBL1201861 |
| no-10 |
IC50 |
= |
87895.71 |
nM |
SANGER: Inhibition of human no-10 cell growth in a cell viability assay. |
CHEMBL1201861 |
| no-11 |
IC50 |
= |
215862.58 |
nM |
SANGER: Inhibition of human no-11 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HCE-T |
IC50 |
= |
530972.91 |
nM |
SANGER: Inhibition of human HCE-T cell growth in a cell viability assay. |
CHEMBL1201861 |
| KMOE-2 |
IC50 |
= |
171934.05 |
nM |
SANGER: Inhibition of human KMOE-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KMS-12-PE |
IC50 |
= |
1386464.14 |
nM |
SANGER: Inhibition of human KMS-12-PE cell growth in a cell viability assay. |
CHEMBL1201861 |
| LB831-BLC |
IC50 |
= |
11562.35 |
nM |
SANGER: Inhibition of human LB831-BLC cell growth in a cell viability assay. |
CHEMBL1201861 |
| LB996-RCC |
IC50 |
= |
59920.46 |
nM |
SANGER: Inhibition of human LB996-RCC cell growth in a cell viability assay. |
CHEMBL1201861 |
| MZ2-MEL |
IC50 |
= |
553126.65 |
nM |
SANGER: Inhibition of human MZ2-MEL cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1650 |
IC50 |
= |
2627163.43 |
nM |
SANGER: Inhibition of human NCI-H1650 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H446 |
IC50 |
= |
1310157.97 |
nM |
SANGER: Inhibition of human NCI-H446 cell growth in a cell viability assay. |
CHEMBL1201861 |
| RKO |
IC50 |
= |
33596.87 |
nM |
SANGER: Inhibition of human RKO cell growth in a cell viability assay. |
CHEMBL1201861 |
| SIG-M5 |
IC50 |
= |
31683.34 |
nM |
SANGER: Inhibition of human SIG-M5 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SIMA |
IC50 |
= |
3053925.22 |
nM |
SANGER: Inhibition of human SIMA cell growth in a cell viability assay. |
CHEMBL1201861 |
| TE-6 |
IC50 |
= |
36324.56 |
nM |
SANGER: Inhibition of human TE-6 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TE-8 |
IC50 |
= |
28907.96 |
nM |
SANGER: Inhibition of human TE-8 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HD-MY-Z |
IC50 |
= |
16824.65 |
nM |
SANGER: Inhibition of human HD-MY-Z cell growth in a cell viability assay. |
CHEMBL1201861 |
| KNS-42 |
IC50 |
= |
72108.79 |
nM |
SANGER: Inhibition of human KNS-42 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KNS-81-FD |
IC50 |
= |
78078.44 |
nM |
SANGER: Inhibition of human KNS-81-FD cell growth in a cell viability assay. |
CHEMBL1201861 |
| LC-1F |
IC50 |
= |
41570.47 |
nM |
SANGER: Inhibition of human LC-1F cell growth in a cell viability assay. |
CHEMBL1201861 |
| LC-2-ad |
IC50 |
= |
363635.14 |
nM |
SANGER: Inhibition of human LC-2-ad cell growth in a cell viability assay. |
CHEMBL1201861 |
| MZ7-mel |
IC50 |
= |
762104.74 |
nM |
SANGER: Inhibition of human MZ7-mel cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1694 |
IC50 |
= |
119199.31 |
nM |
SANGER: Inhibition of human NCI-H1694 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H510A |
IC50 |
= |
30032.86 |
nM |
SANGER: Inhibition of human NCI-H510A cell growth in a cell viability assay. |
CHEMBL1201861 |
| OCI-AML2 |
IC50 |
= |
15648.22 |
nM |
SANGER: Inhibition of human OCI-AML2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| RL |
IC50 |
= |
3550039.47 |
nM |
SANGER: Inhibition of human RL cell growth in a cell viability assay. |
CHEMBL1201861 |
| RL95-2 |
IC50 |
= |
82234.34 |
nM |
SANGER: Inhibition of human RL95-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| SJSA-1 |
IC50 |
= |
50104.81 |
nM |
SANGER: Inhibition of human SJSA-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TE-9 |
IC50 |
= |
28796.91 |
nM |
SANGER: Inhibition of human TE-9 cell growth in a cell viability assay. |
CHEMBL1201861 |
| GB-1 |
IC50 |
= |
113128.24 |
nM |
SANGER: Inhibition of human GB-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| GCIY |
IC50 |
= |
12861.34 |
nM |
SANGER: Inhibition of human GCIY cell growth in a cell viability assay. |
CHEMBL1201861 |
| HDLM-2 |
IC50 |
= |
1593659.14 |
nM |
SANGER: Inhibition of human HDLM-2 cell growth in a cell viability assay. |
CHEMBL1201861 |
| IM-9 |
IC50 |
= |
4134790.74 |
nM |
SANGER: Inhibition of human IM-9 cell growth in a cell viability assay. |
CHEMBL1201861 |
| IMR-5 |
IC50 |
= |
35313.88 |
nM |
SANGER: Inhibition of human IMR-5 cell growth in a cell viability assay. |
CHEMBL1201861 |
| LC4-1 |
IC50 |
= |
18873.45 |
nM |
SANGER: Inhibition of human LC4-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| MEG-01 |
IC50 |
= |
13837.88 |
nM |
SANGER: Inhibition of human MEG-01 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NALM-6 |
IC50 |
= |
77040.4 |
nM |
SANGER: Inhibition of human NALM-6 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB1 |
IC50 |
= |
12330.75 |
nM |
SANGER: Inhibition of human NB1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H524 |
IC50 |
= |
61357.78 |
nM |
SANGER: Inhibition of human NCI-H524 cell growth in a cell viability assay. |
CHEMBL1201861 |
| OCUB-M |
IC50 |
= |
215710.45 |
nM |
SANGER: Inhibition of human OCUB-M cell growth in a cell viability assay. |
CHEMBL1201861 |
| SK-LMS-1 |
IC50 |
= |
1502931.78 |
nM |
SANGER: Inhibition of human SK-LMS-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| TGBC1TKB |
IC50 |
= |
501318.19 |
nM |
SANGER: Inhibition of human TGBC1TKB cell growth in a cell viability assay. |
CHEMBL1201861 |
| GDM-1 |
IC50 |
= |
117740.38 |
nM |
SANGER: Inhibition of human GDM-1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| HEL |
IC50 |
= |
52077.03 |
nM |
SANGER: Inhibition of human HEL cell growth in a cell viability assay. |
CHEMBL1201861 |
| IST-MEL1 |
IC50 |
= |
146076.73 |
nM |
SANGER: Inhibition of human IST-MEL1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| IST-MES1 |
IC50 |
= |
1095906.33 |
nM |
SANGER: Inhibition of human IST-MES1 cell growth in a cell viability assay. |
CHEMBL1201861 |
| KP-N-YS |
IC50 |
= |
1751971.49 |
nM |
SANGER: Inhibition of human KP-N-YS cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB10 |
IC50 |
= |
55603.6 |
nM |
SANGER: Inhibition of human NB10 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NB12 |
IC50 |
= |
848063.91 |
nM |
SANGER: Inhibition of human NB12 cell growth in a cell viability assay. |
CHEMBL1201861 |
| NCI-H1770 |
IC50 |
= |
1559987.36 |
nM |
SANGER: Inhibition of human NCI-H1770 cell growth in a cell viability assay. |
CHEMBL1201861 |
| A549 |
Activity |
|
|
|
Induction of apoptosis in human A549 cells assessed as DNA fragmentation at 2 uM after 48 hrs by agarose gel electrophoresis |
CHEMBL2384939 |
| A549 |
Activity |
= |
46.75 |
% |
Cell cycle arrest at human A549 cells assessed as accumulation at G0/G1 phase at 2 uM after 48 hrs by propidium iodide-staining-based FACS flow cytometric analysis (Rvb = 81.33%) |
CHEMBL2384939 |
| A549 |
Activity |
= |
40.69 |
% |
Cell cycle arrest at human A549 cells assessed as accumulation at G2/M phase at 2 uM after 48 hrs by propidium iodide-staining-based FACS flow cytometric analysis (Rvb = 13.17%) |
CHEMBL2384939 |
| A549 |
Activity |
= |
7.3 |
% |
Cell cycle arrest at human A549 cells assessed as accumulation at sub G1 phase at 2 uM after 48 hrs by propidium iodide-staining-based FACS flow cytometric analysis (Rvb = 1.02%) |
CHEMBL2384939 |
| A549 |
Activity |
= |
5.26 |
% |
Cell cycle arrest at human A549 cells assessed as accumulation at S phase at 2 uM after 48 hrs by propidium iodide-staining-based FACS flow cytometric analysis (Rvb = 4.48%) |
CHEMBL2384939 |
| A549 |
FC |
= |
4.0 |
|
Induction of apoptosis in human A549 cells assessed as activation of caspase-3 at 2 uM after 48 hrs by ELISA relative to control |
CHEMBL2384939 |
| MCF7 |
IC50 |
= |
3980.0 |
nM |
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay |
CHEMBL2384939 |
| ACHN |
IC50 |
= |
2880.0 |
nM |
Cytotoxicity against human ACHN cells after 48 hrs by MTT assay |
CHEMBL2384939 |
| A549 |
IC50 |
= |
2180.0 |
nM |
Cytotoxicity against human A549 cells after 48 hrs by MTT assay |
CHEMBL2384939 |
| DU-145 |
IC50 |
= |
1900.0 |
nM |
Cytotoxicity against human DU145 cells after 48 hrs by MTT assay |
CHEMBL2384939 |
| HeLa |
IC50 |
= |
1810.0 |
nM |
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay |
CHEMBL2384939 |
| HeLa |
IC50 |
= |
28600.0 |
nM |
Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay |
CHEMBL2401709 |
| HCT-116 |
IC50 |
= |
14400.0 |
nM |
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay |
CHEMBL2401709 |
| HOS |
IC50 |
= |
24300.0 |
nM |
Cytotoxicity against human HOS cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay |
CHEMBL2401709 |
| G-361 |
IC50 |
= |
22400.0 |
nM |
Cytotoxicity against human G361 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay |
CHEMBL2401709 |
| MCF7 |
IC50 |
= |
12300.0 |
nM |
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay |
CHEMBL2401709 |
| K562 |
IC50 |
= |
45500.0 |
nM |
Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by calcein AM staining-based fluoroscence assay |
CHEMBL2401709 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
170.0 |
nM |
Inhibition of human recombinant CDK2/Cyclin E expressed in baculovirus infected sf9 cells using histone H1 as substrate |
CHEMBL2401709 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
2421.0 |
nM |
Inhibition of human recombinant CDK1 |
CHEMBL2401709 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
930.0 |
nM |
Inhibition of CDK5/p25 (unknown origin) after 30 mins by SDS-PAGE analysis |
CHEMBL2417543 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
500.0 |
nM |
Inhibition of human N-terminal hexahistidine-tagged CDK2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate after 10 mins in presence of [gamma-32P]-ATP |
CHEMBL2424530 |
| MCF7 |
IC50 |
= |
12300.0 |
nM |
Cytotoxicity against human MCF7 cells after 72 hrs by calcein-AM assay |
CHEMBL2424632 |
| K562 |
IC50 |
= |
45500.0 |
nM |
Cytotoxicity against human K562 cells after 72 hrs by calcein-AM assay |
CHEMBL2424632 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
IC50 |
= |
3100.0 |
nM |
Inhibition of human GST-fused DYRK1A expressed in Escherichia coli using KISGRLSPIMTEQ as substrate |
CHEMBL3102826 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
490.0 |
nM |
Inhibition of His-6-tagged recombinant human CDK7/cyclinH expressed in baculovirus-infected sf9 cells using biotinyl-Ahx-(YSPTSPS)4 as substrate after 45 mins by liquid scintillation counting in presence of [gamma-32P]ATP |
CHEMBL3112420 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
100.0 |
nM |
Inhibition of His-6-tagged recombinant human CDK2/cyclinE expressed in baculovirus-infected sf9 cells using histone H1 as substrate after 10 mins by liquid scintillation counting in presence of [gamma-32P]ATP |
CHEMBL3112420 |
| Cyclin-dependent kinase 4/cyclin D1 |
IC50 |
= |
14210.0 |
nM |
Inhibition of His-6-tagged recombinant human CDK4/cyclinD1 using GST-retinoblastoma (773 to 928) as substrate after 45 mins by liquid scintillation counting in presence of [gamma-32P]ATP |
CHEMBL3112420 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
2690.0 |
nM |
Inhibition of His-6-tagged recombinant human CDK1/cyclinB1 expressed in baculovirus-infected sf9 cells by liquid scintillation counting in presence of [gamma-32P]ATP |
CHEMBL3112420 |
| Unchecked |
Potency |
|
10000.0 |
nM |
PubChem BioAssay. qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
22387.2 |
nM |
PubChem BioAssay. qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosine-protein kinase ABL |
IC50 |
> |
100000.0 |
nM |
Inhibition of recombinant Abl kinase (unknown origin) expressed in Sf9 cells using GGEAIYAAPFKK as substrate in presence of [gamma33P]ATP |
CHEMBL3232722 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2/cyclin E (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of [gamma33P]ATP |
CHEMBL3232722 |
| Unchecked |
IC50 |
= |
330.0 |
nM |
Inhibition of starfish CDK1/cyclinB using [gamma-33P]ATP after 30 mins incubation by scintillation counting analysis |
CHEMBL3286202 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
280.0 |
nM |
Inhibition of human recombinant CDK5/p25 using [gamma-33P]ATP after 30 mins incubation by scintillation counting analysis |
CHEMBL3286202 |
| Glycogen synthase kinase-3 |
IC50 |
= |
60000.0 |
nM |
Inhibition of pig brain GSK-3alpha/beta using GS-1 substrate |
CHEMBL3286202 |
| ADMET |
PPB |
|
92.8 |
% |
ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma at 37C for >5hrs. Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound. |
CHEMBL3301361 |
| ADMET |
PPB |
|
92.8 |
% |
ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma at 37C for >5hrs. Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound. |
CHEMBL3301361 |
| ADMET |
CL |
|
107.15 |
uL.min-1.(10^6cells)-1 |
ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736 |
CHEMBL3301361 |
| ADMET |
CL |
|
123.03 |
mL.min-1.g-1 |
ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736. |
CHEMBL3301361 |
| No relevant target |
LogD7.4 |
|
3.63 |
|
ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5 |
CHEMBL3301361 |
| No relevant target |
Solubility |
|
74100.0 |
nM |
ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM |
CHEMBL3301361 |
| MCF7 |
IC50 |
= |
11000.0 |
nM |
Cytotoxicity against human MCF7 cells after 72 hrs using Calcein AM by fluorescence assay |
CHEMBL3400118 |
| K562 |
IC50 |
= |
42000.0 |
nM |
Cytotoxicity against human K562 cells after 72 hrs using Calcein AM by fluorescence assay |
CHEMBL3400118 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2/Cyclin E (unknown origin) using histone H1 as substrate by [gamma-33P]ATP assay |
CHEMBL3400118 |
| Tyrosine-protein kinase ABL |
IC50 |
> |
100000.0 |
nM |
Inhibition of Abl (unknown origin) using GGEAIYAAPFKK peptide as substrate by [gamma-33P]ATP assay |
CHEMBL3400118 |
| NCI-H460 |
IC50 |
= |
11600.0 |
nM |
Growth inhibition of human NCI-H460 cells after 72 hrs by MTS/PMS system based colorimetric assay |
CHEMBL3421594 |
| MCF7 |
IC50 |
= |
19600.0 |
nM |
Growth inhibition of human MCF7 cells after 72 hrs by MTS/PMS system based colorimetric assay |
CHEMBL3421594 |
| NON-PROTEIN TARGET |
IC50 |
= |
9000.0 |
nM |
Growth inhibition of human Hep3B cells after 72 hrs by MTS/PMS system based colorimetric assay |
CHEMBL3421594 |
| KB |
IC50 |
= |
24600.0 |
nM |
Growth inhibition of human KB cells after 72 hrs by MTS/PMS system based colorimetric assay |
CHEMBL3421594 |
| SF-268 |
IC50 |
= |
8800.0 |
nM |
Growth inhibition of human SF268 cells after 72 hrs by MTS/PMS system based colorimetric assay |
CHEMBL3421594 |
| NON-PROTEIN TARGET |
IC50 |
= |
7600.0 |
nM |
Growth inhibition of human MKN45 cells after 72 hrs by MTS/PMS system based colorimetric assay |
CHEMBL3421594 |
| BJ |
Activity |
= |
106.3 |
% |
Cytotoxicity against human BJ cells assessed as cell viability at 30 uM after 72 hrs by fluorescence assay relative to control |
CHEMBL3421618 |
| Unchecked |
Activity |
= |
57.1 |
% |
Leshmanicidal activity against promastigote stage of Leishmania turanica MRHO/MN/08/BZ18 at 30 uM after 72 hrs by alamar blue staining-based fluorescence assay relative to control |
CHEMBL3421618 |
| Unchecked |
Inhibition |
= |
38.6 |
% |
Inhibition of Leishmania CRK3/CYC6 using histone H1/[gamma33-P]ATP as substrate at 30 uM after 30 mins relative to control |
CHEMBL3421618 |
| AMP-activated protein kinase, alpha-2 subunit |
Thermal melting change |
= |
0.4 |
degrees C |
Delta TM value showing the stabilisation of AMPKA2 produced by compound binding |
CHEMBL1145498 |
| CaM kinase I delta |
Thermal melting change |
= |
0.0 |
degrees C |
Delta TM value showing the stabilisation of CAMK1D produced by compound binding |
CHEMBL1145498 |
| CaM kinase I gamma |
Thermal melting change |
= |
0.0 |
degrees C |
Delta TM value showing the stabilisation of CAMK1G produced by compound binding |
CHEMBL1145498 |
| CaM kinase II alpha |
Thermal melting change |
= |
-0.1 |
degrees C |
Delta TM value showing the stabilisation of CAMK2A produced by compound binding |
CHEMBL1145498 |
| CaM kinase II beta |
Thermal melting change |
= |
0.3 |
degrees C |
Delta TM value showing the stabilisation of CAMK2B produced by compound binding |
CHEMBL1145498 |
| CaM kinase II delta |
Thermal melting change |
= |
0.1 |
degrees C |
Delta TM value showing the stabilisation of CAMK2D produced by compound binding |
CHEMBL1145498 |
| CaM kinase II gamma |
Thermal melting change |
= |
0.3 |
degrees C |
Delta TM value showing the stabilisation of CAMK2G produced by compound binding |
CHEMBL1145498 |
| CaM kinase IV |
Thermal melting change |
= |
0.2 |
degrees C |
Delta TM value showing the stabilisation of CAMK4 produced by compound binding |
CHEMBL1145498 |
| CaM-kinase kinase beta |
Thermal melting change |
= |
0.3 |
degrees C |
Delta TM value showing the stabilisation of CAMKK2 produced by compound binding |
CHEMBL1145498 |
| Cyclin-dependent kinase 2 |
Thermal melting change |
= |
1.5 |
degrees C |
Delta TM value showing the stabilisation of CDK2 produced by compound binding |
CHEMBL1145498 |
| Cyclin-dependent kinase 6 |
Thermal melting change |
= |
0.2 |
degrees C |
Delta TM value showing the stabilisation of CDK6 produced by compound binding |
CHEMBL1145498 |
| Cyclin-dependent kinase-like 1 |
Thermal melting change |
= |
0.2 |
degrees C |
Delta TM value showing the stabilisation of CDKL1 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase Chk2 |
Thermal melting change |
= |
0.0 |
degrees C |
Delta TM value showing the stabilisation of CHEK2 produced by compound binding |
CHEMBL1145498 |
| Dual specificty protein kinase CLK1 |
Thermal melting change |
= |
2.1 |
degrees C |
Delta TM value showing the stabilisation of CLK1 produced by compound binding |
CHEMBL1145498 |
| Dual specificity protein kinase CLK2 |
Thermal melting change |
= |
2.3 |
degrees C |
Delta TM value showing the stabilisation of CLK2 produced by compound binding |
CHEMBL1145498 |
| Dual specificity protein kinase CLK3 |
Thermal melting change |
= |
0.8 |
degrees C |
Delta TM value showing the stabilisation of CLK3 produced by compound binding |
CHEMBL1145498 |
| Casein kinase I gamma 1 |
Thermal melting change |
= |
1.2 |
degrees C |
Delta TM value showing the stabilisation of CK1G1 produced by compound binding |
CHEMBL1145498 |
| Casein kinase I gamma 2 |
Thermal melting change |
= |
1.2 |
degrees C |
Delta TM value showing the stabilisation of CK1G2 produced by compound binding |
CHEMBL1145498 |
| Casein kinase I isoform gamma-3 |
Thermal melting change |
= |
0.9 |
degrees C |
Delta TM value showing the stabilisation of CK1G3 produced by compound binding |
CHEMBL1145498 |
| Death-associated protein kinase 3 |
Thermal melting change |
= |
-0.1 |
degrees C |
Delta TM value showing the stabilisation of DAPK3 produced by compound binding |
CHEMBL1145498 |
| Myotonin-protein kinase |
Thermal melting change |
= |
-0.7 |
degrees C |
Delta TM value showing the stabilisation of DMPK1 produced by compound binding |
CHEMBL1145498 |
| Glycogen synthase kinase-3 beta |
Thermal melting change |
= |
0.4 |
degrees C |
Delta TM value showing the stabilisation of GSK3B produced by compound binding |
CHEMBL1145498 |
| Tyrosine-protein kinase JAK1 |
Thermal melting change |
= |
0.1 |
degrees C |
Delta TM value showing the stabilisation of JAK1~B produced by compound binding |
CHEMBL1145498 |
| Dual specificity mitogen-activated protein kinase kinase 2 |
Thermal melting change |
= |
-0.1 |
degrees C |
Delta TM value showing the stabilisation of MEK2 produced by compound binding |
CHEMBL1145498 |
| Dual specificity mitogen-activated protein kinase kinase 6 |
Thermal melting change |
= |
0.2 |
degrees C |
Delta TM value showing the stabilisation of MAP2K6 produced by compound binding |
CHEMBL1145498 |
| Mitogen-activated protein kinase kinase kinase 5 |
Thermal melting change |
= |
1.0 |
degrees C |
Delta TM value showing the stabilisation of ASK1 produced by compound binding |
CHEMBL1145498 |
| MAP kinase p38 beta |
Thermal melting change |
= |
1.0 |
degrees C |
Delta TM value showing the stabilisation of p38beta produced by compound binding |
CHEMBL1145498 |
| MAP kinase ERK1 |
Thermal melting change |
= |
0.4 |
degrees C |
Delta TM value showing the stabilisation of ERK1 produced by compound binding |
CHEMBL1145498 |
| Mitogen-activated protein kinase 6 |
Thermal melting change |
= |
-0.4 |
degrees C |
Delta TM value showing the stabilisation of ERK3 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase MST4 |
Thermal melting change |
= |
0.6 |
degrees C |
Delta TM value showing the stabilisation of MST4(1) produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase NEK2 |
Thermal melting change |
= |
0.7 |
degrees C |
Delta TM value showing the stabilisation of NEK2 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase NEK6 |
Thermal melting change |
= |
-0.1 |
degrees C |
Delta TM value showing the stabilisation of NEK6 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase OSR1 |
Thermal melting change |
= |
1.0 |
degrees C |
Delta TM value showing the stabilisation of OSR1 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase PAK 4 |
Thermal melting change |
= |
1.7 |
degrees C |
Delta TM value showing the stabilisation of PAK4 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase PAK7 |
Thermal melting change |
= |
0.6 |
degrees C |
Delta TM value showing the stabilisation of PAK5 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase PAK6 |
Thermal melting change |
= |
0.5 |
degrees C |
Delta TM value showing the stabilisation of PAK6 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase PCTAIRE-1 |
Thermal melting change |
= |
-0.1 |
degrees C |
Delta TM value showing the stabilisation of PCTK1 produced by compound binding |
CHEMBL1145498 |
| 3-phosphoinositide dependent protein kinase-1 |
Thermal melting change |
= |
0.2 |
degrees C |
Delta TM value showing the stabilisation of PDK1 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase PIM1 |
Thermal melting change |
= |
-1.0 |
degrees C |
Delta TM value showing the stabilisation of PIM1 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase PIM2 |
Thermal melting change |
= |
0.3 |
degrees C |
Delta TM value showing the stabilisation of PIM2 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase PIM3 |
Thermal melting change |
= |
0.5 |
degrees C |
Delta TM value showing the stabilisation of PIM3 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase PLK1 |
Thermal melting change |
= |
1.0 |
degrees C |
Delta TM value showing the stabilisation of PLK1 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase PLK4 |
Thermal melting change |
= |
0.3 |
degrees C |
Delta TM value showing the stabilisation of PLK4 produced by compound binding |
CHEMBL1145498 |
| cAMP-dependent protein kinase alpha-catalytic subunit |
Thermal melting change |
= |
0.2 |
degrees C |
Delta TM value showing the stabilisation of PRKACA produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase RIO2 |
Thermal melting change |
= |
0.0 |
degrees C |
Delta TM value showing the stabilisation of RIOK2 produced by compound binding |
CHEMBL1145498 |
| Ribosomal protein S6 kinase alpha 3 |
Thermal melting change |
= |
1.1 |
degrees C |
Delta TM value showing the stabilisation of RSK2a produced by compound binding |
CHEMBL1145498 |
| Ribosomal protein S6 kinase alpha 3 |
Thermal melting change |
= |
1.4 |
degrees C |
Delta TM value showing the stabilisation of RSK2b produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase 2 |
Thermal melting change |
= |
0.2 |
degrees C |
Delta TM value showing the stabilisation of SLK produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase 10 |
Thermal melting change |
= |
0.9 |
degrees C |
Delta TM value showing the stabilisation of LOK produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase 16 |
Thermal melting change |
= |
0.8 |
degrees C |
Delta TM value showing the stabilisation of MPSK1 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase 17A |
Thermal melting change |
= |
-0.5 |
degrees C |
Delta TM value showing the stabilisation of DRAK1 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase 38 |
Thermal melting change |
= |
0.3 |
degrees C |
Delta TM value showing the stabilisation of NDR1 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase MST4 |
Thermal melting change |
= |
0.3 |
degrees C |
Delta TM value showing the stabilisation of MST4 (2) produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase MST1 |
Thermal melting change |
= |
0.3 |
degrees C |
Delta TM value showing the stabilisation of MST1 produced by compound binding |
CHEMBL1145498 |
| TRAF2- and NCK-interacting kinase |
Thermal melting change |
= |
0.4 |
degrees C |
Delta TM value showing the stabilisation of TNIK produced by compound binding |
CHEMBL1145498 |
| PDZ-binding kinase |
Thermal melting change |
= |
0.8 |
degrees C |
Delta TM value showing the stabilisation of PBK produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase VRK1 |
Thermal melting change |
= |
0.0 |
degrees C |
Delta TM value showing the stabilisation of VRK1 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase VRK2 |
Thermal melting change |
= |
2.1 |
degrees C |
Delta TM value showing the stabilisation of VRK2 produced by compound binding |
CHEMBL1145498 |
| Inactive serine/threonine-protein kinase VRK3 |
Thermal melting change |
= |
0.6 |
degrees C |
Delta TM value showing the stabilisation of VRK3 produced by compound binding |
CHEMBL1145498 |
| Serine/threonine-protein kinase 25 |
Thermal melting change |
= |
0.3 |
degrees C |
Delta TM value showing the stabilisation of YSK1 produced by compound binding |
CHEMBL1145498 |
| Voltage-gated L-type calcium channel alpha-1C subunit |
IC50 |
= |
23400.0 |
nM |
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit |
CHEMBL3436046 |
| NON-PROTEIN TARGET |
IC50 |
= |
5000.0 |
nM |
Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay |
CHEMBL3608270 |
| Caco-2 |
IC50 |
= |
3000.0 |
nM |
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay |
CHEMBL3608270 |
| MDA-MB-231 |
IC50 |
= |
3000.0 |
nM |
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay |
CHEMBL3608270 |
| HCT-116 |
IC50 |
= |
2000.0 |
nM |
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay |
CHEMBL3608270 |
| PC-3 |
IC50 |
= |
2000.0 |
nM |
Cytotoxicity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay |
CHEMBL3608270 |
| NCI-H727 |
IC50 |
= |
4000.0 |
nM |
Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst 3342 staining based assay |
CHEMBL3608270 |
| MCF7 |
IC50 |
= |
11000.0 |
nM |
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation |
CHEMBL3751823 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
200.0 |
nM |
Inhibition of CDK2/Cyclin E (unknown origin) expressed in baculoviral infected insect Sf9 cells using histone H1 as substrate in presence of [gamma-33P]ATP |
CHEMBL3763042 |
| K562 |
IC50 |
= |
30900.0 |
nM |
Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method |
CHEMBL3763042 |
| MCF7 |
IC50 |
= |
27200.0 |
nM |
Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method |
CHEMBL3763042 |
| NON-PROTEIN TARGET |
IC50 |
= |
20800.0 |
nM |
Cytotoxicity against human G361 cells assessed as cell viability after 72 hrs by fluorescence microplate reader method |
CHEMBL3763042 |
| G-361 |
FC |
|
|
|
Induction of apoptosis in human G361 cells assessed as activation of caspases-3/7 at 50 uM using Ac-DEVD-AMC as substrate after 6 hrs by fluorescence microplate reader method relative to control |
CHEMBL3763042 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
707.95 |
nM |
Inhibition of CDK2/Cyclin E (unknown origin) |
CHEMBL3763042 |
| NON-PROTEIN TARGET |
IC50 |
= |
14420.0 |
nM |
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay |
CHEMBL3774312 |
| NON-PROTEIN TARGET |
IC50 |
= |
22400.0 |
nM |
Cytotoxicity against human G361 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay |
CHEMBL3774312 |
| MCF7 |
IC50 |
= |
12250.0 |
nM |
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay |
CHEMBL3774312 |
| K562 |
IC50 |
= |
45500.0 |
nM |
Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay |
CHEMBL3774312 |
| Cyclin-dependent kinase 5 |
IC50 |
= |
1069.0 |
nM |
Inhibition of CDK5 (unknown origin) using histone H1 as substrate in presence of [gamma33P]-ATP |
CHEMBL3774312 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
158.0 |
nM |
Inhibition of CDK2/Cyclin E (unknown origin) expressed in sf9 cells using histone H1 as substrate in presence of [gamma33P]-ATP |
CHEMBL3774312 |
| NON-PROTEIN TARGET |
IC50 |
= |
5000.0 |
nM |
Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 3342 staining analysis |
CHEMBL3784980 |
| NON-PROTEIN TARGET |
IC50 |
= |
3000.0 |
nM |
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 3342 staining analysis |
CHEMBL3784980 |
| MDA-MB-231 |
IC50 |
= |
3000.0 |
nM |
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 3342 staining analysis |
CHEMBL3784980 |
| NON-PROTEIN TARGET |
IC50 |
= |
2000.0 |
nM |
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 3342 staining analysis |
CHEMBL3784980 |
| NON-PROTEIN TARGET |
IC50 |
= |
2000.0 |
nM |
Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 3342 staining analysis |
CHEMBL3784980 |
| NCI-H727 |
IC50 |
= |
4000.0 |
nM |
Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 3342 staining analysis |
CHEMBL3784980 |
| K562 |
IC50 |
= |
45500.0 |
nM |
Cytotoxicity against human K562 cells |
CHEMBL3808286 |
| MCF7 |
IC50 |
= |
12300.0 |
nM |
Cytotoxicity against human MCF7 cells |
CHEMBL3808286 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
2900.0 |
nM |
Inhibition of CDK1/Cyclin B (unknown origin) |
CHEMBL3808286 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2/Cyclin E (unknown origin) |
CHEMBL3808286 |
| Tyrosine-protein kinase ABL |
IC50 |
> |
10000.0 |
nM |
Inhibition of Abl (unknown origin) |
CHEMBL3808286 |
| Synapsin-1 |
IC50 |
= |
1000.0 |
nM |
Inhibition of bovine brain synapsin-1 incubated for 1 hr by ATP-[gamma35S] binding assay |
CHEMBL3817815 |
| Adaptor-associated kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase ABL |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase ABL2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Acyl-CoA dehydrogenase family member 10 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Acyl-CoA dehydrogenase family member 11 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Very long-chain specific acyl-CoA dehydrogenase, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Peroxisomal acyl-coenzyme A oxidase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Peroxisomal acyl-coenzyme A oxidase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Long-chain-fatty-acid--CoA ligase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Actin-related protein 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Actin-related protein 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Activin receptor type-1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Activin receptor type-1B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Activin receptor type-2B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Uncharacterized aarF domain-containing protein kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Chaperone activity of bc1 complex-like, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Adenosine kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| G-protein coupled receptor kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Adenylate kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase AKT |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase AKT2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase AKT3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Adenine phosphoribosyltransferase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase A-Raf |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Aurora-A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Aurora-B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Breakpoint cluster region protein |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| BMP-2-inducible protein kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Bone morphogenetic protein receptor type-1A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Bone morphogenetic protein receptor type-1B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Bone morphogenetic protein receptor type-2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase B-raf |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase BTK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitotic checkpoint serine/threonine-protein kinase BUB1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| CaM kinase II delta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| CaM kinase II gamma |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| CaM kinase IV |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| CaM-kinase kinase beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cysteine--tRNA ligase, cytoplasmic |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MRCK-A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MRCK beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MRCK gamma |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 10 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 12 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 13 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PCTAIRE-1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PCTAIRE-2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 7 |
Kd |
= |
3705.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 9 |
Kd |
= |
4860.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase-like 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Chromodomain-helicase-DNA-binding protein 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Chk1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Citron Rho-interacting kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificty protein kinase CLK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity protein kinase CLK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| UMP-CMP kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase CSK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I delta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I epsilon |
Kd |
= |
12409.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I gamma 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I gamma 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I isoform gamma-3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Unchecked |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase II alpha (prime) |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cytochrome c1, heme protein, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Deoxycytidine kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| dCTP pyrophosphatase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Epithelial discoidin domain-containing receptor 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Discoidin domain-containing receptor 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ATP-dependent RNA helicase DDX1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ATP-dependent RNA helicase DDX3X |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ATP-dependent RNA helicase DDX42 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Probable ATP-dependent RNA helicase DDX6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Delta(24)-sterol reductase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| DnaJ homolog subfamily A member 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Kd |
= |
40291.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Eukaryotic translation initiation factor 2-alpha kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Unchecked |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 7 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-B receptor 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-B receptor 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-B receptor 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-B receptor 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| General transcription and DNA repair factor IIH helicase subunit XPD |
Kd |
= |
12022.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase/endoribonuclease IRE1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase/endoribonuclease IRE2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Electron transfer flavoprotein subunit beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phenylalanine--tRNA ligase beta subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ferrochelatase, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FER |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FES |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Fibroblast growth factor receptor 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FGR |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase receptor FLT3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FRK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FYN |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase GAK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Glycine--tRNA ligase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Glycogen synthase kinase-3 alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Glycogen synthase kinase-3 beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Nucleolar GTP-binding protein 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase HCK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Heme oxygenase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Putative heat shock protein HSP 90-beta 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Isoleucine--tRNA ligase, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase ICK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Insulin-like growth factor I receptor |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Inhibitor of nuclear factor kappa B kinase epsilon subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase ILK-1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Inosine-5'-monophosphate dehydrogenase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Insulin receptor |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Interleukin-1 receptor-associated kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Interleukin-1 receptor-associated kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Interleukin-1 receptor-associated kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase JAK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase JAK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase LATS1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase LCK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| LIM domain kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| LIM domain kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase Lyn |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 11 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase ERK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| c-Jun N-terminal kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase p38 beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase p38 alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase 15 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase ERK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase 7 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| c-Jun N-terminal kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| c-Jun N-terminal kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase-activated protein kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase-activated protein kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP/microtubule affinity-regulating kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase c-TAK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP/microtubule affinity-regulating kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| S-adenosylmethionine synthase isoform type-2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| DNA replication licensing factor MCM4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Midasin |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Maternal embryonic leucine zipper kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Hepatocyte growth factor receptor |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Macrophage-stimulating protein receptor |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Myosin-10 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Myosin-14 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Myosin light chain kinase, smooth muscle |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Myosin light chain kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| RNA cytidine acetyltransferase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Nek1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase NEK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Nek3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase NEK7 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase NEK9 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine protein kinase NLK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Quinone reductase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Nerve growth factor receptor Trk-A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| NUAK family SNF1-like kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Obg-like ATPase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dynamin-like 120 kDa protein, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Multifunctional protein ADE2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PAK 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PAK 4 |
Kd |
= |
5024.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| PAS domain-containing serine/threonine-protein kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Choline-phosphate cytidylyltransferase A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Platelet-derived growth factor receptor beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Unchecked |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Pyridoxal kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphatidylethanolamine-binding protein 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphofructokinase platelet type |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphorylase kinase gamma subunit 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PIM1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PIM2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphatidylinositol-5-phosphate 4-kinase type-2 alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphatidylinositol-5-phosphate 4-kinase type-2 gamma |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine- and threonine-specific cdc2-inhibitory kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase N1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase N2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase N3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PLK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PLK4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| AMP-activated protein kinase, alpha-1 subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cAMP-dependent protein kinase alpha-catalytic subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cAMP-dependent protein kinase beta-1 catalytic subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cAMP-dependent protein kinase, gamma catalytic subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| AMP-activated protein kinase, gamma-1 subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| AMP-activated protein kinase, gamma-2 subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cAMP-dependent protein kinase type II-alpha regulatory subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C delta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Unchecked |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C iota |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C theta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C zeta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase D2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C nu |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cGMP-dependent protein kinase 1 beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Unchecked |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| 26S protease regulatory subunit 6B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Focal adhesion kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein tyrosine kinase 2 beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase BRK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Brain glycogen phosphorylase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Liver glycogen phosphorylase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Uncharacterized protein FLJ45252 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ras-related protein Rab-10 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ras-related protein Rab-27A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Rab-like protein 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| GTP-binding nuclear protein Ran |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase receptor RET |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase RIPK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Receptor-interacting serine/threonine-protein kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Rho-associated protein kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Rho-associated protein kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Septin-9 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase SIK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase SIK3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Exosome RNA helicase MTR4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ADP/ATP translocase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ADP/ATP translocase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Structural maintenance of chromosomes protein 1A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Structural maintenance of chromosomes protein 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| U5 small nuclear ribonucleoprotein 200 kDa helicase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase SRC |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Signal recognition particle receptor subunit alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 10 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 11 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 16 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 24 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MST4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MST2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MST1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| STE20-related kinase adapter protein alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase SYK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase TAO1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase TAO2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase TAO3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase TBK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase TEC |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity testis-specific protein kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity testis-specific protein kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| TGF-beta receptor type I |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| TGF-beta receptor type II |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Thyroid hormone receptor-associated protein 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| TRAF2- and NCK-interacting kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Non-receptor tyrosine-protein kinase TNK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine kinase non-receptor protein 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| DNA topoisomerase II alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| DNA topoisomerase II beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| TP53-regulating kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity protein kinase TTK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Elongation factor Tu, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase TYK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase ULK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase ULK3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase WEE1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosyl-tRNA synthetase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase YES |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mixed lineage kinase 7 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Huh-7 |
IC50 |
= |
15400.0 |
nM |
Cytotoxicity against human HuH7 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| Caco-2 |
IC50 |
= |
12900.0 |
nM |
Cytotoxicity against human Caco2 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| MDA-MB-231 |
IC50 |
= |
16800.0 |
nM |
Cytotoxicity against human MDA-MB-231 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| HCT-116 |
IC50 |
= |
8000.0 |
nM |
Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| PC-3 |
IC50 |
= |
16500.0 |
nM |
Cytotoxicity against human PC3 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| NCI-H727 |
IC50 |
> |
20000.0 |
nM |
Cytotoxicity against human NCI-H727 cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| HaCaT |
IC50 |
= |
16700.0 |
nM |
Cytotoxicity against human HaCaT cells assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| Unchecked |
IC50 |
> |
20000.0 |
nM |
Cytotoxicity against human fibroblasts assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| RL |
IC50 |
= |
900.0 |
nM |
Cytotoxicity against human RL assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| MCF7 |
IC50 |
= |
10200.0 |
nM |
Cytotoxicity against human MCF7 assessed as cell viability after 48 hrs by Hoechst 33342 staining based assay |
CHEMBL3992552 |
| Unchecked |
Ratio IC50 |
= |
6.4 |
|
Selectivity index, ratio of IC50 for human fibroblasts to IC50 for human HuH7 cells |
CHEMBL3992552 |
| Unchecked |
Ratio IC50 |
= |
7.6 |
|
Selectivity index, ratio of IC50 for human fibroblasts to IC50 for human Caco2 cells |
CHEMBL3992552 |
| Unchecked |
Ratio IC50 |
= |
5.8 |
|
Selectivity index, ratio of IC50 for human fibroblasts to IC50 for human MDA-MB-231 cells |
CHEMBL3992552 |
| Unchecked |
Ratio IC50 |
= |
12.2 |
|
Selectivity index, ratio of IC50 for human fibroblasts to IC50 for human HCT116 cells |
CHEMBL3992552 |
| Unchecked |
Ratio IC50 |
= |
5.9 |
|
Selectivity index, ratio of IC50 for human fibroblasts to IC50 for human PC3 cells |
CHEMBL3992552 |
| Unchecked |
Ratio IC50 |
= |
5.9 |
|
Selectivity index, ratio of IC50 for human fibroblasts to IC50 for human HaCaT cells |
CHEMBL3992552 |
| Unchecked |
Ratio IC50 |
= |
108.6 |
|
Selectivity index, ratio of IC50 for human fibroblasts to IC50 for human RL cells |
CHEMBL3992552 |
| Unchecked |
Ratio IC50 |
= |
9.7 |
|
Selectivity index, ratio of IC50 for human fibroblasts to IC50 for human MCF7 cells |
CHEMBL3992552 |
| Huh-7 |
Activity_index |
= |
0.3 |
|
Cell cycle arrest in human HuH7 cells assessed as mitotic index at 10 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.2 No_unit) |
CHEMBL3992552 |
| Huh-7 |
Activity |
= |
16.0 |
% |
Cell cycle arrest in human HuH7 cells assessed as accumulation at S phase at 10 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 44%) |
CHEMBL3992552 |
| Caco-2 |
Activity_index |
= |
1.7 |
|
Cell cycle arrest in human Caco2 cells assessed as mitotic index at 10 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 3.6 No_unit) |
CHEMBL3992552 |
| Caco-2 |
Activity |
= |
45.0 |
% |
Cell cycle arrest in human Caco2 cells assessed as accumulation at S phase at 10 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 52.4%) |
CHEMBL3992552 |
| MDA-MB-231 |
Activity_index |
= |
0.5 |
|
Cell cycle arrest in human MDA-MB-231 cells harboring p53 mutant assessed as mitotic index at 10 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.1 No_unit) |
CHEMBL3992552 |
| MDA-MB-231 |
Activity |
= |
27.0 |
% |
Cell cycle arrest in human MDA-MB-231 cells harboring p53 mutant assessed as accumulation at S phase at 10 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 42.2%) |
CHEMBL3992552 |
| HCT-116 |
Activity_index |
= |
1.2 |
|
Cell cycle arrest in human HCT116 cells harboring wild-type p53 assessed as mitotic index at 10 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.3 No_unit) |
CHEMBL3992552 |
| HCT-116 |
Activity |
= |
25.0 |
% |
Cell cycle arrest in human HCT116 cells harboring wild-type p53 assessed as accumulation at S phase at 10 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 68.4%) |
CHEMBL3992552 |
| PC-3 |
Activity_index |
= |
1.3 |
|
Cell cycle arrest in human PC3 cells harboring p53 mutant assessed as mitotic index at 10 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.5 No_unit) |
CHEMBL3992552 |
| PC-3 |
Activity |
= |
17.0 |
% |
Cell cycle arrest in human PC3 cells harboring p53 mutant assessed as accumulation at S phase at 10 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 40.8%) |
CHEMBL3992552 |
| NCI-H727 |
Activity |
|
|
|
Cell cycle arrest in human NCI-H727 cells harboring p53 mutant assessed as mitotic index at 10 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 1.1 No_unit) |
CHEMBL3992552 |
| NCI-H727 |
Activity |
|
|
|
Cell cycle arrest in human NCI-H727 cells harboring p53 mutant assessed as accumulation at S phase at 10 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 40.3%) |
CHEMBL3992552 |
| HaCaT |
Activity_index |
= |
1.7 |
|
Cell cycle arrest in human HaCaT cells harboring wild-type p53 assessed as mitotic index at 10 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.6 No_unit) |
CHEMBL3992552 |
| HaCaT |
Activity |
= |
26.0 |
% |
Cell cycle arrest in human HaCaT cells harboring wild-type p53 assessed as accumulation at S phase at 10 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 52.3%) |
CHEMBL3992552 |
| Huh-7 |
Activity_index |
= |
0.1 |
|
Cell cycle arrest in human HuH7 cells assessed as mitotic index at 25 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.2 No_unit) |
CHEMBL3992552 |
| Huh-7 |
Activity |
= |
9.0 |
% |
Cell cycle arrest in human HuH7 cells assessed as accumulation at S phase at 25 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 44%) |
CHEMBL3992552 |
| Caco-2 |
Activity_index |
= |
0.0 |
|
Cell cycle arrest in human Caco2 cells assessed as mitotic index at 25 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 3.6 No_unit) |
CHEMBL3992552 |
| Caco-2 |
Activity |
= |
46.0 |
% |
Cell cycle arrest in human Caco2 cells assessed as accumulation at S phase at 25 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 52.4%) |
CHEMBL3992552 |
| MDA-MB-231 |
Activity_index |
= |
0.0 |
|
Cell cycle arrest in human MDA-MB-231 cells harboring p53 mutant assessed as mitotic index at 25 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.1 No_unit) |
CHEMBL3992552 |
| MDA-MB-231 |
Activity |
= |
25.0 |
% |
Cell cycle arrest in human MDA-MB-231 cells harboring p53 mutant assessed as accumulation at S phase at 25 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 42.2%) |
CHEMBL3992552 |
| HCT-116 |
Activity_index |
= |
0.6 |
|
Cell cycle arrest in human HCT116 cells harboring wild-type p53 assessed as mitotic index at 25 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.3 No_unit) |
CHEMBL3992552 |
| HCT-116 |
Activity |
= |
17.0 |
% |
Cell cycle arrest in human HCT116 cells harboring wild-type p53 assessed as accumulation at S phase at 25 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 68.4%) |
CHEMBL3992552 |
| PC-3 |
Activity_index |
= |
1.9 |
|
Cell cycle arrest in human PC3 cells harboring p53 mutant assessed as mitotic index at 25 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.5 No_unit) |
CHEMBL3992552 |
| PC-3 |
Activity |
= |
38.0 |
% |
Cell cycle arrest in human PC3 cells harboring p53 mutant assessed as accumulation at S phase at 25 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 40.8%) |
CHEMBL3992552 |
| NCI-H727 |
Activity |
|
|
|
Cell cycle arrest in human NCI-H727 cells harboring p53 mutant assessed as mitotic index at 25 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 1.1 No_unit) |
CHEMBL3992552 |
| NCI-H727 |
Activity |
|
|
|
Cell cycle arrest in human NCI-H727 cells harboring p53 mutant assessed as accumulation at S phase at 25 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 40.3%) |
CHEMBL3992552 |
| HaCaT |
Activity_index |
= |
0.0 |
|
Cell cycle arrest in human HaCaT cells harboring wild-type p53 assessed as mitotic index at 25 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.6 No_unit) |
CHEMBL3992552 |
| HaCaT |
Activity |
= |
3.0 |
% |
Cell cycle arrest in human HaCaT cells harboring wild-type p53 assessed as accumulation at S phase at 25 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 52.3%) |
CHEMBL3992552 |
| HCT-116 |
Activity |
= |
1.2 |
% |
Cell cycle arrest in human HCT116 cells harboring wild-type p53 assessed as accumulation at M phase at 25 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.3 to 2.5%) |
CHEMBL3992552 |
| HCT-116 |
Activity |
= |
0.6 |
% |
Cell cycle arrest in human HCT116 cells harboring wild-type p53 assessed as accumulation at M phase at 50 uM measured after 48 hrs by Hoechst staining based fluorescence assay (Rvb = 2.3 to 2.5%) |
CHEMBL3992552 |
| HCT-116 |
Activity |
= |
17.0 |
% |
Cell cycle arrest in human HCT116 cells harboring wild-type p53 assessed as accumulation at S phase at 50 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 68%) |
CHEMBL3992552 |
| Huh-7 |
Activity |
|
|
|
Cell cycle arrest in human HuH7 cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay |
CHEMBL3992552 |
| Caco-2 |
Activity |
|
|
|
Cell cycle arrest in human Caco2 cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay |
CHEMBL3992552 |
| MDA-MB-231 |
Activity |
|
|
|
Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay |
CHEMBL3992552 |
| HCT-116 |
Activity |
|
|
|
Cell cycle arrest in human HCT116 cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay |
CHEMBL3992552 |
| HaCaT |
Activity |
|
|
|
Cell cycle arrest in human HaCaT cells assessed as accumulation at G1/S phase by Hoechst staining based fluorescence assay |
CHEMBL3992552 |
| PC-3 |
Activity |
|
|
|
Cell cycle arrest in human PC3 cells assessed as accumulation at G2/M phase by Hoechst staining based fluorescence assay |
CHEMBL3992552 |
| HCT-116 |
Activity |
= |
25.0 |
% |
Cell cycle arrest in human HCT116 cells harboring wild-type p53 assessed as accumulation at S phase at 25 uM measured after 48 hrs by Hoechst/BrdU staining based fluorescence assay (Rvb = 68%) |
CHEMBL3992552 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
7890.0 |
nM |
Inhibition of full length human C-terminal His6-tagged CDK1/N-terminal GST-tagged CyclinB expressed in baculovirus infected sf21 cells after 10 mins in presence of [gamma32P]ATP by beta counting method |
CHEMBL4014343 |
| CDK2/Cyclin A2 |
IC50 |
= |
3490.0 |
nM |
Inhibition of full length human C-terminal His6-tagged CDK2/N-terminal GST-tagged CyclinA expressed in baculovirus infected sf21 cells after 10 mins in presence of [gamma32P]ATP by beta counting method |
CHEMBL4014343 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
620.0 |
nM |
Inhibition of full length human C-terminal His6-tagged CDK2/N-terminal GST-tagged CyclinE expressed in baculovirus infected sf21 cells after 10 mins in presence of [gamma32P]ATP by beta counting method |
CHEMBL4014343 |
| CDK6/cyclin D3 |
IC50 |
> |
10000.0 |
nM |
Inhibition of full length human N-terminal His6-tagged CDK6/N-terminal GST-tagged CyclinD3 expressed in sf21 cells after 10 mins in presence of [gamma32P]ATP by beta counting method |
CHEMBL4014343 |
| Glycogen synthase kinase-3 beta |
IC50 |
|
|
|
Inhibition of recombinant GSK3beta (unknown origin) after 10 mins in presence of [gamma32P]ATP by beta counting method |
CHEMBL4014343 |
| Leishmania amazonensis |
Inhibition |
= |
-20.3 |
% |
Antileishmanial activity against Leishmania amazonensis LV79 MPRO/BR/1972/M1841 promastigotes assessed as parasite growth inhibition under axenic condition at 20 uM by resazurin-based assay relative to control |
CHEMBL4041493 |
| Leishmania amazonensis |
Inhibition |
= |
-3.8 |
% |
Antileishmanial activity against Leishmania amazonensis LV79 MPRO/BR/1972/M1841 promastigotes assessed as parasite growth inhibition under axenic condition at 4 uM by resazurin-based assay relative to control |
CHEMBL4041493 |
| Leishmania amazonensis |
Inhibition |
= |
-8.8 |
% |
Antileishmanial activity against Leishmania amazonensis LV79 MPRO/BR/1972/M1841 promastigotes assessed as parasite growth inhibition under axenic condition at 0.8 uM by resazurin-based assay relative to control |
CHEMBL4041493 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
IC50 |
= |
3100.0 |
nM |
Inhibition of DYRK1A (unknown origin) by cell-based assay |
CHEMBL4265878 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
700.0 |
nM |
Inhibition of CDK2 (unknown origin) |
CHEMBL4270504 |
| Cyclin-dependent kinase 5 |
IC50 |
= |
160.0 |
nM |
Inhibition of CDK5 (unknown origin) |
CHEMBL4270504 |
| Unchecked |
IC50 |
= |
310.0 |
nM |
Inhibition of M-phase starfish oocytes CDK1/cyclin B after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| CDK2/Cyclin A2 |
IC50 |
= |
72.0 |
nM |
Inhibition of recombinant human CDK2/cyclin A after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
200.0 |
nM |
Inhibition of recombinant human CDK5/p25 after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| CDK9/cyclin T1 |
IC50 |
= |
220.0 |
nM |
Inhibition of recombinant human CDK9/cyclin T expressed in insect cells using CDK7/9-tide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Unchecked |
IC50 |
= |
730.0 |
nM |
Inhibition of porcine brain CK1delta/CK1epsilon using CKS peptide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Dual specificity protein kinase CLK1 |
IC50 |
= |
1200.0 |
nM |
Inhibition of recombinant GST-tagged mouse CLK1 expressed in Escherichia coli using RS peptide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Dual specificity protein kinase CLK2 |
IC50 |
= |
710.0 |
nM |
Inhibition of recombinant GST-tagged mouse CLK2 expressed in Escherichia coli using RS peptide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Dual specificity protein kinase CLK3 |
IC50 |
> |
10000.0 |
nM |
Inhibition of recombinant GST-tagged mouse CLK3 expressed in Escherichia coli using RS peptide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Dual specificity protein kinase CLK4 |
IC50 |
= |
620.0 |
nM |
Inhibition of recombinant GST-tagged mouse CLK4 expressed in Escherichia coli using RS peptide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
IC50 |
= |
1200.0 |
nM |
Inhibition of recombinant GST-tagged human DYRK1A expressed in Escherichia coli using woodtide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1B |
IC50 |
= |
1200.0 |
nM |
Inhibition of recombinant GST-tagged human DYRK1B expressed in Escherichia coli using woodtide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 2 |
IC50 |
= |
1700.0 |
nM |
Inhibition of recombinant GST-tagged human DYRK2 expressed in Escherichia coli using woodtide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 3 |
IC50 |
> |
10000.0 |
nM |
Inhibition of recombinant GST-tagged human DYRK3 expressed in Escherichia coli using woodtide as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| Glycogen synthase kinase-3 |
IC50 |
> |
10000.0 |
nM |
Inhibition of porcine brain GSK3 using GS-1 as substrate after 30 mins in presence of [gamma-33P] by scintillation counting method |
CHEMBL4270644 |
| SH-SY5Y |
IC50 |
= |
21000.0 |
nM |
Antiproliferative activity against human SH-SY5Y cells after 2 days by XTT assay |
CHEMBL4270644 |
| IMR-32 |
IC50 |
= |
17000.0 |
nM |
Antiproliferative activity against human IMR32 cells after 2 days by XTT assay |
CHEMBL4270644 |
| Unchecked |
IC50 |
= |
32000.0 |
nM |
Antiproliferative activity against human SC1 cells after 2 days by XTT assay |
CHEMBL4270644 |
| Unchecked |
IC50 |
= |
21000.0 |
nM |
Antiproliferative activity against human SC2 cells after 2 days by XTT assay |
CHEMBL4270644 |
| SK-OV-3 |
IC50 |
= |
29000.0 |
nM |
Antiproliferative activity against human Scov3 cells after 2 days by XTT assay |
CHEMBL4270644 |
| OVCAR-3 |
IC50 |
= |
37000.0 |
nM |
Antiproliferative activity against human OVCAR3 cells after 2 days by XTT assay |
CHEMBL4270644 |
| SARS-CoV-2 |
Inhibition |
= |
-5.01 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging |
CHEMBL4303101 |
| Unchecked |
IC50 |
= |
21700.0 |
nM |
Antiproliferative activity against human S2-013 cells after 72 hrs by prestoblue assay |
CHEMBL4325851 |
| Unchecked |
IC50 |
= |
14801.0 |
nM |
Antiproliferative activity against human SUIT2 cells after 72 hrs by prestoblue assay |
CHEMBL4325851 |
| MIA PaCa-2 |
IC50 |
= |
18214.0 |
nM |
Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by prestoblue assay |
CHEMBL4325851 |
| BXPC-3 |
IC50 |
= |
15284.0 |
nM |
Antiproliferative activity against human BxPC3 cells after 72 hrs by prestoblue assay |
CHEMBL4325851 |
| ASPC1 |
IC50 |
= |
17767.0 |
nM |
Antiproliferative activity against human AsPC1 cells after 72 hrs by prestoblue assay |
CHEMBL4325851 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
330.0 |
nM |
Inhibition of CDK1 (unknown origin) |
CHEMBL4346699 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
220.0 |
nM |
Inhibition of CDK2 (unknown origin) |
CHEMBL4346699 |
| Cyclin-dependent kinase 4 |
IC50 |
> |
10000.0 |
nM |
Inhibition of CDK4 (unknown origin) |
CHEMBL4346699 |
| Cyclin-dependent kinase 5 |
IC50 |
= |
270.0 |
nM |
Inhibition of CDK5 (unknown origin) |
CHEMBL4346699 |
| Cyclin-dependent kinase 7 |
IC50 |
= |
800.0 |
nM |
Inhibition of CDK7 (unknown origin) |
CHEMBL4346699 |
| Cyclin-dependent kinase 9 |
IC50 |
= |
230.0 |
nM |
Inhibition of CDK9 (unknown origin) |
CHEMBL4346699 |
| Histone deacetylase 1 |
Inhibition |
|
|
% |
Inhibition of recombinant human full-length C-terminal FLAG-tagged HDAC1 expressed in baculovirus expression system at 10 nM using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay relative to control |
CHEMBL4387776 |
| Histone deacetylase 1 |
Inhibition |
|
|
% |
Inhibition of recombinant human full-length C-terminal FLAG-tagged HDAC1 expressed in baculovirus expression system at 1000 nM using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay relative to control |
CHEMBL4387776 |
| Histone deacetylase 1 |
IC50 |
|
|
|
Inhibition of recombinant human full-length C-terminal FLAG-tagged HDAC1 expressed in baculovirus expression system using Ac-peptide-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay |
CHEMBL4387776 |
| CDK2/Cyclin A2 |
Inhibition |
|
|
% |
Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells at 10 nM using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay relative to control |
CHEMBL4387776 |
| CDK2/Cyclin A2 |
Inhibition |
|
|
% |
Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells at 100 nM using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay relative to control |
CHEMBL4387776 |
| CDK2/Cyclin A2 |
IC50 |
= |
193.0 |
nM |
Inhibition of wild-type human N-terminal GST-tagged CDK2/cycA2 expressed in Sf21 insect cells using FAM-labelled substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay |
CHEMBL4387776 |
| A549 |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human A549 cells measured after 72 hrs by CCK8 assay |
CHEMBL4387776 |
| HepG2 |
IC50 |
= |
15760.0 |
nM |
Antiproliferative activity against human HepG2 cells measured after 72 hrs by CCK8 assay |
CHEMBL4387776 |
| CAL-148 |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human CAL148 cells measured after 72 hrs by CCK8 assay |
CHEMBL4387776 |
| Cyclin-dependent kinase 5/CDK5 activator 1 |
IC50 |
= |
270.0 |
nM |
Inhibition of recombinant full length N-terminal GST tagged human CDK5/p25 expressed in baculovirus infected sf9 cells using histone H1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay |
CHEMBL4396883 |
| C6 |
Activity |
= |
100.0 |
% |
Antitumour activity against rat C6 cells implanted in Wistar rat assessed as reduction in reactive astrocytes induced peri-tumoral areas at 25 mg/kg, ip administered on alternate days in total 3 doses and measured on day 7 co-treated with temozolomide by immunohistochemical analysis relative to control |
CHEMBL4402522 |
| C6 |
Activity |
= |
100.0 |
% |
Antitumour activity against rat C6 cells implanted in Wistar rat assessed as reduction in reactive astrocytes induced areas of blood vessels at 25 mg/kg, ip administered on alternate days in total 3 doses and measured on day 7 co-treated with temozolomide by immunohistochemical analysis relative to control |
CHEMBL4402522 |
| Cyclin-dependent kinase 7 |
IC50 |
= |
480.0 |
nM |
Inhibition of CDK7 (unknown origin) |
CHEMBL4402527 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
1500.0 |
nM |
Inhibition of CDK1 (unknown origin) |
CHEMBL4402527 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
90.0 |
nM |
Inhibition of CDK2 (unknown origin) |
CHEMBL4402527 |
| Cyclin-dependent kinase 4 |
IC50 |
= |
16400.0 |
nM |
Inhibition of CDK4 (unknown origin) |
CHEMBL4402527 |
| Cyclin-dependent kinase 5 |
IC50 |
= |
200.0 |
nM |
Inhibition of CDK5 (unknown origin) |
CHEMBL4402527 |
| Cyclin-dependent kinase 6 |
IC50 |
= |
24500.0 |
nM |
Inhibition of CDK6 (unknown origin) |
CHEMBL4402527 |
| Cyclin-dependent kinase 9 |
IC50 |
= |
1050.0 |
nM |
Inhibition of CDK9 (unknown origin) |
CHEMBL4402527 |
| MDA-MB-231 |
IC50 |
= |
15000.0 |
nM |
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability |
CHEMBL4402527 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
520.0 |
nM |
Competitive irreversible inhibition of CDK7/cyclinH (unknown origin) |
CHEMBL4406837 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
220.0 |
nM |
Competitive reversible inhibition of CDK2/cyclin E (unknown origin) |
CHEMBL4406837 |
| Huh-7 |
IC50 |
= |
20000.0 |
nM |
Antiproliferative activity against human HuH7 cells after 48 hrs by Hoechst 33342 staining-based assay |
CHEMBL4422646 |
| Huh-7 |
Activity |
= |
90.0 |
% |
Antiproliferative activity against human HuH7 cells at 0.1 to 25 uM after 48 hrs by Hoechst 33342 staining-based assay relative to control |
CHEMBL4422646 |
| Caco-2 |
IC50 |
= |
10000.0 |
nM |
Antiproliferative activity against human Caco2 cells after 48 hrs by Hoechst 33342 staining-based assay |
CHEMBL4422646 |
| Caco-2 |
Activity |
= |
90.0 |
% |
Antiproliferative activity against human Caco2 cells at 0.1 to 25 uM after 48 hrs by Hoechst 33342 staining-based assay relative to control |
CHEMBL4422646 |
| MDA-MB-231 |
IC50 |
= |
12000.0 |
nM |
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by Hoechst 33342 staining-based assay |
CHEMBL4422646 |
| MDA-MB-231 |
Activity |
= |
80.0 |
% |
Antiproliferative activity against human MDA-MB-231 cells at 0.1 to 25 uM after 48 hrs by Hoechst 33342 staining-based assay relative to control |
CHEMBL4422646 |
| HCT-116 |
IC50 |
= |
9000.0 |
nM |
Antiproliferative activity against human HCT116 cells after 48 hrs by Hoechst 33342 staining-based assay |
CHEMBL4422646 |
| HCT-116 |
Activity |
= |
100.0 |
% |
Antiproliferative activity against human HCT116 cells at 0.1 to 25 uM after 48 hrs by Hoechst 33342 staining-based assay relative to control |
CHEMBL4422646 |
| PC-3 |
IC50 |
= |
12000.0 |
nM |
Antiproliferative activity against human PC3 cells after 48 hrs by Hoechst 33342 staining-based assay |
CHEMBL4422646 |
| PC-3 |
Activity |
= |
8.0 |
% |
Antiproliferative activity against human PC3 cells at 0.1 to 25 uM after 48 hrs by Hoechst 33342 staining-based assay relative to control |
CHEMBL4422646 |
| NCI-H727 |
IC50 |
= |
20000.0 |
nM |
Antiproliferative activity against human NCI-H727 cells after 48 hrs by Hoechst 33342 staining-based assay |
CHEMBL4422646 |
| NCI-H727 |
Activity |
= |
40.0 |
% |
Antiproliferative activity against human NCI-H727 cells at 0.1 to 25 uM after 48 hrs by Hoechst 33342 staining-based assay relative to control |
CHEMBL4422646 |
| HaCaT |
IC50 |
= |
12000.0 |
nM |
Antiproliferative activity against human HaCaT cells after 48 hrs by Hoechst 33342 staining-based assay |
CHEMBL4422646 |
| HaCaT |
Activity |
= |
80.0 |
% |
Antiproliferative activity against human HaCaT cells at 0.1 to 25 uM after 48 hrs by Hoechst 33342 staining-based assay relative to control |
CHEMBL4422646 |
| Fibroblasts |
IC50 |
= |
12000.0 |
nM |
Antiproliferative activity against human fibroblast cells after 48 hrs by Hoechst 33342 staining-based assay |
CHEMBL4422646 |
| Fibroblasts |
Activity |
= |
40.0 |
% |
Antiproliferative activity against human fibroblast cells at 0.1 to 25 uM after 48 hrs by Hoechst 33342 staining-based assay relative to control |
CHEMBL4422646 |
| Casein kinase I isoform alpha/delta |
EC |
= |
0.96 |
uM |
Inhibition of CK1alpha/CK1delta in human U2OS cells co-expressing Bmal1-dLuc assessed as modulation circadian clock by measuring drug level causing 1 hr circadian period lengthening measured every 100 mins by luminescence assay |
CHEMBL4422662 |
| Casein kinase I isoform alpha/delta |
EC |
= |
9.0 |
uM |
Inhibition of CK1alpha/CK1delta in human U2OS cells co-expressing Bmal1-dLuc assessed as modulation circadian clock by measuring drug level causing 5 hrs circadian period lengthening measured every 100 mins by luminescence assay |
CHEMBL4422662 |
| Casein kinase I delta |
IC50 |
= |
10000.0 |
nM |
Inhibition of recombinant N-terminal human GST-tagged CK1delta (1 to 294 residues) expressed in Escherichia coli using RKKKAEpSVASLTSQCSYSS peptide as substrate after 3 hrs by kinase-glo luminescent assay relative to control |
CHEMBL4422662 |
| Casein kinase I alpha |
IC50 |
= |
49000.0 |
nM |
Inhibition of recombinant full length human GST-tagged CK1apha expressed in baculovirus using peptide as substrate after 3 hrs by kinase-glo luminescent assay |
CHEMBL4422662 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
400.0 |
nM |
Inhibition of CDK2 (unknown origin) after 3 hrs by kinase-glo luminescent assay relative to control |
CHEMBL4422662 |
| CDK7/Cyclin H/MNAT1 |
IC50 |
= |
2200.0 |
nM |
Inhibition of recombinant full length C-terminal human His-tagged CDK7/cyclin H/N-terminal MAT1 expressed in baculovirus expression system using Cdk7/9 peptide as substrate after 3 hrs by kinase-glo luminescent assay relative to control |
CHEMBL4422662 |
| MAP kinase ERK2 |
IC50 |
= |
75000.0 |
nM |
Inhibition of N-terminal GST-tagged recombinant full-length human MAPK1 expressed in Escherichia coli using MBP1 as substrate after 3 hrs by kinase-glo luminescent assay relative to control |
CHEMBL4422662 |
| c-Jun N-terminal kinase 1 |
IC50 |
= |
170000.0 |
nM |
Inhibition of MAPK8 (unknown origin) using peptide as substrate after 3 hrs by kinase-glo luminescent assay relative to control |
CHEMBL4422662 |
| Fibroblasts |
IC50 |
= |
7000.0 |
nM |
Cytotoxicity against human Fibroblasts assessed as cell growth inhibition |
CHEMBL4431303 |
| Unchecked |
IC50 |
= |
18000.0 |
nM |
Cytotoxicity against human NCI-H2 cells assessed as cell growth inhibition |
CHEMBL4431303 |
| PC-3 |
IC50 |
= |
12000.0 |
nM |
Cytotoxicity against human PC3 cells assessed as cell growth inhibition |
CHEMBL4431303 |
| HCT-116 |
IC50 |
= |
9000.0 |
nM |
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition |
CHEMBL4431303 |
| MDA-MB-231 |
IC50 |
= |
15000.0 |
nM |
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition |
CHEMBL4431303 |
| Caco-2 |
IC50 |
= |
16000.0 |
nM |
Cytotoxicity against human Caco2 cells assessed as cell growth inhibition |
CHEMBL4431303 |
| Unchecked |
IC50 |
= |
15000.0 |
nM |
Cytotoxicity against human Huh7D12 cells assessed as cell growth inhibition |
CHEMBL4431303 |
| Replicase polyprotein 1ab |
Inhibition |
= |
11.33 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| Replicase polyprotein 1ab |
Inhibition |
= |
4.845 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| SARS-CoV-2 |
Inhibition |
= |
1.28 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
2.17 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| Candida albicans |
MIC |
> |
20000.0 |
nM |
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 |
CHEMBL4513161 |
| Filobasidiella neoformans |
MIC |
> |
20000.0 |
nM |
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) |
CHEMBL4513161 |
| Escherichia coli |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Klebsiella pneumoniae |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Pseudomonas aeruginosa |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Acinetobacter baumannii |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 |
CHEMBL4513161 |
| Pseudomonas aeruginosa |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Pseudomonas aeruginosa PAO397 [PAO1 d(mexAB-oprM) d(mexCD-oprJ) d(mexEF-oprN) d(mexJKL) d(mexXY) d(opmH)] (CO-ADD:GN_211); MIC in CAMBH media using NBS plates, by OD(600) |
CHEMBL4513161 |
| Staphylococcus aureus subsp. aureus |
MIC |
> |
20000.0 |
nM |
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) |
CHEMBL4513161 |
| Erythrocyte |
HC10 |
> |
20.0 |
uM |
Haemolysis of human Red Blood Cells (CO-ADD:HA_150); HC10, by OD(450) |
CHEMBL4513161 |
| HEK293 |
CC50 |
> |
20000.0 |
nM |
Cytotoxicity against HEK293 cells (CO-ADD:MA_007); CC50 by cell viability assay in DMEM (10% FBS) media using TC plates, by Resazurin F(560/590) |
CHEMBL4513161 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf21 insect cells in presence of [gamma33P]ATP |
CHEMBL4610077 |
| Cyclin-dependent kinase 7 |
IC50 |
= |
510.0 |
nM |
Inhibition of CDK7 (unknown origin) |
CHEMBL4610077 |
| Cyclin-dependent kinase 5 |
IC50 |
= |
200.0 |
nM |
Inhibition of CDK5 (unknown origin) |
CHEMBL4613207 |
| SH-SY5Y |
IC50 |
= |
41.0 |
nM |
Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by MTS assay |
CHEMBL4613207 |
| SARS-CoV-2 |
Inhibition |
= |
2.17 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
1.28 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
IC50 |
> |
20000.0 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| SARS-CoV-2 |
IC50 |
< |
19952.62 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2/cyclin E (unknown origin) expressed in baculovirus infected Sf21 insect cells using histone H1 as substrate in presence of [gamma33P]ATP |
CHEMBL4680175 |
| CDK9/cyclin T1 |
IC50 |
= |
1800.0 |
nM |
Inhibition of human full-length N-terminal GST/His6-tagged CDK9 (1 to 372 residues)/His6-tagged Cyclin-T1 (1 to 726 residues) expressed in sf9 cells using (YSPTSPS)2KK peptide as substrate in presence of [gamma33P]ATP |
CHEMBL4680175 |
| Huh-7 |
IC50 |
= |
14000.0 |
nM |
Cytotoxicity against human HuH-7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) |
CHEMBL4680342 |
| Caco-2 |
IC50 |
= |
17000.0 |
nM |
Cytotoxicity against human CaCo-2 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) |
CHEMBL4680342 |
| MDA-MB-231 |
IC50 |
= |
15000.0 |
nM |
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) |
CHEMBL4680342 |
| HCT-116 |
IC50 |
= |
9000.0 |
nM |
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) |
CHEMBL4680342 |
| PC-3 |
IC50 |
= |
10000.0 |
nM |
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) |
CHEMBL4680342 |
| NCI-H727 |
IC50 |
= |
28000.0 |
nM |
Cytotoxicity against human NCI-H727 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) |
CHEMBL4680342 |
| MCF7 |
IC50 |
= |
9000.0 |
nM |
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) |
CHEMBL4680342 |
| Fibroblasts |
IC50 |
= |
6000.0 |
nM |
Cytotoxicity against human Fibroblast cells assessed as reduction in cell viability incubated for 48 hrs by Hoechst-33342 staining based cell counting method (Rvb > 25 microM) |
CHEMBL4680342 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2 (unknown origin) |
CHEMBL4699469 |
| Cyclin-dependent kinase 7 |
IC50 |
= |
500.0 |
nM |
Inhibition of CDK7 (unknown origin) |
CHEMBL4699469 |
| Cyclin-dependent kinase 9 |
IC50 |
= |
230.0 |
nM |
Inhibition of CDK9 (unknown origin) |
CHEMBL4699469 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
1.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
1.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
2.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
7.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
5.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
1.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
1.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
1.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HCT-116 |
IC50 |
= |
15540.0 |
nM |
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by MTT assay |
CHEMBL4725331 |
| WI-38 |
IC50 |
= |
24120.0 |
nM |
Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay |
CHEMBL4725331 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
81.7 |
nM |
Inhibition of CDK1/cyclinB (unknown origin) |
CHEMBL4725331 |
| Unchecked |
Ratio IC50 |
= |
1.55 |
|
Selectivity index, ratio of IC50 for human WI-38 cells to IC50 for human HCT116 cells after 48 hrs by MTT assay |
CHEMBL4725331 |
| Cyclin-dependent kinase 1/cyclin B1 |
IC50 |
= |
2690.0 |
nM |
Inhibition of CDK1/cyclin B1 (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay |
CHEMBL4732230 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
490.0 |
nM |
Inhibition of human CDK7/cyclin H (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay |
CHEMBL4732230 |
| Cyclin-dependent kinase 4/cyclin D1 |
IC50 |
= |
14210.0 |
nM |
Inhibition of human CDK4/cyclin D (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay |
CHEMBL4732230 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
100.0 |
nM |
Inhibition of human CDK2/cyclin E (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition by mobility shift assay |
CHEMBL4732230 |
| A-375 |
Activity |
= |
7.03 |
% |
Induction of apoptosis in human A-375 cells assessed as early apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 1.34 %) |
CHEMBL4765302 |
| HCT-116 |
Inhibition |
= |
23.5 |
% |
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control |
CHEMBL4765302 |
| HCT-116 |
Inhibition |
= |
29.1 |
% |
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control |
CHEMBL4765302 |
| HepG2 |
Inhibition |
= |
12.01 |
% |
Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control |
CHEMBL4765302 |
| HepG2 |
Inhibition |
= |
22.11 |
% |
Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control |
CHEMBL4765302 |
| NCI-H460 |
Inhibition |
= |
7.73 |
% |
Antiproliferative activity against human H460 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control |
CHEMBL4765302 |
| NCI-H460 |
Inhibition |
= |
15.56 |
% |
Antiproliferative activity against human H460 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control |
CHEMBL4765302 |
| Histone deacetylase 1 |
Inhibition |
|
|
% |
Inhibition of recombinant human HDAC1 at 10 uM using SIRT1 as substrate incubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay relative to control |
CHEMBL4765302 |
| CDK2/Cyclin A2 |
Inhibition |
= |
81.32 |
% |
Inhibition of recombinant human N-terminal GST-tagged CDK2/CyclinA2 expressed in baculovirus infected Sf21 cells at 10 uM using histone H1 as substrate incubated for 10 mins by luminescence based assay relative to control |
CHEMBL4765302 |
| NCI-H460 |
IC50 |
= |
11900.0 |
nM |
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay |
CHEMBL4765302 |
| A-375 |
IC50 |
= |
11790.0 |
nM |
Antiproliferative activity against human A-375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay |
CHEMBL4765302 |
| HepG2 |
IC50 |
= |
8530.0 |
nM |
Antiproliferative activity against human HepG2 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay |
CHEMBL4765302 |
| HCT-116 |
IC50 |
= |
6760.0 |
nM |
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay |
CHEMBL4765302 |
| HeLa |
IC50 |
= |
11210.0 |
nM |
Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay |
CHEMBL4765302 |
| CDK2/Cyclin A2 |
IC50 |
= |
110.0 |
nM |
Inhibition of recombinant human N-terminal GST-tagged CDK2/CyclinA2 expressed in baculovirus infected Sf21 cells using histone H1 as substrate incubated for 10 mins by luminescence based assay |
CHEMBL4765302 |
| A-375 |
Activity |
= |
50.5 |
% |
Induction of apoptosis in human A-375 cells assessed as viable cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 96.3 %) |
CHEMBL4765302 |
| A-375 |
Activity |
= |
42.3 |
% |
Induction of apoptosis in human A-375 cells assessed as late apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 2.24 %) |
CHEMBL4765302 |
| A-375 |
Activity |
= |
0.189 |
% |
Induction of apoptosis in human A-375 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.139 %) |
CHEMBL4765302 |
| HCT-116 |
Activity |
= |
11.6 |
% |
Induction of apoptosis in human HCT-116 cells assessed as viable cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 93.9 %) |
CHEMBL4765302 |
| HCT-116 |
Activity |
= |
83.9 |
% |
Induction of apoptosis in human HCT-116 cells assessed as early apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 4.14 %) |
CHEMBL4765302 |
| HCT-116 |
Activity |
= |
4.24 |
% |
Induction of apoptosis in human HCT-116 cells assessed as late apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 1.88 %) |
CHEMBL4765302 |
| HCT-116 |
Activity |
= |
0.24 |
% |
Induction of apoptosis in human HCT-116 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.124 %) |
CHEMBL4765302 |
| NCI-H460 |
Activity |
= |
47.0 |
% |
Induction of apoptosis in human NCI-H460 cells assessed as viable cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 90.4 %) |
CHEMBL4765302 |
| NCI-H460 |
Activity |
= |
14.0 |
% |
Induction of apoptosis in human NCI-H460 cells assessed as early apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 2.88 %) |
CHEMBL4765302 |
| NCI-H460 |
Activity |
= |
36.0 |
% |
Induction of apoptosis in human NCI-H460 cells assessed as late apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 6.11 %) |
CHEMBL4765302 |
| NCI-H460 |
Activity |
= |
3.09 |
% |
Induction of apoptosis in human NCI-H460 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.632 %) |
CHEMBL4765302 |
| HeLa |
Activity |
= |
88.4 |
% |
Induction of apoptosis in human HeLa cells assessed as viable cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 98.5 %) |
CHEMBL4765302 |
| HeLa |
Activity |
= |
4.04 |
% |
Induction of apoptosis in human HeLa cells assessed as early apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.528 %) |
CHEMBL4765302 |
| HeLa |
Activity |
= |
7.16 |
% |
Induction of apoptosis in human HeLa cells assessed as late apoptotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.870 %) |
CHEMBL4765302 |
| HeLa |
Activity |
= |
0.424 |
% |
Induction of apoptosis in human HeLa cells assessed as necrotic cells at 2 uM incubated for 48 hrs by annexin V-FITC and PI staining based flow cytometry (Rvb = 0.124 %) |
CHEMBL4765302 |
| CDK2/Cyclin A2 |
IC50 |
= |
43.2 |
nM |
Inhibition of CDK2/Cyclin A2 (unknown origin) after 10 mins by ADP-Glo reagent based assay |
CHEMBL4811242 |
| P-glycoprotein 1 |
Ratio |
= |
3.399 |
|
Substrate activity at P-gp (unknown origin) assessed as net efflux ratio |
CHEMBL4823245 |
| ADMET |
Fu |
= |
0.048 |
|
Unbound plasma concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis |
CHEMBL4823245 |
| ADMET |
Fu |
= |
0.092 |
|
Unbound brain concentration in P-gp knock out Sprague-Dawley rat at 5 mg/ml/kg, po measured upto 4 hrs by LC-MS analysis |
CHEMBL4823245 |
| ADMET |
Ratio |
= |
1.259 |
|
Ratio of drug concentration in brain to plasma of P-gp knock out Sprague-Dawley rat |
CHEMBL4823245 |
| ADMET |
K(p,uu,brain) |
= |
0.205 |
|
Unbound brain-to-plasma concentration ratio in P-gp knock out Sprague-Dawley rat |
CHEMBL4823245 |
| Huh-7 |
IC50 |
= |
9000.0 |
nM |
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability after 48 hrs |
CHEMBL5030547 |
| Caco-2 |
IC50 |
= |
14000.0 |
nM |
Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs |
CHEMBL5030547 |
| MDA-MB-231 |
IC50 |
= |
17000.0 |
nM |
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs |
CHEMBL5030547 |
| MDA-MB-468 |
IC50 |
= |
18000.0 |
nM |
Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs |
CHEMBL5030547 |
| HCT-116 |
IC50 |
= |
9000.0 |
nM |
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs |
CHEMBL5030547 |
| PC-3 |
IC50 |
= |
11000.0 |
nM |
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability after 48 hrs |
CHEMBL5030547 |
| MCF7 |
IC50 |
= |
9000.0 |
nM |
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs |
CHEMBL5030547 |
| Fibroblasts |
IC50 |
= |
15000.0 |
nM |
Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability after 48 hrs |
CHEMBL5030547 |
| Tyrosine-protein kinase ABL |
Delta TM |
= |
0.1033 |
C |
Thermal Shift Assay. Domain: start/stop: S229-K512 |
CHEMBL4632348 |
| Serine/threonine-protein kinase Aurora-A |
Delta TM |
= |
0.2757 |
C |
Thermal Shift Assay. Domain: start/stop: E122-S403 |
CHEMBL4632348 |
| Bromodomain-containing protein 4 |
Delta TM |
= |
-0.1799 |
C |
Thermal Shift Assay. Domain: start/stop: N44-E168 |
CHEMBL4632348 |
| Peregrin |
Delta TM |
= |
1.328 |
C |
Thermal Shift Assay. Domain: start/stop: M626-G746 |
CHEMBL4632348 |
| Cyclin-dependent kinase 2 |
Delta TM |
= |
2.87 |
C |
Thermal Shift Assay. Domain: start/stop: M1-L298 |
CHEMBL4632348 |
| Casein kinase I delta |
Delta TM |
= |
2.664 |
C |
Thermal Shift Assay. Domain: start/stop: M1-K294 |
CHEMBL4632348 |
| Fibroblast growth factor receptor 3 |
Delta TM |
= |
0.05923 |
C |
Thermal Shift Assay. Domain: start/stop: P449-E759 |
CHEMBL4632348 |
| Glycogen synthase kinase-3 beta |
Delta TM |
= |
2.248 |
C |
Thermal Shift Assay. Domain: start/stop: M26-R383 |
CHEMBL4632348 |
| MAP kinase ERK2 |
Delta TM |
= |
1.203 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S360 |
CHEMBL4632348 |
| Transcription intermediary factor 1-alpha |
Delta TM |
= |
0.4728 |
C |
Thermal Shift Assay. Domain: start/stop: G861-E979 |
CHEMBL4632348 |
| Plasmodium falciparum |
IC50 |
= |
25000.0 |
nM |
Antiplasmodial activity against blood stage plasmodium falciparum assessed as inhibition of parasite growth |
CHEMBL5104191 |
| Unchecked |
IC50 |
= |
0.65 |
nM |
Inhibition of starfish oocyte CDK1/Cyclin B using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis |
CHEMBL5120846 |
| CDK2/Cyclin A2 |
IC50 |
= |
0.7 |
nM |
Inhibition of CDK2/cyclin A (unknown origin) expressed in baculovirus infected Sf9 cells using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis |
CHEMBL5120846 |
| Unchecked |
IC50 |
> |
100.0 |
nM |
Inhibition of insect GST-fused CDK4/Cyclin D1 using Rb protein as substrate incubated for 15 mins in presence of [gamma-32P]ATP by densitometry based autoradiography |
CHEMBL5120846 |
| Unchecked |
IC50 |
= |
0.16 |
nM |
Inhibition of bovine brain CDK5/p25 using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by scintillation counter analysis |
CHEMBL5120846 |
| Unchecked |
IC50 |
> |
100.0 |
nM |
Inhibition of insect CDK6/Cyclin D3 using GST-tagged RB protein as substrate incubated for 30 mins in presence of [gamma-32P]ATP by densitometry based autoradiography |
CHEMBL5120846 |
| Cyclin-dependent kinase 7/ cyclin H |
IC50 |
= |
0.46 |
nM |
Inhibition of CDK7/Cyclin H (unknown origin) |
CHEMBL5120846 |
| CDK8/Cyclin C |
IC50 |
> |
100.0 |
nM |
Inhibition of CDK8/Cyclin C (unknown origin) |
CHEMBL5120846 |
| CDK9/cyclin T1 |
IC50 |
> |
0.6 |
nM |
Inhibition of CDK9/Cyclin T1 (unknown origin) |
CHEMBL5120846 |
| Cyclin-dependent kinase 1 |
IC50 |
= |
450.0 |
nM |
Inhibition of CDK1 (unknown origin) |
CHEMBL5131375 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
100.0 |
nM |
Inhibition of CDK2 (unknown origin) |
CHEMBL5131375 |
| Zika virus |
IC50 |
= |
24.0 |
nM |
Antiviral activity against ZIKV- FSS13025 infected in 1 hr pretreated African green monkey Vero E6 cells measured after 24 to 72 hrs |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against wild-type HIV-1 in T cells |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against wild-type HIV-1 in monocyte |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against wild-type HIV-1 in PBMC |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against AZT resistant HIV-1 mutant in T cells |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against AZT resistant HIV-1 mutant in monocyte |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against AZT resistant HIV-1 mutant in PBMC |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against 3TC resistant HIV-1 mutant in T cells |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against 3TC resistant HIV-1 mutant in monocyte |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against 3TC resistant HIV-1 mutant in PBMC |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against TIBO resistant HIV-1 mutant in T cells |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against TIBO resistant HIV-1 mutant in monocyte |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against TIBO resistant HIV-1 mutant in PBMC |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against protease resistant HIV-1 mutant in T cells |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against protease resistant HIV-1 mutant in monocyte |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
IC50 |
= |
0.36 |
nM |
Antiviral activity against protease resistant HIV-1 mutant in PBMC |
CHEMBL5131375 |
| Influenza A virus |
IC50 |
= |
3350.0 |
nM |
Antiviral activity against influenza A virus (A/WSN/1933 (H1N1)) infected in MDCK cells assessed as reduction in cytopathic effect by MTT-based assay |
CHEMBL5131375 |
| Influenza A virus |
IC50 |
= |
7010.0 |
nM |
Antiviral activity against influenza A virus (A/Aichi/2/68 (H3N2)) infected in MDCK cells assessed as reduction in cytopathic effect by MTT-based assay |
CHEMBL5131375 |
| Influenza A virus |
IC50 |
= |
5990.0 |
nM |
Antiviral activity against influenza A virus (A/FMI/47(H1N1)) infected in MDCK cells assessed as reduction in cytopathic effect by MTT-based assay |
CHEMBL5131375 |
| Zika virus |
IC50 |
= |
24.0 |
nM |
Antiviral activity against ZIKV |
CHEMBL5131375 |
| Influenza A virus |
EC50 |
= |
3300.0 |
nM |
Antiviral activity against influenza A virus H3N2 |
CHEMBL5131375 |
| Influenza A virus |
EC50 |
= |
3300.0 |
nM |
Antiviral activity against influenza A virus H1N1 |
CHEMBL5131375 |
| Unchecked |
CC50 |
= |
22000.0 |
nM |
Cytotoxicity against human PBMC |
CHEMBL5131375 |
| Human immunodeficiency virus 1 |
EC50 |
= |
360.0 |
nM |
Antiviral activity against HIV-1 mutant |
CHEMBL5131375 |
| Human herpesvirus 3 |
IC50 |
= |
14000.0 |
nM |
Antiviral activity against VZV |
CHEMBL5131375 |
| Human herpesvirus 5 |
Inhibition |
= |
50.0 |
% |
Antiviral activity against HCMV at 1 uM relative to control |
CHEMBL5131375 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
0.7 |
nM |
Inhibition of CDK2 (unknown origin) |
CHEMBL5131376 |
| Cyclin-dependent kinase 5 |
IC50 |
= |
0.2 |
nM |
Inhibition of CDK5 (unknown origin) |
CHEMBL5131376 |
| Unchecked |
GI50 |
= |
1485.0 |
nM |
Antiproliferative activity against human MINO cells assessed as cell growth inhibition measured after 72 hrs by resazurin dye based microplate reader analysis |
CHEMBL5131567 |
| Unchecked |
GI50 |
= |
3067.0 |
nM |
Antiproliferative activity against human UPF1H cells assessed as cell growth inhibition measured after 72 hrs by resazurin dye based microplate reader analysis |
CHEMBL5131567 |
| Cyclin-dependent kinase 2/cyclin E1 |
IC50 |
= |
18.0 |
nM |
Inhibition of His-tagged CDK2/cyclin E1 (unknown origin) expressed in Sf9 cells using histone H1 as substrate in presence of ATP and [gamma33-P]ATP by radioisotope filter binding assay |
CHEMBL5131567 |
| Unchecked |
IC50 |
= |
650.0 |
nM |
Inhibition of starfish oocyte CDK1 using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by radiometric scintillation assay |
CHEMBL5143610 |
| Cyclin-dependent kinase 2 |
IC50 |
= |
700.0 |
nM |
Inhibition of CDK2 (unknown origin) in baculovirus infected Sf9 insect cell extract using histone H1 as substrate incubated for 10 mins in presence of [gamma-32P]ATP by radiometric scintillation assay |
CHEMBL5143610 |
| Cyclin-dependent kinase 5 |
IC50 |
= |
200.0 |
nM |
Inhibition of bovine brain CDK5 using histone H1 as substrate incubated for 15 mins in presence of [gamma-32P]ATP by radiometric scintillation assay |
CHEMBL5143610 |
| MAP/microtubule affinity-regulating kinase 2 |
Delta TM |
= |
0.0 |
C |
Thermal Shift Assay. Domain: start/stop: M1-K331 |
CHEMBL4632348 |
| Serine/threonine-protein kinase c-TAK1 |
Delta TM |
= |
-0.84 |
C |
Thermal Shift Assay. Domain: start/stop: D48-R366 |
CHEMBL4632348 |
| MAP/microtubule affinity-regulating kinase 4 |
Delta TM |
= |
-0.84 |
C |
Thermal Shift Assay. Domain: start/stop: H18-T397 |
CHEMBL4632348 |
| Adaptor-associated kinase |
Delta TM |
= |
-0.21 |
C |
Thermal Shift Assay. Domain: start/stop: T27-A365 |
CHEMBL4632348 |
| Tyrosine-protein kinase ABL |
Delta TM |
= |
1.01 |
C |
Thermal Shift Assay. Domain: start/stop: S229-K512 |
CHEMBL4632348 |
| Tyrosine-protein kinase BMX |
Delta TM |
= |
0.17 |
C |
Thermal Shift Assay. Domain: start/stop: K264-H675 |
CHEMBL4632348 |
| Serine/threonine-protein kinase B-raf |
Delta TM |
= |
0.27 |
C |
Thermal Shift Assay. Domain: start/stop: R444-P705 |
CHEMBL4632348 |
| CaM-kinase kinase beta |
Delta TM |
= |
2.73 |
C |
Thermal Shift Assay. Domain: start/stop: H149-H449 |
CHEMBL4632348 |
| Peripheral plasma membrane protein CASK |
Delta TM |
= |
-0.14 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S337 |
CHEMBL4632348 |
| Casein kinase I delta |
Delta TM |
= |
3.05 |
C |
Thermal Shift Assay. Domain: start/stop: M1-K294 |
CHEMBL4632348 |
| Casein kinase II alpha |
Delta TM |
= |
0.45 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S337 |
CHEMBL4632348 |
| Casein kinase II alpha (prime) |
Delta TM |
= |
0.19 |
C |
Thermal Shift Assay. Domain: start/stop: M1-P335 |
CHEMBL4632348 |
| CaM kinase II beta |
Delta TM |
= |
-0.25 |
C |
Thermal Shift Assay. Domain: start/stop: T8-Q666 |
CHEMBL4632348 |
| CaM kinase II delta |
Delta TM |
= |
-0.16 |
C |
Thermal Shift Assay. Domain: start/stop: T11-N335 |
CHEMBL4632348 |
| CaM kinase IV |
Delta TM |
= |
0.17 |
C |
Thermal Shift Assay. Domain: start/stop: S15-G340 |
CHEMBL4632348 |
| Serine/threonine-protein kinase MRCK-A |
Delta TM |
= |
-1.25 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S424 |
CHEMBL4632348 |
| Cyclin-dependent kinase 2 |
Delta TM |
= |
4.07 |
C |
Thermal Shift Assay. Domain: start/stop: M1-L298 |
CHEMBL4632348 |
| Cyclin-dependent kinase-like 1 |
Delta TM |
= |
0.44 |
C |
Thermal Shift Assay. Domain: start/stop: M1-H301 |
CHEMBL4632348 |
| Serine/threonine-protein kinase Chk2 |
Delta TM |
= |
1.19 |
C |
Thermal Shift Assay. Domain: start/stop: T205-L543 |
CHEMBL4632348 |
| Dual specificty protein kinase CLK1 |
Delta TM |
= |
4.13 |
C |
Thermal Shift Assay. Domain: start/stop: H148-I484 |
CHEMBL4632348 |
| Dual specificity protein kinase CLK3 |
Delta TM |
= |
0.71 |
C |
Thermal Shift Assay. Domain: start/stop: R134-T484 |
CHEMBL4632348 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 2 |
Delta TM |
= |
0.88 |
C |
Thermal Shift Assay. Domain: start/stop: M73-R479 |
CHEMBL4632348 |
| Casein kinase I epsilon |
Delta TM |
= |
3.4 |
C |
Thermal Shift Assay. Domain: start/stop: M1-K294 |
CHEMBL4632348 |
| Ephrin type-A receptor 4 |
Delta TM |
= |
-0.2 |
C |
Thermal Shift Assay. Domain: start/stop: F612-S896 |
CHEMBL4632348 |
| Ferrochelatase, mitochondrial |
Delta TM |
= |
-1.37 |
C |
Thermal Shift Assay. Domain: start/stop: R65-L423 |
CHEMBL4632348 |
| Homeodomain-interacting protein kinase 2 |
Delta TM |
= |
0.38 |
C |
Thermal Shift Assay. Domain: start/stop: s178-n547 |
CHEMBL4632348 |
| Serine/threonine-protein kinase SRPK3 |
Delta TM |
= |
0.87 |
C |
Thermal Shift Assay. Domain: start/stop: M43-P533 |
CHEMBL4632348 |
| Quinone reductase 2 |
Delta TM |
= |
-0.8 |
C |
Thermal Shift Assay. |
CHEMBL4632348 |
| Death-associated protein kinase 1 |
Delta TM |
= |
-0.59 |
C |
Thermal Shift Assay. Domain: start/stop: M1-D334 |
CHEMBL4632348 |
| Serine/threonine-protein kinase DCLK1 |
Delta TM |
= |
-1.56 |
C |
Thermal Shift Assay. Domain: start/stop: S358-A680 |
CHEMBL4632348 |
| Myotonin-protein kinase |
Delta TM |
= |
-1.29 |
C |
Thermal Shift Assay. Domain: start/stop: A64-P430 |
CHEMBL4632348 |
| Ephrin type-A receptor 5 |
Delta TM |
= |
0.21 |
C |
Thermal Shift Assay. Domain: start/stop: P653-P939 |
CHEMBL4632348 |
| Ephrin type-A receptor 7 |
Delta TM |
= |
-3.85 |
C |
Thermal Shift Assay. Domain: start/stop: Q590-S899 |
CHEMBL4632348 |
| Ephrin type-B receptor 3 |
Delta TM |
= |
0.46 |
C |
Thermal Shift Assay. Domain: start/stop: D616-S910 |
CHEMBL4632348 |
| Fibroblast growth factor receptor 1 |
Delta TM |
= |
0.36 |
C |
Thermal Shift Assay. Domain: start/stop: S461-E765 |
CHEMBL4632348 |
| Fibroblast growth factor receptor 2 |
Delta TM |
= |
-0.08 |
C |
Thermal Shift Assay. Domain: start/stop: T457-E768 |
CHEMBL4632348 |
| Serine/threonine-protein kinase GAK |
Delta TM |
= |
0.55 |
C |
Thermal Shift Assay. Domain: start/stop: P14-V351 |
CHEMBL4632348 |
| Death-associated protein kinase 3 |
Delta TM |
= |
0.62 |
C |
Thermal Shift Assay. Domain: start/stop: V9-G289 |
CHEMBL4632348 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Delta TM |
= |
3.38 |
C |
Thermal Shift Assay. Domain: start/stop: S127-S490 |
CHEMBL4632348 |
| Tyrosine-protein kinase FES |
Delta TM |
= |
0.55 |
C |
Thermal Shift Assay. Domain: start/stop: I448-R822 |
CHEMBL4632348 |
| Serine/threonine-protein kinase haspin |
Delta TM |
= |
-0.21 |
C |
Thermal Shift Assay. Domain: start/stop: G465-K798 |
CHEMBL4632348 |
| Dual specificity protein kinase TTK |
Delta TM |
= |
1.18 |
C |
Thermal Shift Assay. Domain: start/stop: S519-E808 |
CHEMBL4632348 |
| Ephrin type-A receptor 2 |
Delta TM |
= |
0.59 |
C |
Thermal Shift Assay. Domain: start/stop: D596-G900 |
CHEMBL4632348 |
| MAP kinase ERK2 |
Delta TM |
= |
0.41 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S360 |
CHEMBL4632348 |
| Proto-oncogene tyrosine-protein kinase MER |
Delta TM |
= |
-1.06 |
C |
Thermal Shift Assay. Domain: start/stop: E571-V864 |
CHEMBL4632348 |
| Serine/threonine-protein kinase 24 |
Delta TM |
= |
-0.1 |
C |
Thermal Shift Assay. Domain: start/stop: R4-D301 |
CHEMBL4632348 |
| Serine/threonine-protein kinase MST4 |
Delta TM |
= |
-0.14 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S300 |
CHEMBL4632348 |
| G protein-coupled receptor kinase 5 |
Delta TM |
= |
-0.05 |
C |
Thermal Shift Assay. Domain: start/stop: M1-E544 |
CHEMBL4632348 |
| Glycogen synthase kinase-3 beta |
Delta TM |
= |
1.64 |
C |
Thermal Shift Assay. Domain: start/stop: M26-R383 |
CHEMBL4632348 |
| Dual specificity mitogen-activated protein kinase kinase 4 |
Delta TM |
= |
0.56 |
C |
Thermal Shift Assay. Domain: start/stop: S80-D399 |
CHEMBL4632348 |
| Dual specificity mitogen-activated protein kinase kinase 6 |
Delta TM |
= |
0.4 |
C |
Thermal Shift Assay. Domain: start/stop: E47-D334 |
CHEMBL4632348 |
| Mitogen-activated protein kinase kinase kinase 5 |
Delta TM |
= |
0.0 |
C |
Thermal Shift Assay. Domain: start/stop: R659-L951 |
CHEMBL4632348 |
| c-Jun N-terminal kinase 3 |
Delta TM |
= |
-3.31 |
C |
Thermal Shift Assay. |
CHEMBL4632348 |
| MAP kinase p38 delta |
Delta TM |
= |
0.49 |
C |
Thermal Shift Assay. Domain: start/stop: N15-R359 |
CHEMBL4632348 |
| MAP kinase p38 alpha |
Delta TM |
= |
-0.01 |
C |
Thermal Shift Assay. |
CHEMBL4632348 |
| c-Jun N-terminal kinase 1 |
Delta TM |
= |
-1.18 |
C |
Thermal Shift Assay. Domain: start/stop: M1-L363 |
CHEMBL4632348 |
| c-Jun N-terminal kinase 2 |
Delta TM |
= |
-0.46 |
C |
Thermal Shift Assay. Domain: start/stop: M1-A380 |
CHEMBL4632348 |
| Dual specificity mitogen-activated protein kinase kinase 7 |
Delta TM |
= |
-1.29 |
C |
Thermal Shift Assay. Domain: start/stop: S60-R405 |
CHEMBL4632348 |
| Serine/threonine-protein kinase tousled-like 1 |
Delta TM |
= |
-1.68 |
C |
Thermal Shift Assay. Domain: start/stop: D448-N746 |
CHEMBL4632348 |
| Serine/threonine-protein kinase c-TAK1 |
Delta TM |
= |
-1.45 |
C |
Thermal Shift Assay. Domain: start/stop: D48-R366 |
CHEMBL4632348 |
| MAP/microtubule affinity-regulating kinase 4 |
Delta TM |
= |
-1.86 |
C |
Thermal Shift Assay. Domain: start/stop: H18-T397 |
CHEMBL4632348 |
| Maternal embryonic leucine zipper kinase |
Delta TM |
= |
0.9 |
C |
Thermal Shift Assay. Domain: start/stop: M1-T348 |
CHEMBL4632348 |
| Serine/threonine-protein kinase Nek1 |
Delta TM |
= |
0.43 |
C |
Thermal Shift Assay. Domain: start/stop: M1-K328 |
CHEMBL4632348 |
| Serine/threonine-protein kinase NEK2 |
Delta TM |
= |
1.01 |
C |
Thermal Shift Assay. Domain: start/stop: M1-I271 |
CHEMBL4632348 |
| Serine/threonine-protein kinase NEK7 |
Delta TM |
= |
-1.38 |
C |
Thermal Shift Assay. Domain: start/stop: N29-S302 |
CHEMBL4632348 |
| Serine/threonine-protein kinase OSR1 |
Delta TM |
= |
0.8 |
C |
Thermal Shift Assay. Domain: start/stop: M1-P322 |
CHEMBL4632348 |
| Serine/threonine-protein kinase PAK 1 |
Delta TM |
= |
-0.67 |
C |
Thermal Shift Assay. Domain: start/stop: M248-H545 |
CHEMBL4632348 |
| Serine/threonine-protein kinase PIM3 |
Delta TM |
= |
-0.76 |
C |
Thermal Shift Assay. Domain: start/stop: M1-L326 |
CHEMBL4632348 |
| Flotillin-1 |
Delta TM |
= |
0.77 |
C |
Thermal Shift Assay. Domain: start/stop: P801-L1158 |
CHEMBL4632348 |
| Serine/threonine-protein kinase PCTAIRE-1 |
Delta TM |
= |
1.08 |
C |
Thermal Shift Assay. Domain: start/stop: E163-S478 |
CHEMBL4632348 |
| Tyrosine- and threonine-specific cdc2-inhibitory kinase |
Delta TM |
= |
-0.82 |
C |
Thermal Shift Assay. Domain: start/stop: H75-P362 |
CHEMBL4632348 |
| Serine/threonine-protein kinase PLK4 |
Delta TM |
= |
0.15 |
C |
Thermal Shift Assay. Domain: start/stop: M1-M265 |
CHEMBL4632348 |
| Ribosomal protein S6 kinase alpha 5 |
Delta TM |
= |
0.46 |
C |
Thermal Shift Assay. Domain: start/stop: S417-N696 |
CHEMBL4632348 |
| Serine/threonine-protein kinase 2 |
Delta TM |
= |
-1.29 |
C |
Thermal Shift Assay. Domain: start/stop: R26-E320 |
CHEMBL4632348 |
| Tyrosine-protein kinase SRC |
Delta TM |
= |
0.63 |
C |
Thermal Shift Assay. Domain: start/stop: A262-L536 |
CHEMBL4632348 |
| Serine/threonine-protein kinase SRPK1 |
Delta TM |
= |
3.06 |
C |
Thermal Shift Assay. Domain: start/stop: D58-S655 |
CHEMBL4632348 |
| Serine/threonine-protein kinase PAK 4 |
Delta TM |
= |
1.62 |
C |
Thermal Shift Assay. Domain: start/stop: S291-R591 |
CHEMBL4632348 |
| Phosphorylase kinase gamma subunit 2 |
Delta TM |
= |
1.49 |
C |
Thermal Shift Assay. Domain: start/stop: G6-R293 |
CHEMBL4632348 |
| Serine/threonine-protein kinase PIM1 |
Delta TM |
= |
0.64 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S312 |
CHEMBL4632348 |
| Ribosomal protein S6 kinase alpha 1 |
Delta TM |
= |
0.45 |
C |
Thermal Shift Assay. Domain: start/stop: V413-L735 |
CHEMBL4632348 |
| Serine/threonine-protein kinase 10 |
Delta TM |
= |
-1.8 |
C |
Thermal Shift Assay. Domain: start/stop: R18-E317 |
CHEMBL4632348 |
| Serine/threonine-protein kinase AKT3 |
Delta TM |
= |
0.38 |
C |
Thermal Shift Assay. Domain: start/stop: S120-E479 |
CHEMBL4632348 |
| BMP-2-inducible protein kinase |
Delta TM |
= |
-0.32 |
C |
Thermal Shift Assay. Domain: start/stop: S38-E345 |
CHEMBL4632348 |
| Bone morphogenetic protein receptor type-2 |
Delta TM |
= |
0.44 |
C |
Thermal Shift Assay. Domain: start/stop: M189-T517 |
CHEMBL4632348 |
| CaM kinase I delta |
Delta TM |
= |
-2.98 |
C |
Thermal Shift Assay. Domain: start/stop: S10-D329 |
CHEMBL4632348 |
| CaM kinase I gamma |
Delta TM |
= |
-0.96 |
C |
Thermal Shift Assay. Domain: start/stop: Q15-H316 |
CHEMBL4632348 |
| Serine/threonine-protein kinase 17A |
Delta TM |
= |
-0.42 |
C |
Thermal Shift Assay. Domain: start/stop: V50-P350 |
CHEMBL4632348 |
| Serine/threonine-protein kinase 17B |
Delta TM |
= |
-0.86 |
C |
Thermal Shift Assay. Domain: start/stop: M25-S329 |
CHEMBL4632348 |
| Serine/threonine-protein kinase 38-like |
Delta TM |
= |
-0.59 |
C |
Thermal Shift Assay. Domain: start/stop: E76-N410 |
CHEMBL4632348 |
| STE20/SPS1-related proline-alanine-rich protein kinase |
Delta TM |
= |
-0.51 |
C |
Thermal Shift Assay. Domain: start/stop: A53-P357 |
CHEMBL4632348 |
| Bromodomain-containing protein 4 |
Delta TM |
= |
-3.12 |
C |
Thermal Shift Assay. Domain: start/stop: N44-E168 |
CHEMBL4632348 |
| Serine/threonine-protein kinase MST2 |
Delta TM |
= |
-0.37 |
C |
Thermal Shift Assay. Domain: start/stop: S15-E313 |
CHEMBL4632348 |
| Serine/threonine-protein kinase MST1 |
Delta TM |
= |
0.63 |
C |
Thermal Shift Assay. Domain: start/stop: M1-E311 |
CHEMBL4632348 |
| Serine/threonine-protein kinase Aurora-A |
Delta TM |
= |
-0.68 |
C |
Thermal Shift Assay. Domain: start/stop: E122-S403 |
CHEMBL4632348 |
| Serine/threonine-protein kinase ULK3 |
Delta TM |
= |
2.07 |
C |
Thermal Shift Assay. Domain: start/stop: A2-Y204 |
CHEMBL4632348 |
| Serine/threonine-protein kinase VRK1 |
Delta TM |
= |
0.41 |
C |
Thermal Shift Assay. Domain: start/stop: R3-D336 |
CHEMBL4632348 |
| Serine/threonine-protein kinase WNK1 |
Delta TM |
= |
0.0 |
C |
Thermal Shift Assay. Domain: start/stop: Q194-E488 |
CHEMBL4632348 |
| Peregrin |
Delta TM |
= |
-1.38 |
C |
Thermal Shift Assay. Domain: start/stop: M626-G740 |
CHEMBL4632348 |
| Ephrin type-B receptor 1 |
Delta TM |
= |
0.29 |
C |
Thermal Shift Assay. Domain: start/stop: D602-A896 |
CHEMBL4632348 |
| Mitogen-activated protein kinase 15 |
Delta TM |
= |
3.16 |
C |
Thermal Shift Assay. Domain: start/stop: v5-n414 |
CHEMBL4632348 |
| MAP kinase-activated protein kinase 2 |
Delta TM |
= |
-0.06 |
C |
Thermal Shift Assay. Domain: start/stop: H47-K353 |
CHEMBL4632348 |
| Transcription initiation factor TFIID subunit 1 |
Delta TM |
= |
0.07 |
C |
Thermal Shift Assay. Domain: start/stop: D1522-D1656 |
CHEMBL4632348 |
